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Male reproductive health has deteriorated in many countries during the last few decades. In the
1990s, declining semen quality has been reported from Belgium, Denmark, France, and Great
Britain. The incidence of testicular cancer has increased during the same time. Incidences of
hypospadias and cryptorchidism also appear to be increasing. Similar reproductive problems
occur in many wildlife species. There are marked geographic differences in the prevalence of
male reproductive disorders. While the reasons for these differences are currently unknown, both
clinical and laboratory research suggest that the adverse changes may be inter-related and have a
common origin in fetal life or childhood. Exposure of the male fetus to supranormal levels of
estrogens, such as diethlylstilbestrol, can result in the above-mentioned reproductive defects.
The growing number of reports demonstrating that common environmental contaminants and
natural factors possess estrogenic activity presents the working hypothesis that the adverse
trends in male reproductive health may be, at least in part, associated with exposure to estro-
genic or other hormonally active (e.g., antiandrogenic) environmental chemicals during fetal and
childhood development. An extensive research program is needed to understand the extent of
the problem, its underlying etiology, and the development of a strategy for prevention and inter-
vention. Environ Health Perspect 104(Suppl 4):741-803 (1996)
Key words: male reproduction, reproductive disorders, semen quality, testicular neoplasms,
environment, estrogenic chemicals, endocrine disruptors, exposure, pesticides
Introduction
In 1992, a research group at the Department
of Growth and Reproduction, the National
University Hospital (Rigshospitalet), and the
Panum Institute, Copenhagen, Denmark,
published in the British Medical Journal a
metaanalysis of the data from the interna-
tional literature that revealed a significant
decrease in sperm concentration and semen
volume in otherwise normal men over the
period 1938 to 1990. During the same
time period, the incidence of testicular
cancer had markedly increased in many
countries. These and other observations
provided a clue that this apparent decline
in male reproductive health might be
caused by some common environmental
factors. It was recognized that similar abnor-
malities of the male reproductive system
were caused by administration of estrogens
during pregnancy in humans and experi-
mental animals; therefore, a hypothesis was
put forward that environmental chemicals
having estrogenic effects were contributing
agents. In particular, it was suggested that
fetal exposure to an excess of estrogenic
compounds was a key risk factor.
After an intense public debate in the
Danish news media on the possible role of
environmental chemicals, such as pesticides,
detergents, plasticizers, and other industrial
chemicals, the Danish Environmental
Protection Agency (DEPA) of the Ministry
of Environment and Energy in September
1994 decided to support the preparation of
a review summarizing the current knowl-
edge on male reproductive disorders and
environmental chemicals with estrogenic
effects. In addition, the review was to iden-
tify gaps in knowledge and address research
needs and requirements in order for
researchers to perform adequate risk assess-
ments. The DEPA asked Professor Niels E.
Skakkebaek, Department of Growth and
Reproduction at the National University
Hospital and John Chr. Larsen, Division
Head, Institute of Toxicology at the Danish
National Food Agency to prepare the
report. The project received additional
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financial support from the Ministry of
Health through its National Research
Centre for Environmental Medicine.
Dr. Jorma Toppari, Departments of
Pediatrics and Physiology, University of
Turku, Finland, prepared a draft of the
report. This draft was then discussed by a
group of Danish and international experts
invited to a one-week workshop that was
held at Rigshospitalet in Copenhagen,
January 23-27, 1995. The participants
who are the authors of the present publica-
tion actively contributed to the endeavor
both during the workshop and afterward.
The final manuscript was edited by Jorma
Toppari together with Niels E. Skakkebak
and John Chr. Larsen. The present review
is a revised version of the official report
(1), which was printed by the Danish
Ministry of Environment and Energy
mainly for circulation in Denmark.
The review addresses the possible
effects of environmental chemicals known
to possess estrogenic activity on male
reproductive health. The term xenoestro-
gen is often used for such compounds,
whereas the term synthetic estrogens refers
to medical drugs mainly used for contra-
ception and treatment of various diseases.
A number of other environmental
chemicals have been implicated as environ-
mental hormones or endocrine disruptors.
Although not shown (and in many
instances not adequately tested) to possess
direct estrogenic activity, some of these
compounds may in some cases also affect
male reproduction. The mechanisms of
action are not known in detail but they
may involve, for example, antiandrogenic
activity; modulatory effects on enzymes
controlling sex hormone metabolism; or
direct influence on the hormone-producing
organs such as the thyroid gland, pituitary
gland, and adrenal glands. These com-
pounds may also affect estrogen levels
through indirect feedback mechanisms.
The authors are well aware that the
decline in semen quality and the increase
in the incidence of testicular cancer may
be caused by many other environmental,
life-style, or genetic factors. For example,
some chemicals that are now known as
occupational toxicants were shown to
affect the semen quality of the workers
through a toxic action on the gonads, with-
out any apparent estrogenic effects. Such
toxic effects are not the object of the pre-
sent report, but should be kept in mind in
any consideration or scientific investigation
of the adverse effects of environmental
chemicals on male reproductive health.
Secular Trends in the
Incidence of Male
Reproductive Disorders
Trends in Semen Quality
Several reports in the literature have sug-
gested a possible decline in human semen
quality during the last 50 to 60 years
(2-4). However, most of these reports
were based on data from men attending
infertility clinics or from very selected
groups of fertile men and, therefore, the
decline in sperm counts was presumed just
to reflect changes in the policy of infertility
treatment or a bias in selection of patients
150 -
10~~~~~~~~~l 0
100-0
C
a,
0c
50 -
0
rather than a true biological phenomenon.
A systematic metaanalysis of 61 studies
that included 14,947 normal men revealed
a significant decrease in sperm concentra-
tion (113 million/ml vs 66 million/ml;
Figure 1) and semen volume (3.40 ml vs
2.75 ml) over the period of 1938 to 1990
(5). This report stimulated extensive dis-
cussion and some criticisms on the basis of
possible technical errors and known limita-
tions of metaanalysis (6,7). Carlsen and
co-workers responded to these criticisms
(8). Although the data for 1970 to 1990
were compatible with a decrease as well as
with no change or an increase in semen
quality, the cautious general conclusion was
that a real decline occurred during the 50-
year period (9). The findings of Carlsen et
al. (5) were also compared (6) to those of
MacLeod and Wang (10) from the United
States. This comparison is not relevant,
however, because the metaanalysis was
based on semen analyses of normal men,
whereas the American study examined men
who were clients of an infertility clinic.
0
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Figure 1. Linear regression of mean sperm density reported in 61 publications (represented by circles the area of
which is proportional to the logarithm of the number of subjects in the study), each weighted according to number
of subjects, 1938-1990. The figure is based on the data reported by Carlsen et al. 15). A corresponding figure in
that paper was incomplete.
Abbreviations used (continued): HPLC, high-performance liquid chromatography; JMPR, Joint FAO/NHO Expert Meeting on Pesticide Residues; LH, luteinizing hor-
mone; LOAEL, lowest observed adverse effects level; MIS, Mullerian inhibiting substance; MRL, maximal residue limits; NOAEL, no observed adverse effect level;
NOEL, no observed effect level; NP, nonylphenol; OECD, Organisation for Economic Cooperation and Development; OP, octylphenol; OPPT, Office of Pollution
Prevention and Toxics; OPPTS, Office of Prevention, Pesticides and Toxic Substances; PCB, polychlorinated biphenyl; PCDD, polychlorinated dibenzo-p-dioxin; PCDF,
polychlorinated dibenzofuran; PCP, pentachlorophenol; PCT, porphyria cutanea tarda; PE, proliferative efficiency; PNS, peripheral nervous system; 2,4,5-T, 2,4,5-
trichlorophenoxyacetic acid; RfD, reference dose; RPE, relative proliferative efficiency; RPP, relative proliferative potency; SHBG, sex hormone-binding globulin; STW,
sewage treatment water; TBT, tributyltin; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCDD-TEQ, TCDD equivalency; TDI, tolerable daily intake; TEF, toxic equivalency
factor; TWI, tolerable weekly intake; U.S. EPA, U.S. Environmental Protection Agency.
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The metaanalysis of Carlsen et al. (5)
prompted several laboratories to evaluate
their data on the quality of semen obtained
during recent years. In a French study of
1351 healthy men volunteering for sperm
donation, a 2.1% decrease in sperm con-
centration per year from 89 million/ml in
1973 to 60 million/ml in 1992 (p<0.001)
was found (11). Furthermore, the percent-
ages of motile and normal spermatozoa also
decreased significantly (Figure 2), whereas
semen volume remained unchanged (3.8
ml). It is notable that the year of birth of
the study subjects contributed significantly
to the results. Multiple regression analysis
(which allows for separate effects of age
and calendar year at birth) showed yearly
decreases of 2.6% in sperm concentration,
0.3% in motility percentage, and 0.7% in
the percentage of normal spermatozoa
according to the year of birth of the men
(all changes, p < 0.001) (11). Similar results
were obtained in a Scottish study (12) of
577 semen donors where a correlation was
found between the median sperm count and
the year of birth; the median sperm concen-
tration decreased from 98 million/ml
among donors born before 1959 to 78 mil-
lion/ml among donors born after 1970
(p=0.002). The total number of sperm in
the ejaculate fell from 301 million to 214
million (p = 0.0005)(12). The association
between declining semen quality and a
more recent year of birth lends support to
the concept that adverse prenatal factors
may influence the sperm production capac-
ity in adult life. Deterioration of sperm
counts as well as motility among semen
donor candidates during the past two
decades was also observed in a smaller
Belgian study (13). Ginsburg and Hardiman
(14) reported a decrease in sperm concentra-
tions (105 million/ml in 1978-1983 vs 76
million/ml in 1984-1989) of the partners of
women treated for infertility and living in
the Thames water supply area of London,
whereas no decrease was found among those
who lived in other water supply areas of
London. However, the mean percentage of
abnormal spermatozoa increased in all
areas during the study period (18-19% vs
30-32%) (14). The data in all the studies
cited above originated in individual labo-
ratories that used consistently the same
methods for semen analysis throughout
the period.
The decreasing trend in semen quality
may not be global. In contrast to the Paris
area, no change in sperm concentration
was found in the Toulouse area in France
during 1977 to 1992 (15). The mean
sperm count of samples from 302 healthy
fertile donors was 83 million/ml (15).
Furthermore, the sperm concentration in
semen of Finnish men has remained
unchanged between 1958 and 1992 (111
million/ml vs 124 million/ml) and is
higher than elsewhere in Europe (16). It is
of interest that the incidence of testicular
cancer, and perhaps also hypospadias, in
Finland is much lower than that in other
Nordic countries (below), suggesting that
these phenomena may be related in some
way. The reason remains unknown, but
further examination may provide impor-
tant clues to the etiology of decreasing
sperm quality worldwide. Urban areas
(e.g., Paris) appear to have a declining
trend in sperm counts, whereas rural areas
(e.g., Toulouse or Finland) seem to have
stable sperm concentrations in semen.
Incidence of Testicular Cancer
Testicular cancer is now the most com-
mon malignancy of young men in many
countries; and although it is still rare com-
pared to the malignant diseases most preva-
lent in old age, the lifetime risk of
developing testicular cancer now approaches
1% in a country such as Denmark. The
incidence of testicular cancer has increased
for several decades (17). On the basis of
data from cancer registries, increases in inci-
dence are evident in England and Wales
(18,19), Scotland (20), the Nordic and
Baltic countries (21,22), Australia (23),
New Zealand (24,25), and the United
States (26). The observed increase has
been approximately 2 to 4% per annum in
men under 50 years of age (Figures 3, 4)
and occurred in the same age group in
which testicular cancer incidence peaks,
i.e., young adults (Figure 5). Table 1 dis-
plays the changes that have occurred dur-
ing the last 25 years. There are marked
racial and geographic differences. For
example, Denmark has a 4-fold higher
incidence of testicular cancer than does
nearby Finland, and Caucasians are 3-fold
more susceptible to this disease than are
African Americans in the United States.
Nevertheless, it is obvious that there is a
worldwide trend toward an increased inci-
dence of testicular cancer as illustrated in
Figures 3-5. The incidences of both semi-
nomas and nonseminomas have increased
(17). Mortality due to testicular cancer
increased from the beginning of this cen-
tury until the early 1970s when, because of
the development of good medical treat-
ment, mortality began to decline (17).
However, we still do not know the etiology
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Figure 2. Changes in the sperm concentration (A),the
percentage of motile sperm (B), and the percentage of
morphologically normal sperm (C) in 1351 fertile men,
1973-1992. Linear regression analysis revealed a
decrease of 2.1% per year in the mean sperm concen-
tration, from 89x 106 per milliliter in 1973 to 60x 106
per milliliter in 1992. The concomitant decreases in the
mean percentages of motile and normal spermatozoa
were 0.6 and 0.5% per year, respectively. Reproduced
with permission from Auger et al. (11).
of testicular cancer and cannot therefore
develop any preventive measures.
Incidence ofCryptorchidism
Birth data from several reports have indi-
cated a substantial increase in the incidence
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Figure 3. Secular, racial, and geographic trends in the incidence of testicular cancer, 1953-1987. Compilation of data from IARC (318-323).
of cryptorchidism (maldescent of the testis).
However, estimates of the prevalence of
cryptorchidism obtained from different
studies are difficult to compare. It is often
not clear how a cryptorchid testis was
defined, and inclusion of different propor-
tions of boys with retractile testes could
account for the reported differences. The
sources of data used in these reports also
differ considerably. The prevalence rates
have varied between 0.03 and 13.4% on
the basis of data from birth to 1 year of age
from hospital or central registers (including
different proportions of preterm babies)
(27-48); 0.16 to 13.3% in surveys from
school, army, etc. (36,38,49-57); and 2 to
4.7% in cohort studies based on discharge
diagnosis (41,58,59). A few studies include
ethnic data on non-Caucasians: birth data
from India (33), Formosa (Taiwan) (38),
and Korea (44) indicated prevalences of
1.6, 1.4, and 0.7% of cryptorchidism,
respectively. A school survey from Nigeria
(56) indicated a prevalence of 0.5%. The
incidence of cryptorchidism among African
Americans was reported to be only one-
third that among whites (34), although
another study (48) did not find a significant
difference. Racial and ethnic data are pooled
in most studies. Unfortunately, very few
studies exist examining temporal changes in
the incidence of cryptorchidism, confined
to the same population and geographic
areas and using an identical definition of
the condition.
Discharge data from the Hospital
Inpatient Enquiry from England and
Wales showed that the proportion of boys
undergoing orchidopexy (operation to
bring the testis into the scrotum) before 15
years of age increased from 1.4% for a
1952 birth cohort to 2.9% for a 1977 birth
Environmental Health Perspectives * Vol 104, Supplement 4 * August 1996
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10.0 indicated an incidence of cryptorchidism
Denmark of approximately 2% (59).
Lithuania In a study from the late 1950s that
v Estonia examined more than 3500 male infants
- Poland ,- delivered in a hospital in London and fol-
7
-5- Norway lowed up to 1 year of age, Scorer (31)
Saar-Filand found that the incidences of cryp-
S aGermany torchidism at 3 months of age in boys with
.--------- Sweden birth weights <2500 g and >2500 g were
5.0- Latvia 1.74 and 0.91%, respectively. Scorer used
very accurate definitions of the positions ofyg7+r.--testes, and therefore, this well-conducted
study has served as a reference for later
2.5 ~ ............research. In a large study from the 1980s,2.5 -
----------
comprising 7441 male infants from Oxford
(47), the very same examination technique
,,,,, _ and definitions of cryptorchidism were
used; the rates of cryptorchidism at the age
oo9 of 3 months in boys with birth weights
1943 1948 1953 1958 1963 1968 1973 1978 1983 1988 < 2500 g and > 2500 g were 5.2 and
1.61%, respectively, indicating a significant
3-year moving average was used increase compared to Scorer's figures. In
another study from the late 1980s com-
gure 4. Trends in age-standardized (world standard population) incidence rates of testicular cancer. From Adami posed of 6935 male infants from New
al. (22); reprinted with permission from Wiley-Liss, Inc. York (8 (us ing altstudyNesYork (48) (using identical study techniques
and case definition), prevalence rates of
cryptorchidism at the age of 3 months in
25 A Sweden boys with birth weights <2500 g and
v Denmark >2500 g were 1.94 and 0.91%, respec-
/Z' Norway tively. However, the study population was
20 * Finland racially and ethnically heterogeneous.
o Poland From these three large studies, one can
* East Germany conclude that there has been a significant
15 - increase in the incidence of cryptorchidism
in England, but the incidence in the
racially and ethnically mixed population of
10
, \ < w vNew York is similar to that reported in the
10\w < \ \ 1950s in England.
`1g \ ~N \The epidemiological data indicative of
an increasing incidence of cryptorchidism
5 o G 1\ ~ \ :g are not unequivocal. This important issue
necessitates large regional prospective
studies in which standard criteria are
0 adopted for an accurate description of
20,24 2529 3034 35-39 4044 45-49 5054 5559 60-4 6569 70-74 75-79 80+ cryptorchidism.
Age
Figure 5. Age-specific incidence of testicular cancer 1985-1989 in the Nordic countries, Poland, and former East
Germany. From Adami et al. (22); reprinted with permission from Wiley-Liss, Inc.
cohort (58). However, it is not known
whether this is a reflection of a true increase
in the prevalence of cryptorchidism or
whether a considerable number of boys
with retractile testes were undergoing orchi-
dopexy. In Scotland, the annual number of
discharges of boys 0 to 14 years of age with
the diagnosis of cryptorchidism also
showed a substantial increase during 1961
to 1985 (41). In Denmark, the prevalence
of cryptorchidism at birth in male infants
weighing > 2500 g varied between 1 and
1.8% in three different data sets obtained
in the late 1950s (60). School surveys sug-
gested higher prevalence rates up to 7%
during 1940 to 1966, but these figures
apparently included retractile testes (55).
Cohort analysis of data from the Danish
National Register of Hospital In- and
Outpatients, from the period 1982 to 1985,
Incidence of Hypospadias
Birth data from several reports have indi-
cated a substantial increase in prevalence of
hypospadias (Figures 6, 7). Figures of birth
prevalence of hypospadias in the world lit-
erature vary considerably-from 0.37 to 41
per 10,000 infants (61,62)-and are
difficult to compare. There are several fac-
tors that may contribute to the reported
differences: different levels of ascertain-
ment, different inclusion of minor forms of
hypospadias or differences in ethnical
origin of the population. As reported for
cryptorchidism, very few longitudinal
studies confined to the same population
Environmental Health Perspectives - Vol 104, Supplement 4 - August 1996
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Table 1. The incidence of testicular ca
191
Nordic countries
Denmark
Finland
Iceland
Norway
United Kingdom
England and Wales
Brimingham region
Birmingham and West Midlands
Liverpool region
Southern Metropolitan region
Southwest region
Northwest
Urban
Rural
Sheffield region
Oxford
South Thames
Trent
Mersey
Yorkshire
Scotland
East Scotland
North Scotland
Northeast Scotland
Southeast Scotland
West Scotland
Western Europe
France
Bas-Rhin
Urban
Rural
Doubs
Urban
Rural
Germany
Saarland
Urban
Rural
Hamburg
Italy
Varese
Parma
Ragusa
Netherlands
3 provinces
Eindhoven
Spain
Navarra
Zaragoza
Urban
Rural
Switzerland
Basel
Geneva
Neuchatel
St. Gall
Vaud
Urban
Rural
ancer, 1953 to 1987.a and geographic area exist. The increasing
60-1963 1964-1968 1969-1972 1973-1977 1978-1982 1983-1987 incidence of hypospadias has been reportedprimarily in England and Wales (39),
Hungary (63,64), Sweden (65-67),
3.8 4.5 4.9 6.7 7.8 8.4 Norway (67,68) and Denmark (66,67).
1.2 0.8 1.1 1.7 1.5 1.8 No increasing trend was noticed in
3 - - - 3.2 4.7 Finland, Spain, New Zealand, Australia, or
3.3 3.6 4.4 4.4 5.9 6.6 Czechoslovakia (67).England and Wales. The data from
England and Wales are based on the
national register that includes the whole
population. Analysis of the data indicated a
2.1 2.1 2.7 2.9 3.1 - steady increase in the prevalence of
-
- - - - 3.5 hypospadias from 7.3 per 10,000 births in
2.4 2.2 24 - - 1964 to approximately 16 per 10,000
2.1 2.4 2.6 - 3.8 5 births in the early 1980s, when the number
- - - 3.2 3.3 4 of cases stabilized (Figure 6). In 1990 the
- - - 3.3 - - prevalence of hypospadias showed a
-
-
- 2.9
- - decrease to 11.7 per 0,000.
- 2.1 2.4 - - - Hungary. The Hungarian data are
- 2.5 2.6 3.7 3.9 4 based on the national register of the whole
-
- - 3.4 3.5 3.5
- - - 3 3.4 3.8 population. As shown in Figure 6, there
- - - 2.3 4 - was a rapid increase in the prevalence of
- - - - - 4.1 hypospadias from 5.5 per 10,000 births in
- 2.5 - - 4.4 5 1964 to 23.9 per 10,000 in 1978. Since
- - - 3.6 3.8 5.3 then, the prevalence of hypospadias,
- - - 4.3 4.2 4.4 although fluctuating, has remained at
- - - 4 5.5 5.3 approximately the same level.
- - - 4.3 5.3 5.1 Scandinavian Countries. The data
- - - 2.9 3.9 4.8
on the incidence of hypospadias in
Scandinavia (Figure 7) are all based on the
national registers that include the whole
populations. The Danish data from 1970
- -
- 3.5 4.3 5.9 to 1981 indicated a significant increase for
-
- - 4.2 - - this period (from approximately 7.5 to 12
- - - 2.6 - - per 10,000 births) (66). A further increase
-
- - 2.3 3.4 3.8
- - - 2 3.3 - was noticed during the period 1982 to
- -
- - 3.8 - 1988 (67). However, this increase may be
difficult to interpret as a new registration
- - 3 3.4 5.4 6.2 system was introduced. Nevertheless, this
- - - - 5.5 - increase was similar to that reported for the
- - - - 5.4 - years 1970 to 1981.
2.6 4 4.7 5.4 5.7 - The data from Sweden also indicated a
marked increase in the early 1970s: preva-
- - -
2.3 3.3 4 lence of hypospadias at birth was 40%
- - - - 0.6 12.4 higher between 1974 and 1982 than forthe period 1965 to 1968 (66,69).
2.8 - -- - - However, the data obtained in the earlier2
-
- - 3.2 3 period could be more complete, because
they included both hospital records and
- 1.3 1.2 1.4 registry data.
- - 1.1 1.7 1.3 1.5 Also in Norway the prevalence of
- - - 1.6 - - hypospadias at birth increased from 7 to 8
- - - 2 - - per 10,000 births between 1967 and 1971
to 13 per 10,000 in 1973 (68). In 1988, the
- -
- - 8.3 8.4 prevalence was 20.7 per 10,000 births (67).
- - 4.4 5.1 6.3 6.2 Ethnic Differences. The incidence of
- -
- 9.1 5.4 7 hypospadias in the United States is higher
- - - 9.9 7.7 8.5 in Caucasians than in African Americans
- - - 8.9 9.9 - (ratio of 1.3-3.9:1) (70-73). In British
- - - 10.5 6.5 - Columbia, Canada, Native Americans were
(continued)
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Table 1. (continued)
1960-1963 1964-1968 1969-1972 1973-1977 1978-1982 1983-1987
Zurich - - - - 7.4 8.8
Urban - - - 1.9 - -
Rural - - - 1.4
Eastern Europe - - - - -
Czechoslovakia - - - 2.4 2.7 3.8
Urban - - - 3.6 4.8 -
Rural - - - 2.2 2.4 -
East Germany (GDR) - 2.6 3.3 4 - 7
Hungary
Szabolcs - 1 1.8 1.5 1.2 2.7
Urban - - - - 1.7 -
Rural - - - - 1.1 -
Vas - 1.2 1 3.4 3.3 6.1
Urban - 4.1 4.6 4.7 6.6 -
Rural - 3.3 4.3 4.2 5.5
Poland
Cieszyn - - - 2 -
Urban - - - 2.8
Rural - - - 1.5 - -
Cracow city - 1 1.4 1.5 2.4 2.6
Katowice - 0.9 1.2 1.1 - -
Urban - - - 1.1
Rural - - - 0.9 - -
Nowy Sacz - - - 1.1 1.2 1.2
Warsaw city - 0.8 1.7 2.4 2 3.3
Warsaw rural - - 0.6 0.9 - 1.9
Romania
County Cluj - - - 1.3 1.3 1.4
Urban - - - - 1.7 -
Yugoslavia
Slovenia 1.3 1.6 1.9 2.1 2.8 3.4
Canada - - - - 3 3.6
Alberta 3 3 3 3.8 3.6 3.7
British Columbia - - 3.1 3.3 3 4.2
Manitoba 3 2.7 3.1 3.4 4 4
Maritime Provinces - - 1.9 2.3 2.8 3
New Brunswick 1.6 1.4 - - 2.7 2.6
Nova Scotia - - - - 3.2 3.2
Newfoundland 1.5 1.7 1.7 2.1 2.6 2.3
Ontario - - - 2.7 3.4 4.2
Quebec - 1.1 1.4 1.6 2 2.4
Northwest Territory and Yukon - - - 5.5 - 4.8
Saskatchewan 2.2 3.3 3.5 3 3.3 4.5
United States
SEER, White
SEER, Black
Connecticut
White
Black
California
Alameda
White
Black
Bay Area
White
Black
reported to have a lower incidence of
hypospadias than the general Caucasian
population. with a ratio of 1:6.7 (74,75).
Geographic Variation. Considerable
variation exists in the prevalence of
hypospadias among different countries.
Interestingly, some populations with a low
incidence of testicular cancer (e.g., Finland)
(22) have a very low prevalence of hypospa-
dias (Figure 7). Furthermore, there seems
to be considerable geographic variation in
the prevalence of hypospadias within differ-
ent countries (66,76).
Incidence of Male Breast Cancer
As xenoestrogens were implicated as possi-
ble factors involved in the pathogenesis of
breast cancer in women (77), the trends in
the incidence of this disease in males
should be monitored. Male breast cancer is
a rare disease; only a few studies exist on
geographical and temporal trends. Ewertz
et al. (78) studied the incidence of male
breast cancer in four Nordic countries and
found a weak increase with calendar time
in Denmark (1943-1982) but no change
in Finland, Norway, and Sweden over the
period 1953 (1958 for Sweden) to 1982.
Ewertz et al. noted a remarkable geographi-
cal trend, with Denmark having an inci-
dence about twice that of Finland.
Summnary
Semen quality has deteriorated in many
countries during the last 50 years. The inci-
dence of testicular cancer has been increas-
ing almost invariably worldwide. Increases
in the incidences of cryptorchidism and
hypospadias have been observed in coun-
tries in which longitudinal studies have
been performed. However, there are clear
regional differences. The prevalence of male
breast cancer has been rising and is higher
in Denmark than in Finland.
Changes in Male
Reproduction in Wildlife.
Estrogenic Effects on
Developing Animals
- - - - -
4.9 Changes in male reproduction in wildlife0.7 involve such issues as feminization, demas-
2.4 - 2.8 3.6 - - culinization, reduced fertility, reduced
-
- - - 4.2 0.6 hatchability, reduced viability of offspring,impaired hormone secretion or activity, and
altered sexual behavior (79). Since it is not
- 3.1 4.4 3.9 5.4 5.9 possible to review all of the data in detail,
- 0 0.5 1.2 0.9 0.7 the reader is referred to a recent workshop
publication titled "Chemically-induced
- - 4.5 4 4.9 5.3 Alterations in Sexual and Functional
1 1 1.1 0.8 Development: The Wildlife/Human
(continued)
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Table 1. (continued)
1960-1963 1964-1968 1969-1972 1973-1977 1978-1982 1983-1987
Chinese - - 3.3 2.2 1.3 -
Japanese - - - 3 0.6 -
Los Angeles
White - - - 3.6 4.7 5.8
Spanish - - - 3.1 2.5 3.3
Black - - - 0.9 0.7 0.6
Japanese - - - 1.7 1.9 2.4
Chinese - - - 0.4 0.6 1.9
New York State 2.1 - 2.3 3.2 - -
New York City - - - - 2.5 2.9
New York State less city - - - - 4.1 4.6
Georgia
Atlanta
White - - - 4 3.8 -
Black - - - 1 0.5 -
Iowa - - 3.7 3.6 4.1 4.4
Louisiana
New Orleans
White - - - 3.4 4 3.7
Black - - - 0.6 1.3 0.9
Michigan
Detroit
White - - 3.2 3.5 4.1 5
Black - - 0.9 0.8 1.1 0.9
New Mexico
Hispanic - - 2.8 2.9 3.1 -
Other White - - 4.1 4.2 4.2
American Indian - - 1 1.8 2.1
Texas
El Paso
Hispanic - 2.8 2.9 - - -
Utah - - 3.1 4.7 4 4.4
Washington
Seattle - - - 4.3 4.7 5.7
Latin America
Brazil
Porto Alegre - - - - 2.5 4.1
Recife - - 0.8 - 0.4 -
Sao Paolo - - 1.1 1.4 2 -
Columbia
Cali 2.2 2 1.1 1.5 1.5 1.6
Cuba - - 0.2 0.3 - 0.6
Jamaica
Kingston 0.8 - 0.1 0.6 - -
Netherlands Antilles - - - 1.1 0.5 -
Costa Rica - - - - 2.1 1.6
Puerto Rico 0.3 0.7 - 0.5 1 1.2
Asia
China
Shanghai
Tianjin
Hong Kong
India
Bombay
Bangalore
Madras
Poona
Connection" (80). Many of the reproduc-
tive disorders listed above have been associ-
ated with xenoestrogenic effects on the
fetus. It has usually not been possible to
ascribe lowered reproductive success and
signs of feminization and demasculiniza-
tion in wildlife to a single agent; in these
cases, chemical analyses of specimens have
revealed the presence of multiple com-
pounds, some of which are known to have
hormonelike activity. There is experimen-
tal evidence that xenoestrogens act cumula-
tively, i.e., 10 compounds administered
simultaneously, each one at 1/10 of their
effective dose, resulted in a potent estro-
genic response (81). Cumulative exposure
to nongonadal estrogens is easily docu-
mented in male birds, amphibians, and fish
by measuring plasma vitellogenin levels.
Gastropod Species
Pseudohermaphroditism or imposex-
females developing male characteristics-in
marine gastropod species has been reported
worldwide: the northeastern United States
(82), the United Kingdom (83), Alaska
(84), and Southeast Asia (85). This phe-
nomenon is caused by tributyltin (TBT)
compounds leached from marine antifoul-
ing paints used on ships, boats, and
mariculture pen nets (83). Very low con-
centrations (1 ng/liter) of TBT-derived tin
are effective in induction of imposex (83),
and marine areas averaging 6 to 8 ng/liter
of TBT suffer reproductive failure and
local extinction due to female sterility
(86). The use ofTBT was restricted in the
1980s, and recovery of some species has
been reported after that (87). However,
imposex still remains a problem for gastro-
pod species in several marine areas. The
mechanism of action of TBT is unknown.
The effect mimics that of an antiestrogen,
and therefore presents an example of the
drastic hormonelike effect of a xenobiotic
threatening the existence of several species,
even though higher species seem to be far
less sensitive to TBT.
Reptiles
Lake Apopka, Florida, was extensively pol-
luted with dicofol (86), 1,1, l-trichloro-
- - - 0.9 0.7 0.8 2,2-bis(p-chlorophenyl)ethane (DDT)
- - - - 0.6 0o5 (and its metabolites 1,1-dichloro-2,2-bis(p-
- - - 1.4 1.2 1.1 chlorophenyl)ethane [DDD], 1,1-dichloro-
2,2-bis(p-chlorophenyl)ethylene [DDE]
- 0.9 0.7 0.9 1 1 and chloro-DDT), and sulfuric acid spilled
-
- - - 0.7 0.7 accidentally from a chemical company in
- - - - 0.7 0.6 1980. Further contamination of the lake
- --
1 1 - by agricultural sewage dumping has made
(continued) this lake one of Florida's most polluted
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Table 1. (continued)
1960-1963 1964-1968 1969-1972 1973-1977 1978-1982 1983-1987
Israel
All Jews - 1.5 1.6 1.9 2.2 2.2
Born in Israel - 2.2 1.3 2.1 1.8 2.7
Born Europe/America - 2 2.6 2.7 3.8 3.4
Born Africa/Asia - 0.8 0.8 1 4.9 0.8
Non-Jews - 0.8 0.2 0.8 0.7 1.1
Total population 1.6 - - - - -
Japan
Hiroshima - - - - 1.7 -
Miyagi 0.6 0.4 0.8 0.8 1 1.3
Urban - - - 1 1 -
Rural - - - 0.5 0.9
Okayama - 1.2 1.2 - - -
Nagasaki - - - 1.1 0.8 1.9
Osaka - - 0.7 0.8 1.4 1.4
Urban - - - 0.8 - -
Rural - - - 0.5 -
Kuwait
Kuwaitis - - - - 1.1 0.8
Non-Kuwaitis - - - - 1.3 0.6
Singapore
Indian - - 0.5 0.7 0.6 1.2
Malay - - 0.3 1.2 0.4 1.3
Chinese 0.5 - 0.9 0.8 0.9 0.9
Pacific Region
Australia
Capital Territory - - - - 4.1 4.2
New South Wales - - - 3 3.5 3.7
Urban - - - 2.9 3.7 -
Rural - - - 3.1 2.9 -
South - - - 3.2 3.4 3.4
Tasmania - - - - 3.8 5
Victoria - - - - 4.2 4.2
Western - - - - 4 3.6
New Zealand 3.5 - - - - -
Pacific Polynesian Islands - - - - 1.8 -
Maori - 3.4 4.3 4.3 7.9 6
Non-Maori - - 3.7 4.5 5.3 5.3
European - 3.2 - - - -
Hawaii
All groups 2.2 - - - - -
Caucasian 3.1 2.9 3.3 5 4.2 5.4
Japanese 1.4 1.2 0.3 1.1 1.4 2.9
Hawaiian ethnic 3.3 2.9 3 3.9 3.3 3.6
Filippino - 0.2 0.3 0.2 0.3 -
Chinese - 0.7 2.2 0.5 1.2 7.1
"Based on data from IARC (318-323).
wetlands. A number of these pollutants are
known to have estrogenic or endocrine-dis-
rupting effects (89). The chemical spill was
followed in the subsequent 3 years by a
significant decline in the number of
juvenile alligators, whereas alligator popu-
lations elsewhere were increasing or stable
at the same time (90). The population
decline was associated with reproductive
disorders that were hypothesized to be
caused by endocrine-disrupting xenobiotics
(91). There are extensive data supporting
the hypothesis (92,93): female alligators
from Lake Apopka had plasma estradiol
concentrations 2 times that of normal
females from the control lake, Lake
Woodruff. The females exhibited abnormal
ovarian morphology. Likewise, in males
abnormal germ cells were observed in the
testes. Furthermore, Lake Apopka male alli-
gators had abnormally small phalli. Basal
and luteinizing hormone (LH)-stimulated
plasma testosterone concentrations of male
juvenile alligators in Lake Apopka were
significantly lower than those of Lake
Woodruff males, equaling those of females.
The plasma estrogen concentrations of
male alligators from these two lakes did not
differ. However, testes from Lake Apopka
alligators produced significantly more
estradiol in vitro than testes from control
alligators; testosterone production was sim-
ilar (93). The discordance in the in vitro
and in vivo findings suggests additional
significant differences in steroid metabo-
lism and liver function between the alliga-
tors from these two lakes, emphasizing the
complexity of environmental influences.
Reptiles have temperature-sensitive sex
determination that can be altered by estro-
gen treatment (94). This has been demon-
strated both in alligators (95) and turtles
(96). The data from Lake Apopka sug-
gested that the gonads of alligators had
been permanently modified, altering
steroidogenesis and inhibiting normal sex-
ual maturation (91,97,98).
A recent study (99) has demonstrated
that a number of PCB metabolites are
capable of acting as synthetic estrogens. As
with crocodilians, many turtles exhibit
environmental sex determination so that
the temperature at which the egg is incu-
bated determines the sex of the offspring
(97). Turtle eggs incubated at 26'C pro-
duce 100% males. However, if eggs incu-
bated at a male-producing temperature are
"painted" with either one of two PCB
metabolites (2',4',6'-trichloro-4-bipheny-
lol or 2',3',4',5'-tetrachloro-4-biphenylol)
sex reversal occurs as if the eggs were
treated with the natural estrogen, 170-
estradiol (99). Interestingly, if eggs are
treated with a dose of both compounds
(100 pg of each)-a dose that produced a
small percentage of sex-reversed turtles (20
and 0%, respectively)-they act synergisti-
cally, producing sex reversal in 80% of the
eggs treated. Thus, animals that should
have developed as males are modified so
that their internal and external morphol-
ogy is that of a normal female. It is
unknown if this sex reversal produces
fertile adult females.
Fish
Modifications in reproductive functioning
of male fish living downstream from kraft
pulp mills have been well documented. For
example, white sucker (Catostomis commer-
soni) collected from sites receiving primary
effluent exhibited delayed maturation,
smaller gonads, and an absence of secondary
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Figure 6. Prevalence of hypospadias at birth (rate per 10,000 births) in England and Wales, and Hungary. Based on
data from WHO (67).
25 - - - - - - - - - - - - -A Sweden
O Norway
v Denmarknd
15------------ --------
1970 1980
Years
Figure 7. Prevalence of hypospadias at birth (rate per 10,000 births) in the Scandinavian countries. Based on data
from WHO (67).
sex characteristics (100). Furthermore, these
males had significantly reduced serum
testosterone concentrations and dysfunc-
tional hypothalamic control of the pitu-
itary-gonadal axis. A similar reduction in
gonad size was reported for both male and
female perch (Perca fluviatilis) inhabiting
sites receiving primary effluent from a kraft
mill on the coast of the Gulf of Bothnia
(101). The effects observed in these perch
were graded along the pollution gradient
(2-8 km) from the mill. Masculinization
and behavioral changes of female mos-
quito fish (Gambusia affinis) were observed
in Florida rivers downstream from paper
and pulp mills (102). Laboratory studies
corroborated the hypothesis that kraft mill
effluents containing large amounts of the
plant steroids sitosterol and stigmastanol
caused the changes (103). However, the
etiologic agents in paper-mill effluents have
not been identified unequivocally. Other
effects of paper-mill effluents on fish have
been reviewed by Owens (104) and
Leatherland (105).
The effect of PCB exposure on testicular
function in fish also has been examined. In
the Atlantic cod (Gadus morhua), testicular
steroidogenesis is disrupted by dietary expo-
sure to PCBs (106). Additionally, Freeman
et al. (107) observed that cod exposed to
PCBs in vivo exhibited increased metabolism
of steroid hormones in vitro by kidney and
liver tissues. Further, dietary exposure of
juvenile males to PCBs precluded the rise in
plasma testosterone concentrations associ-
ated with sexual maturity. These data suggest
that PCBs modify both testicular androgen
synthesis and steroid utilization/degradation
in peripheral tissues. Exposure to crude oil
also induced a decrease in plasma testos-
terone concentrations in the winter flounder,
Pseudopleuronectus americanus (108).
Organochlorines have also been impli-
cated in a number of developmental and
reproductive abnormalities in fish living in
the Laurentian Great Lakes of North
America. Male coho salmon (Oncorhynchus
kisutch) living in Lake Erie exhibit a num-
ber of abnormalities, including decreased
fertility, lower plasma concentrations of
gonadotropins and steroids (testosterone,
11-ketotestosterone), poor expression of
secondary sex characteristics, and high pre-
cocious sexual maturation (109,110). It is
unknown at this time if the above deficien-
cies are all related or represent different
effects. It is hypothesized that some may be
due to modifications of the developing
embryo (organizational effects), whereas
others may be due to disruptive activa-
tional events in adults.
The observation of an increased preva-
lence of hermaphroditism in fish in sewage
treatment water (STW) lagoons in England
and Wales initiated a series of studies exam-
ining environmental estrogens using a
bioassay involving vitellogenin synthesis in
STW-exposed rainbow trout (Oncorhynchus
mykiss) (111,112). Vitellogenin is produced
in the liver under estrogen control by
female fish for the growth of ova (113).
Males produce it only after exogenous
estrogen treatment (114). Vitellogenin
production by male fish can therefore be
used as a biomarker of environmental
estrogenic activity. STW exposure of caged
rainbow trout induced increases of 500- to
100,000-fold in plasma vitellogenin con-
centration, and males were shown to
achieve vitellogenin levels almost as high as
females, indicating the contamination of
water by estrogenic compounds (112). In
vitro studies with trout hepatocytes estab-
lished a dose-response relationship with
estrogen exposure and vitellogenesis (111).
Using this culture system, it was demon-
strated that degradation products of several
alkylphenol-polyethoxylates, a major
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group of surfactants present in sewage, are
estrogenic to fish (111). Their effect on
trout hepatocytes could be blocked with an
antiestrogen, Tamoxifen, demonstrating
that the compounds act through the estro-
gen receptor. Although the estrogenic
activity of individual xenobiotics was low,
their effects may be additive in nature.
Birds
Feminization of gulls and terns in several
locations along the Pacific coast of the
United States has been associated with
DDT and DDE pollution (115,116). Fry
and Toone (115) demonstrated the femi-
nizing capacity of some DDT compounds
by injecting gull eggs. Feminization leads
to a skewed male/female ratio, which is
known to increase female-female pairing.
Supernormal clutches, i.e., five to six gull
eggs per nest instead of the normal three,
are often laid after this type of pairing, and
the fertility of the eggs is poor (117).
There is some controversy as to whether
feminization of males or differential mor-
tality of males resulted in a skewed sex
ratio (118). Fox (86) considered both the
feminization of males and their increased
mortality, when compared to females, as
possible reasons for the female-female pair-
ing and supranormal clutches in the gulls.
Mammals
Although the mechanism is unknown at
this time, elevated PCBs and DDE concen-
trations are associated with a decrease in
plasma testosterone concentrations in
Dall's porpoises, Phocoenoides dalli (119).
Testicular steroidogenesis in vitro has been
studied in the gray seal (Halichoerus grypus)
in association with exposure to methyl
mercury (MeHg), cadmium (Cd), arsenic
(As), selenium (Se), and a PCB mixture
(Aroclor 1254). All contaminants except
As and Se, stimulated testosterone synthe-
sis in vitro from seal testicular tissue (120).
The mechanism by which this stimulation
occurs is unknown. Gonadal steroidogene-
sis is not the only target for PCBs, as a
number of PCB metabolites have been
shown to decrease thyroid function in vivo
in the common seal, Phoca vitulina (121).
The majority of the remaining (approxi-
mately 35 individuals) endangered Florida
panthers (Felis concolor coryi) exhibit a
number of developmental abnormalities
and reproductive defects (122). Specifically,
males (n = 12) showed low ejaculate vol-
ume, low sperm concentrations (3-15 x 106
sperm/ml semen), poor sperm motility, and
a very high proportion (92.9%) of sperm
with morphological abnormalities (123).
Cryptorchidism (both uni- and bilateral)
has increased exponentially in male cubs
since 1975 so that today > 90% of the male
population exhibits this phenomenon
(eight of nine cubs born since 1985). Male
sterility may be a problem as well. Female
panthers (n= 3) have high body burdens of
various contaminants including p,p'-DDE
(5.45-57.65 mg/g lipid fresh weight),
PCBs (7.32-27.06 mg/g lipid fresh
weight), oxychlordane (< 0.0098-2.00
mg/g lipid fresh weight) and trans-
nonachlor (< 0.0098-4.82 mg/g lipid fresh
weight) (122). Panthers also have elevated
tissue levels of mercury, methoxychlor, and
other lipophilic organochlorine com-
pounds. These contaminants are derived
primarily from their major food item, the
raccoon (124). The reproductive abnor-
malities described above were suggested to
be due to the contamination of mothers by
endocrine-disrupting environmental xeno-
biotics rather than to problems associated
with inbreeding (122).
Summary
Reproductive disorders in gastropod species,
reptiles, fish, birds, and mammals have been
associated with environmental factors.
Several of the disorders, such as sex reversal
in reptiles and vitellogenin production by
male fish, may result from estrogenic action
of chemicals in the environment. Fewer data
are available concerning the mammals.
However, some endangered species such as
Florida panthers that are exposed to estro-
genic and/or other endocrine-disrupting
contaminants show reproductive disorders
comparable to those found in the human.
Sexual Differentiation and the
Physiological Role of
Estrogens
Seal Differentiation
Sexual differentiation occurs during the
first trimester of human pregnancy (125).
An indifferent gonad develops into a testis
under the influence of the SRYgene on the
Y chromosome. In addition to SRY, there
are several downstream effectors and auto-
somal genes (e.g., SOX9 and SF-1) that are
required for normal differentiation of the
testis (126,127). Sertoli cells in the newly
differentiated testis produce Miillerian
inhibiting substance (MIS), which induces
regression of the Mullerian ducts that
would otherwise develop into the oviducts,
uterus, and upper part of the vagina. Sertoli
cells also regulate development and early
function of the Leydig cells that secrete
testosterone to promote differentiation of
the embryonic Wolffian ducts into the
male accessory sex organs, epididymides,
seminal vesicles, and vasa deferentia.
Masculinization of the external genitalia
and the rest of the body, except the brain, is
also controlled by androgens and occurs
after conversion of testosterone from the
testis into 5ax-dihydrotestosterone in the tar-
get tissue. Female reproductive organs
develop in the absence of SRYand thereby
in the absence of the testis (128). The
female developmental pattern seems to be a
genetic default pathway, and it is largely
independent of hormonal regulation.
Disturbances in sexual differentiation occur
when factors in the male developmental cas-
cade go wrong or when the genetic female is
exposed to an elevated plasma-androgen
concentration. In the first instance, a genetic
male will develop a female phenotype and in
the latter case a female will be virilized.
Disorders ofGenital Development and
Testicular Malignancy
The association between disorders of genital
development and sexual differentiation and
gonadal malignancy has been observed since
the beginning of this century and is now
well established (129-131). The most fre-
quent abnormality leading to neoplasia is
gonadal dysgenesis with the presence of Y
chromosomal material; other disorders
include true hermaphroditism and andro-
gen-insensitivity syndrome. Although the
general prevalence of disorders of sex differ-
entiation is low, the high incidence of germ
cell tumors makes the intersex gonad a good
model for the study of factors involved in
the pathogenesis of germ-cell neoplasia.
Malignant growth frequently appears in the
intersex gonad in early childhood, thus sug-
gesting that the carcinogenic process begins
in utero. The intersex syndrome comprises a
variety of genetic disorders, as different
from each other as, for example, XY/XO
mosaicism and a mutation in the androgen
receptor gene. The phenomenon of hetero-
geneous genetic defects leading to a com-
mon result, malignancy of germ cells,
indicates that any disruption of early
gonadal development may render the germ
cells susceptible to neoplastic transforma-
tion by yet unknown mechanisms. There
are some hypotheses concerning possible
mechanisms of neoplastic transformation
-e.g., arrested differentiation of immature
germ cells (132)-or an imbalance in fetal
hormonal environment (133). Androgen-
insensitivity syndrome provides a clue that
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the lack of the appropriate inductive hor-
monal environment may arrest fetal gonadal
differentiation and lead to neoplasia later in
life. It is possible that high levels of testicular
androgens have a protective function during
gonadal development; for example, a relative
excess of maternal testosterone during early
pregnancy was shown in black women com-
pared to a matched white group, providing
a possible explanation for the lower inci-
dence of testicular cancer in black men
(134). There is some experimental evidence
that androgens and estrogens may have
opposite effects on certain pathways in the
developing gonad; e.g., free estrogen may
decrease expression of MIS (135,136),
whereas androgens seem to have a stimula-
tory effect (137).
The Physiological Role ofEstrogens in
Sexual Differentiation
Estrogens act through a nuclear receptor that
is a ligand-activated transcription factor. In
addition, steroid hormones may effect the
cell membrane. Estrogens are essential in the
development of female secondary sexual
characteristics and in the female reproductive
cycle, fertility, and maintenance of preg-
nancy. In the developing male, the physio-
logical role(s) of estrogens is unclear, though
by analogy to the situation in adulthood,
they probably play a role in regulating the
differentiation and function of Leydig cells
(138). The role of estrogen action in embry-
onic sexual differentiation is controversial.
In rats and rabbits (139,140), estrogen syn-
thesis is activated in male and female
embryos at the time of blastocyst implanta-
tion in the uterus. Estrogen receptor mRNA
can be detected in blastocysts and two-cell
stage embryos (141). Immunohistochemical
studies by Greco et al. (142) demonstrated
estrogen receptor expression in both male
and female mouse gonads on fetal day 13
and 15. The gonads lose their estrogen
receptor expression at later ages. These
studies suggested a role for estrogens in
development of the gonads (143). A putative
molecular target of estrogens could be the
MIS gene that contains a DNA sequence
similar to the estrogen response element in
the upstream regulatory region (144). In
contrast, the classical organ ablation studies
by Jost (145) demonstrated that gonadec-
tomy of the embryo always resulted in a
female phenotype. However, maternal and
placental estrogens might still have con-
tributed to this developmental pattern.
Defects in the Estrogen Receptor Gene
Recent reports on estrogen receptor gene-
deleted mice (146) and a male patient
with a defective estrogen receptor (147)
have begun to clarify the possible impor-
tance of endogenous estrogens in sexual
development. Lubahn et al. (146) dis-
rupted the estrogen receptor gene by tar-
geted deletion that resulted in complete
estrogen resistance. Both male and female
mice survived to adulthood without appar-
ent morphological anomalies. However,
females were infertile with hypoplastic
uteri and hyperemic ovaries that contained
no corpora lutea. Fertility of the males was
also decreased. Only 3 of 15 males that
paired with normal females produced any
offspring, and even those that were initially
fertile lost their ability to sire subsequent
litters. Testicular weights were low and
sperm counts (in the testis and epididymis)
were only 10% of control. Weights of sem-
inal vesicles and coagulating gland were
normal. These findings suggest that estro-
gens are necessary but not indispensable for
fetal sexual development; i.e., development
is overtly normal, but the sexual organs do
not reach their normal size and function.
There is only one reported patient case
of estrogen resistance-a 28-year-old white
male (147). This man had incomplete epi-
physeal closure and therefore continued
linear growth into adulthood despite other-
wise normal pubertal development. He was
normally masculinized and had normal
male genitalia with bilateral descended
testes (20 and 25 ml) and a normal-sized
prostate gland. His sexual functions were
normal including morning erections and
nocturnal emissions. However, his semen
quality was subnormal: sperm concentra-
tion was 25 million/ml and viability 18%
(normal values: > 20 million; > 50%,
respectively). His serum testosterone con-
centration was normal, whereas estradiol,
estrone, follicle-stimulating hormone
(FSH), and LH concentrations were ele-
vated. The elevated gonadotropin concen-
trations suggest that estrogens play a role in
the regulation of gonadotropin secretion in
males, and thereby may have several indi-
rect effects. The patient case and the recep-
tor gene-deleted mice demonstrate that a
normal male phenotype develops in the
absence of estrogen receptor-mediated
influences, but semen quality and probably
fertility may be compromised as a result.
Overexpression ofthe
Estrogen Receptor
In transgenic mice that overexpress the
estrogen receptor, normal differentiation of
sexual organs was observed (148). However,
females in several transgenic lines had
fertility problems and their gestational
length was significantly prolonged, result-
ing in loss of litters due to difficulties in
parturition. No major fertility problems
were reported in the male transgenics. The
only abnormalities described in the males
(as well as in the females) were hernias of
the abdominal wall musculature. This is of
interest, since estrogen administration has
been reported to induce inguinal hernias in
male mice (149), and dogs (150,151), and
there is some indication that inguinal her-
nias are a risk factor for testicular cancer
(152). It is not known yet whether trans-
genic male mice that overexpress the estro-
gen receptor will develop testicular tumors
later in life.
Nonmammalian Vertebrates
Amphibians and birds differ from mam-
mals in their sexual differentiation (153).
That is, the female phenotype in birds
develops under estrogen control, whereas
the male phenotype appears in the absence
of estrogen (154). Exogenous estrogen
administration causes sex reversal in male
birds and frogs. Some reptiles (crocodilians
and some turtles) have temperature-depen-
dent sex determination; for example, in
turtles, female hatchlings are produced by
incubation of the eggs at a higher tempera-
ture than males, but an excess of estrogen
causes feminine differentiation also at low
temperatures typical of males (155,156).
Estrogen-induced sex reversal can be used
as a biomarker of the estrogenicity of an
environmental pollutant, as demonstrated
recently for PCBs (99). Estrogen receptors
are expressed both in female and male chick
embryos in the Miillerian ducts (154).
Interestingly, the left Miillerian duct that
develops into an oviduct in females
(regresses in male) has higher estrogen bind-
ing capacity than the right, which regresses
in both sexes (157). Treatment of chick
embryos with diethylstilbestrol (DES) on
day 5 prevented regression of the Miullerian
ducts in both sexes (158). Similar findings
in the mouse are reviewed in the section
"Effects of Synthetic Estrogens on the Testis
in Animal Models."
Estrogens and Sperm
Production Capacity
Sperm production is dependent on permis-
sive actions of FSH and testosterone (and
therefore LH). Sperm production capacity
depends on the number of Sertoli cells in
the seminiferous tubules (which is directly
related to the length of the tubules) (159),
since each Sertoli cell supports a finite
number of germ cells (160). Sertoli cells pro-
liferate quickly in rats from embryonic day
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19 to day 15 after birth, then slow down and
cease multiplication approximately on post-
natal day 20 (161,162). Multiplication is
largely dependent on FSH stimulation
(162). In humans, regulation of Sertoli-cell
proliferation may be very similar. Men
with hypogonadotropic hypogonadism do
not develop normal-sized testes after
gonadotropin treatment, which may be a
consequence of inadequate Sertoli cell
multiplication in early childhood. This
hypothesis is supported by findings in the
monkey (163): Sertoli cells proliferate in the
neonatal and infantile period but not during
or after puberty. Estrogens suppress
gonadotropin production in animals at all
ages preceding puberty (164). It is hypothe-
sized that this is the case also in humans.
Decreased gonadotropin stimulation during
the critical developmental phase may result
in inadequate Sertoli cell proliferation and
small testes (165). Specific FSH gene dele-
tion experiments also demonstrated that
FSH regulates the size of the testis (TR
Kumaar, personal communication). At pre-
sent it is not known whether the number of
Sertoli cells in human testes has decreased
and whether this might be a reason for
decreased sperm counts.
Summary
Normal masculine differentiation occurs
under the influence of the SRYgene and
several other autosomal genes, and andro-
gens are required for this process. Disorders
of gonadal development are frequently asso-
ciated with testicular germ cell neoplasia.
Estrogens act through a specific nuclear
receptor. Normal masculine differentiation
occurs even in the absence of a functioning
estrogen receptor, but the patient with the
receptor defect had poor semen quality.
Estrogen receptor-deficient male mice were
subfertile and few were able to sire one lit-
ter. Estrogens are involved in the feedback
regulation of gonadotropin secretion, and
the suppression of FSH secretion during the
period of Sertoli cell proliferation (perinatal
period) may result in small testes and a low
sperm production capacity in adult life.
Occurrence of Abnormalities
in the Reproductive System
of the Sons of Women
Exposed to Diethylstilbestrol
during Pregnancy
Exposure
Diethylstilbestrol (DES) was prescribed to
more than five million pregnant women
from the late 1940s to the early 1970s to
prevent abortions and pregnancy complica-
tions (166). Dieckmann and co-workers
performed a double-blind placebo-con-
trolled study on the therapeutic value of
DES during pregnancy in the early 1950s
(167). DES was given to 840 pregnant
women and placebo to 806 controls.
Compliance was verified by a dye indicator
in the urine during the whole study. The
women entered the study between weeks 7
and 20 of pregnancy (the majority during
weeks 10-12) and received increasing doses
of DES until pregnancy week 35 (5-150
mg/day). This study clearly indicated that
the medication was not efficacious in the
indications for which it was used (167).
Instead, in the reanalysis of the material of
Dieckmann et al. (167), DES was associ-
ated with significant increases in abortions,
neonatal deaths, and premature births
(168). When Herbst and co-workers
(169,170) reported the high incidence of a
very rare cancer, clear cell adenocarcinoma
of the vagina, in pubertal girls exposed to
DES in utero, the U.S. Food and Drug
Administration (FDA) banned the use of
DES during pregnancy. Medical authori-
ties in Europe that had allowed DES use
for pregnant women soon followed FDA
regulations. In Europe, approximately
200,000 French, more than 150,000
Dutch, 63,000 Czechoslovakian, and 7000
British women were exposed to DES,
whereas in the United States 4.8 million
women were prescribed DES during preg-
nancy. In addition, DES was used as an
anabolic agent in livestock, and the general
population that used dairy products and
meat may have been exposed to the hor-
mone via this route to an unknown, and
probably variable, extent. Some of the
DES-exposed daughters and sons have
been followed since the 1970s and a
significant number of abnormalities in the
structure and function of reproductive
organs have been described (171).
Structural Anomalies
Structural anomalies of the reproductive
organs that are significantly more frequent
in DES-exposed male subjects than in con-
trols include meatal stenosis (12.9 vs
1.8%); hypospadias (4.4 vs 0%); epididy-
mal cysts (20.8 vs 4.9%); testicular abnor-
malities, including hypoplastic testis,
cryptorchidism, and capsular induration
(11.4 vs 2.9%); and microphallus (4 cases
vs 0 cases) (172-174). The data of Bibbo
and Gill and their co-workers (173,174)
are based on the follow-up studies of the
offspring of mothers who took part in the
double-blind study of the effects of DES
on pregnancy in 1953 (167), and therefore
the studies can be considered prospective.
There were 308 men exposed to DES and
307 men exposed to placebo included in
the study; 31.5% of men exposed to DES
had an abnormality of their reproductive
tract, whereas only 7.8% of controls had
an anomaly (174). In the recent follow-up
study of these males, it was found that the
men who were exposed to DES before
week 11 of gestation had twice as high a
frequency of genital anomalies than did
those who were exposed only later (175).
This finding indicates the importance of
the timing of the exposure (time of organo-
genesis). In a small study comprising 17
DES-exposed men, 12 nonexposed volun-
teers, and 11 fertile control men, genital
anomalies (varicocele, epididymal cysts,
absent testes) were reported in 13 of the
DES-exposed subjects, 4 of the volunteers
and 4 of the fertile normal controls (176).
Whitehead and Leiter (177) reported geni-
tal abnormalities in 29 of 48 men exposed
to DES. Hypertrophy and squamous meta-
plasia of the prostatic utricle was found
more frequently in aborted male fetuses
that had been exposed to DES than in
nonexposed controls (178), suggesting that
DES-exposed males may have an increased
risk of prostatic hyperplasia and/or cancer
when aging. The data connecting DES
exposure to several structural abnormalities
of the male reproductive tract are convinc-
ing and leave little space for speculation on
confounding factors. However, no associa-
tion was found between first-trimester
exposure to sex hormones, other than
DES, and external genital abnormalities in
a recent metaanalysis of 14 studies (179).
In a large cryptorchidism study, no associa-
tion between the disorder and exposure to
estrogens during the pregnancy could be
found (180).
Semen Quality
Gill et al. (181) studied semen samples
from 88 men exposed to DES and 85 men
exposed to placebo, who were offspring of
the mothers from the 1953 study performed
by Dieckmann and co-workers (167).
Sperm concentration of men exposed to
DES was significantly lower than in the
controls (83 million/ml vs 123 million/ml,
p < 0.02). There was no difference in semen
volume, whereas the total sperm count,
sperm motility grade, the total number of
motile sperm, the percentage of sperm with
normal morphology, and the quality score
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were all statistically lower in men exposed
to DES. Azoospermia was found only in
men exposed to DES, and 20.5% com-
pared to 3.5% of men who received
placebo had a sperm concentration in
semen of less than 20 million/ml. The
groups did not differ in their testosterone,
FSH, or LH levels (173). In a later study
on the same men (20 controls declined to
participate), sperm concentrations still dif-
fered significantly, whereas other semen
characteristics were similar between the
groups (182). Similar results were obtained
in another study (176) in which the mean
sperm concentration of men exposed to
DES was 66.4 million/ml compared to
101.7 million/ml in normal volunteers
(p < 0.05). In this study, the zona-free
hamster egg penetration assay was also per-
formed: sperm from 14 of 17 men exposed
to DES failed to penetrate more than 14%
of the eggs (which is the reference value for
the normal fertility range), suggesting
infertility, whereas only 2 of 12 unexposed
volunteers and none of 11 fertile normal
controls had an abnormal test result. In the
study performed by Whitehead and Leiter
(177), only 33% of the men exposed to
DES had normal semen quality. However,
Andonian and Kessler (183) found no dif-
ference in semen quality between 24 men
exposed to DES and 24 age-matched
control men. Again, the large 1953 study
population that has been followed prospec-
tively appears the most valid for evaluation
of semen quality. On the basis of that find-
ing, DES exposure resulted in a significant
decrease in semen quality.
Semen quality and fertility are not in
direct correlation. In the latest follow-up
study of the Dieckmann cohort, no differ-
ence in the fertility between men exposed to
DES and their controls were found (175).
This is compatible with the earlier findings
(181) that the majority of the men exposed
to DES had sperm concentrations well
above the limit at which fertility is supposed
to be disturbed (20 million/ml), although
the mean sperm concentrations of exposed
men were lower than those of controls.
Testicular Cancer
There is no conclusive evidence to indicate
an increased risk of testicular cancer in
men exposed to DES (184), although the
incidence of cryptorchidism is a well-
known risk factor for testicular cancer and
has been observed more frequently in this
group (171). Two patient cases with
seminoma in men exposed to DES have
been reported (185), but epidemiological
studies have failed to show a statistically
significant relationship between DES expo-
sure and testicular cancer. There have been a
few case-control studies that evaluated pre-
natal hormonal risk factors for testicular
cancer (186-191). In the first study (186),
131 testicular cancer patients, under age
40, and their matched controls were ana-
lyzed. In 6 cases of cancer the mothers had
been treated with hormones during preg-
nancy, whereas only one mother of the
control cases had received any hormones.
The difference was not statistically
significant, but if another factor, nausea,
was combined with hormone treatment,
they formed a significant risk factor (rela-
tive risk 4.33).
In the case-control study of Depue et
al. (187), 108 testicular cancer patients,
under age 30, were studied. Mothers of 9
cancer patients had been treated with hor-
mones (2 with DES, 1 with estrogen, 1
with progestin, and 5 had pregnancy tests
consisting of a single injection of an estro-
gen-progestin preparation), whereas 2 con-
trols had either estrogen treatment or a
pregnancy test. The relative risk (8.00) was
significantly increased in the men exposed
to hormones (p = 0.02). However, the
exposures were very heterogeneous, and
single pregnancy tests can hardly be com-
pared to long-term DES treatment.
In a similar study comprising 202
cancer cases and 206 controls, Brown et al.
(189) found no excess risk associated with
the use of hormones during pregnancy:
mothers of 4 cancer patients and 5 control
mothers had received hormone treatment.
Two mothers in each group had been
treated with DES, 1 control with estrogen,
1 case with progesterone, 1 in each group
had a hormone pregnancy test, and 1 con-
trol had an unidentified hormone treat-
ment. However, it should be noted that 19
mothers in this study were medicated for
bleeding problems, but only 2 (both case
mothers) mentioned a specific hormone
used; 13 of the treated were case mothers
and 6 were control mothers.
In a case-control study of 273 testicular
cancer patients from northern California
(190), no association was found with the
mother's hormone exposure or DES expo-
sure. Mothers of 9 cases and 10 controls
had been treated with hormones (odds
ratio 0.9). Four of the case mothers and 2
control mothers were exposed to DES.
The case-control study of Schottenfeld
et al. (188) was based on questionnaires
received from 190 testicular cancer patients
(The Sloan Kettering Cancer Hospital,
New York), 166 hospital controls, and 143
neighborhood controls. There was no sta-
tistically significant association between
hormone treatment and cancer: 5.8%
(n = 11) of cases had been exposed to DES
or other hormones, whereas 2.1% (n =3)
of the neighborhood controls and 2.5%
(n = 4) of the hospital controls had received
exogenous hormones. Similarly, a
case-control study of 79 testicular cancer
patients from the Connecticut Tumor
Registry failed to show any increased
cancer risk in men exposed to DES (191).
The studies above have been described
in detail because they illustrate two major
problems. First, DES treatment may have
been initiated at various times during preg-
nancy; therefore, the presumed critical
period during which adverse effects of
estrogens might occur may have been
missed in some of these studies. Second,
the investigated populations of testicular
cancer patients have been too small to
determine if a significant difference truly
exists between DES-exposed and nonex-
posed men. When we combined the data
presented above in a metaanalysis, a mar-
ginally significant increase in testicular
cancer incidence for the individuals
exposed to hormones (including all hor-
mones) was found; Mantel-Haenszel esti-
mates of the common odds ratio was 2.1
with 95% confidence intervals of 1.3 to
3.3. Exposure to DES was a significant risk
factor for testicular cancer on the basis of
our metaanalysis: odds ratio was 2.6 with
95% confidence limits of 1.1 to 6.1. It
would be most important to obtain addi-
tional information on the incidence of tes-
ticular cancer in men born to mothers who
participated in the double-blind, placebo-
controlled DES trial in the 1950s (167).
Summary
Exposure to DES during pregnancy results
in an increased risk for several male repro-
ductive disorders, such as cryptorchidism,
urethral abnormalities, epididymal cysts,
and testicular hypoplasia. In addition, the
semen quality of DES sons is worse than
that of controls. Incidence of testicular
cancer is approximately doubled among
DES sons compared to the general popula-
tion, but whether this represents a true
increase of the cancer risk is equivocal.
Effects of Synthetic
Estrogens on the Testis in
Animal Models
Synthetic estrogens, such as DES, ethinyl
estradiol, and estradiol benzoate have been
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thoroughly studied in several animal models
because of their pharmaceutical applica-
tions. There are comprehensive reviews
covering this topic (164,192,193).
Mechanism ofAction
The effects of estrogens depend on the
dose, time, and probably the duration of
exposure. Estrogens also act at several levels
in the reproductive system, i.e., they
influence specific neuronal areas in the
brain, they modulate gonadotropin secre-
tion from the pituitary gland, and they
directly affect the reproductive organs.
Estrogens probably exert most or all of
their effects through a specific receptor;
such receptors are present in the brain,
pituitary, gonads, and accessory sex organs
at one or another time during fetal, prepu-
bertal, or adult life (143). However, the
precise localization and temporal expres-
sion of estrogen receptors during differenti-
ation and development of the testis and
male reproductive tract are poorly
described and further, more definitive,
studies are needed. The effects of DES are
not unique to this compound but are prob-
ably shared by all estrogens (164). Many of
the synthetic estrogens are more effective
in lower doses than endogenous estradiol
because they are not bound by sex hor-
mone-binding globulin (SHBG), which
normally binds approximately 95% of cir-
culating estradiol, rendering it biologically
inactive. Estrogens are metabolized rapidly
in the testes, e.g., by specific sulfotrans-
ferases, after which they cannot bind to
their receptor (194). If the active center of
the enzyme is occupied by a xenobiotic,
metabolism of endogenous estrogens may
be disturbed and high levels of active hor-
mone may be available. This is particularly
important during fetal development when
the levels of ambient estrogens are high.
Adverse Effects of
Neonatal Estrogen Treatment
Long-lasting suppression of spermatogene-
sis and atrophy of reproductive organs in
neonatally estrogen-treated rats and mice
have been described by many workers since
the 1950s (164). A single injection of
estradiol benzoate (250 pg on day 5)
resulted in a marked delay of the onset of
puberty in rats (195). When mice were
treated with repeated doses of estradiol on
days 1 to 5 after birth, the testes were irre-
versibly damaged, and subsequent treat-
ment with testosterone and gonadotropins
failed to maintain spermatogenesis in the
majority of these estrogenized mice (196).
These two studies are cited because they
indicate that estrogens given neonatally act
directly on both the testes and the pituitary
gland. It is noteworthy that the neonatal
period in rodents corresponds in many ways
to the second and third trimesters of preg-
nancy in the human.
Adverse Effects of
Prenatal Estrogen Treatment
Prenatal (day 11 and 12 postcoitum) expo-
sure of mice from the Sv-Sl CP strain (a
strain in which the males are susceptible to
testicular teratomas) to ethinyl estradiol
resulted in an increased incidence of cryp-
torchidism (p= 0.0001), and 19 of 224
exposed male animals developed testicular
teratoma compared to 4 out of 107 controls
(the odds ratio of 2.4 was not significantly
different) (197).
McLachlan and co-workers have per-
formed a large series of studies on the
effects of prenatal exposure of mice to DES
(192,193). In most of the studies, preg-
nant mice were treated with 0.01, 1, 10, or
100 pg/kg/day DES or corn oil on days 9
to 16 of pregnancy (time of sexual differen-
tiation). The high doses are closely equiva-
lent to those used for pregnant women
(173). Male offspring from these pregnan-
cies suffered from the same structural and
functional anomalies reported in men
exposed to DES, i.e., epididymal cysts, cel-
lular atypia in the prostate, cryptorchidism,
testicular hypoplasia, poor semen quality,
and subfertility (192). In addition, Sertoli-
cell hyperplasia, interstitial testicular
tumors, squamous metaplasia of the semi-
nal vesicles, and rete testis adenocarcinoma
were found frequently in the male offspring
of mice exposed to DES during pregnancy
(198). The analogy between the findings
in the human and the mouse illustrates
how informative and relevant the results
from animal studies are.
Estrogen Effects on the
Mullerian Ducts
Miillerian inhibiting substance secreted by
Sertoli cells is responsible for regression of
the Mullerian ducts. Analysis of male
mouse embryos exposed to DES revealed
delayed and incomplete regression of the
Mullerian ducts (192). In vitro organ cul-
ture experiments verified the inhibitory
action of DES on Mullerian duct regres-
sion (136). Estrogen receptors were found
both in the Miillerian ducts and Sertoli
cells at the time of regression (143).
Estrogens could either affect the Mullerian
ducts directly or influence the expression of
the MIS gene in the Sertoli cells. Some of
the structural abnormalities observed after
birth may arise as a result of incomplete
regression of the Miillerian ducts (198).
Estrogen Effects on the
Developing Testis
Reports on various experimental animals
(e.g., sheep, rats, mice) describe how expo-
sure to exogenous estrogens during the
neonatal period causes drastic reductions in
the secretion of FSH from the pituitary
gland and the presumption is that similar
effects would occur before birth (199). As
FSH plays a vital role in controlling multi-
plication of Sertoli cells at this time (138)
the prediction would be that estrogen-
induced suppression of FSH levels would
lead to a slower rate of Sertoli cell multipli-
cation. As the number of Sertoli cells
formed in fetal/neonatal life is an important
factor influencing the maximum level of
sperm production in adult life, the conse-
quences of such a change in terms of sperm
counts is obvious; moreover, such an effect
is irreversible once Sertoli cell multiplica-
tion stops in early postnatal life. There is
abundant evidence from man (hypogo-
nadotropic hypogonadism) and from animal
species that suppression of FSH levels in
early postnatal life results in just such
changes [reviewed by Sharpe (138)]. Recent
evidence from the fetal sheep (165) also
shows that suppression of FSH secretion in
the fetal male during the second half of
gestation results at birth in testes that con-
tain 40% fewer Sertoli cells than occurs in
control animals.
It is therefore hypothesized that pro-
longed exposure of the developing male,
during both fetal and postnatal life, to
exogenous estrogens (perhaps even at low
levels) could reduce Sertoli cell number
and thus reduce sperm output (and sperm
counts) in adult life. Experiments involving
exposure of rats to various xenoestrogens
during the period of Sertoli cell multiplica-
tion have shown that in adult life such
exposure results in small (8-12%) but
highly significant reductions in testis size
and a corresponding decrease in daily
sperm production (200). These effects
have been achieved after exposure to rela-
tively low levels of the chemicals (alkylphe-
nols, phthalates; 1 mg/liter in drinking
water of pregnant rats) under test. For
example, butylbenzyl phthalate has been
found to occur in butter and margarine at
concentrations as high as 47.8 mg/kg (201).
Such findings suggest that there is the theo-
retical possibility that human exposure to
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such chemicals might have contributed to
the decline in sperm counts in men
described earlier.
Summary
Diethylstilbestrol treatment of experimental
animals in utero results in increased inci-
dence of cryptorchidism; urethral abnor-
malities; testicular hypoplasia; poor semen
quality; and infertility, abnormalities in
accessory sex organs, rete testis adenocarci-
noma, interstitial cell hyperplasia, and
tumors. Thus, the outcome of DES expo-
sure of experimental animals is highly analo-
gous to the findings in humans. Recent data
in the rat suggest that perinatal exposure to
xenoestrogens, such as butylbenzyl phtha-
late, results in decreased size of the testes
and daily sperm production in adult life.
Environmental Chemicals
with Known Estrogenic
Effects
Estrogenic effects are not restricted to a
small group of therapeutic agents but
appear in several groups of compounds
that are used daily in industry, agriculture,
or in the home (79,80,202-204). The
major groups of environmental chemicals,
such as organochlorine pesticides, PCBs,
dioxins, alkylphenol polyethoxylates, phy-
toestrogens, and other xenoestrogens, cur-
rently known to have estrogenic effects in
vertebrates or in assays in vitro are dis-
cussed here. A major problem is the deter-
mination of those chemicals that are
estrogenic (or otherwise endocrine-disrupt-
ing, i.e., disturbing normal endocrine
homeostasis). At present, tens of thousands
of man-made chemicals are being used, yet
the effects on the endocrine system have
been studied for only a few of these. The
estrogenic activity of the majority of chem-
icals (e.g., alkylphenols, phthalate esters,
bisphenol-A) has been detected by acci-
dent, not by intent, although recently some
screening of chemicals used in large vol-
umes has been attempted (204). Hence, it
is highly possible that other estrogenic
chemicals remain unidentified. However, it
should be remembered that many of the
chemicals to which man is exposed have
been tested (often in two- or three-genera-
tion studies) before being approved for use;
and hence, if any of these chemicals were a
strong estrogen, this would probably have
been discovered. This is especially the case
for chemicals that are currently approved for
use in food production, such as food addi-
tives and pesticides, and for new chemicals
that have been produced in large amounts
from the early 1980s in the European
Union (EU). The current legislation
demands extensive documentation for
safety by regulatory agencies before a
chemical can be used in foods or commer-
cial products. However, many chemicals
were introduced before these strict regula-
tions were enforced. Thus, the present situ-
ation is that man and wildlife are exposed
to a very wide range of chemicals. For the
majority of these we do not know whether
they are estrogenic, whether their effects
are additive, or even what the true expo-
sure to these chemicals is.
A xenoestrogen can induce its estro-
genic effect in multiple ways: it may act
directly through estrogen receptors, or it
may disturb estrogen metabolism, thus
increasing the levels of the endogenously
produced ligand. Different estrogenic and
antiestrogenic ligands form functionally
different complexes with the estrogen
receptor, and their transcriptional effects
depend on the cell type and promoter
(205). Thus, the same compound may
potentially have an estrogenic effect in one
system or at one concentration, and an
antiestrogenic effect in another system or at
another concentration. Furthermore, effects
of many compounds influencing other hor-
mone systems (e.g., antiandrogens) may
mimic those of estrogens.
A number of chemicals, mainly pesti-
cides and many of which are currently
being used, have been implicated as envi-
ronmental hormones possessing endocrine-
disrupting properties (80). In the public
debate on male reproductive disorders, this
has misled many to suppose that all of
these chemicals are estrogenic. In fact,
many of these compounds have not been
adequately tested for estrogenic activity.
However, for many others, a large toxico-
logical database exists, including data on
reproductive toxicity, effects on steroid-
metabolizing enzymes, and effects on hor-
mone-producing tissues. A short summary
of the most relevant toxicologic effects
known for a number of xenoestrogens and
other environmental chemicals that have
been implicated as environmental hormones
is given in "Appendix A." It also outlines the
safety assessment procedures and principles
applied world-wide by regulatory agencies.
Below is a short examination of each of
the groups of chemicals that are known to
be estrogenic.
Organochlorine Pesticides
Organochlorine pesticides include
dichlorodiphenylethanes (DDT, DDD,
DDE, dicofol, perthane, methoxychlor),
cyclodienes (chlordane, oxychlordane, trans-
nonachlor, heptachlor, heptachlorepoxide,
aldrin, and dieldrin), hexachlorobenzene,
and hexachlorocyclohexanes (206). Many
of these, most notably DDT, were used in
large quantities until the 1960s when the
use of DDT was banned or restricted in
Western countries. Hexachlorobenzene,
however, was used in the United States
until 1985. DDT products are still used
widely in many developing countries.
Despite restrictions on their use, these
compounds are still circulating in the envi-
ronment because many of them bioaccu-
mulate and become concentrated in body
lipids (biomagnify). The breakdown and
elimination of these compounds is very
slow; therefore, their effects can be persis-
tent, lasting for generations (DDT has a
half-life of > 60 years in the environment).
Long-term exposure to small amounts of
organochlorine contaminants leads to the
accumulation of considerable burdens in
animal and human tissues (207,208). It is
therefore not the amount ofDDT to which
a mother is exposed during pregnancy that
is critical but rather her lifetime exposure
that will determine the level of exposure of
the fetus and the breast-fed infant.
Commercial DDT contains several iso-
mers of which p,p'-DDT is the most preva-
lent (75-80%), whereas the proportion of
the most estrogenic isomer o,p'-DDT is 10
to 25% (89,209). The o,p'-isomers are less
stable than the p,p' configurations and are
therefore found only in low concentrations
in nature (210). However, p,p'-DDT was
also reported to have estrogenic actions
both on the rat uterus (211) and in the
MCF-7 breast cancer cell line (212). The
estrogenic activity of DDT isomers
compared to that of estradiol is very weak
(103_106 times less potent). However, the
long half-life and bioaccumulative proper-
ties of DDT indicate that levels of human
exposure may be sufficient to induce
estrogenic effects in certain circumstances.
This is particularly true for the period
from the 1940s to 1960s when DDT was
used widely including in direct application
to humans.
Antiandrogenic (demasculinizing) and
estrogenic (feminizing) effects often mani-
fest themselves in the same way, although
through distinct receptors (213). Therefore
the recent discovery that p,p'-DDE, the
main metabolite of DDT in the body, is a
potent antiandrogen (214) may explain
some of the estrogenic effects observed in
the environment; many of these effects
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may occur due to an antiandrogen activity
of a xenobiotic.
Fry and Toone (115) induced femi-
nization in male California gulls (Larus
californicus) by injecting eggs with DDT in
amounts that were comparable to those
found in seabird eggs in southern California
in the late 1 960s. A skewed sex ratio in favor
of females in large gull populations
suggested the possibility of a causal relation-
ship with the estrogenic action of DDT
(86). The effects of DDT metabolites and
dicofol in reptiles have been discussed in the
section "Changes in Male Reproduction in
Wildlife. Estrogenic Effects on Developing
Animals." In mammals, the effects of DDT
compounds on male reproductive function
are less apparent (215).
Methoxychlor is estrogenic in the E-
SCREEN assay (204). It was also found to
be estrogenic in vivo in rats (216).
Methoxychlor or DDT exposure of neona-
tal rats did not affect male reproductive
organ weights in adulthood (217), and
neither induced epididymal cysts (218),
which were found frequently in mice
exposed to DES (192). However, exposure
throughout gestation and lactation in
rodents resulted in slightly smaller testes and
epididymides and in lower sperm counts in
male offspring than in controls (219,220).
It was suggested that the inability of the
neonatal rodent to metabolize methoxychlor
to its active estrogenic form might explain
the discrepancy between these studies (220).
Chlorinated cyclodienes induce liver
enzymes that hydroxylate testosterone
(221). Chlordane disturbed spermatogene-
sis and caused dose-related damage to the
testes of mice fed for 30 days with 0.08 mg
or 0.25 mg of the active ingredient (222).
Mating studies of dieldrin-exposed rats sug-
gest male-dependent disturbances in fertility
(223). In the E-SCREEN assay, chlordane
and heptachlor were not estrogenic, but the
heptachlor derivative 1-hydroxy chlordane
was (212). In addition, dieldrin was shown
to be estrogenic (81).
Hexachlorobenzene was also reported
to induce liver enzymes hydroxylating
androgens (221). Long-term studies have
demonstrated liver and kidney anomalies
in exposed animals but indicate no effect
on fertility (224).
Hexachlorocyclohexanes (HCHs) com-
prise several isomeric forms; these com-
pounds are also called benzene hexachloride
(BHC). y-HCH has the common name lin-
dane and is the most acutely toxic of the
isomers (215). The most persistent and
bioaccumulating isomer is ,-HCH, which
accounts for 90% of the total HCH found
in human milk (225). Lindane was reported
to have both estrogenic and antiestrogenic
effects in female rats (226). In male wean-
ling rats fed with ,B-HCH (0, 2, 10, 50, or
250 mg/kg) for 13 weeks, liver enzyme
induction occurred at doses > 2 mg/kg;
testis weights decreased at doses > 50
mg/kg; and testicular atrophy resulted
from a dose of 250 mg/kg (227).
In hamsters, a single injection of the
weakly estrogenic chlordecone (Kepone) in
neonatal males reduced testicular and epi-
didymal weight (228). Estrogenicity of
chlordecone was also demonstrated in rats
(229) and birds (230).
Polychiorinated Biphenyls
Polychlorinated biphenyls are industrial
chemicals used since 1929 as heat transfer
and hydraulic fluids, adhesives, flame retar-
dants, dielectric fluids for capacitors and
transformers, and waxes (231). PCBs con-
sist of 209 congeners, which are found in
different mixtures in commercial products.
Before the production of PCBs was banned
in the United States in 1977, hundreds of
millions of kilograms were produced, and a
large proportion of the synthesized product
is still in the environment because of bioac-
cumulation and slow biotransformation.
The biological effects caused by the var-
ious congeners differ, not only in potency
but also qualitatively. Several non-ortho-
and mono-ortho-substituted PCB con-
geners induce effects similar to those
caused by chlorinated dioxins and dibenzo-
furans; i.e., the toxicity is probably medi-
ated through interaction with the aryl
hydrocarbon (Ah) receptor. Other PCB
congeners presumably act by different
mechanisms. In addition, there are PCB
congeners that are intermediate in this
respect; i.e., they elicit a mixed spectrum of
effects. Our knowledge of possible interac-
tions between the various groups of PCBs
is still very limited (232).
Both estrogenic and antiestrogenic
effects have been reported for different
PCB congeners (233). The estrogenic
potency appears to depend on the percent-
age of chlorine: less-chlorinated PCBs
(Aroclors 1221, 1232, 1242, and 1248)
have estrogenic activity whereas more chlo-
rinated congeners do not (209). The stabil-
ity of the compounds increases with higher
chlorination. Less-chlorinated compounds
were shown to transfer more readily across
the placenta than were the highly chlori-
nated PCBs (234). PCBs are hydroxylated
in animals, and these hydroxybiphenyls are
quite active as estrogenic compounds [i.e.,
more than 1/100 of estradiol activity
(235)]. Antiestrogenic effects have been
found in MCF-7 breast cancer cells with
3,3',4,4'-tetrachloro-biphenyl (a dioxinlike
PCB), a form known to bind to the Ah
receptor, mediating the effect (233).
Reproductive failure of seals in the Wadden
Sea has been attributed to PCBs (236), and
has been supported by laboratory studies
(121). However, this relationship may not
necessarily have been a consequence of the
estrogenicity of the PCBs.
Dioxins and Furans. Polychlorinated
dibenzo-p-dioxins (PCDDs) and polychlori-
nated dibenzofurans (PCDFs) consist of 75
and 135 different congeners, respectively
(237). The most toxic congener is 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), com-
monly referred to as dioxin. These
compounds are formed as unwanted by-
products in the manufacture of chlorinated
hydrocarbons. Other sources include incin-
eration processes, paper and pulp bleach-
ing, and emissions from steel foundries and
from motor vehicles (238).
Most of the animal studies on dioxins
have been performed with TCDD
[reviewed by Peterson et al. (239)].
Dioxins act through an Ah receptor that is
also involved in mediating the antiestro-
genic effects of TCDD (240,241).
However, the role of the Ah receptor has
not been established for several of the toxic
effects that are found in males exposed to
TCDD (242). There is considerable litera-
ture documenting the toxic effects of diox-
ins on the male reproductive system
(239,242). Prenatal and lactational expo-
sure of male rats to TCDD profoundly dis-
turbed the developing male reproductive
organs: anogenital distance was shortened,
testicular descent was delayed, and the
weights of all sex organs were reduced
(243). Furthermore, spermatogenesis was
inhibited, sexual behavior was feminized
and demasculinized, and the regulation of
LH secretion was feminized (244-246).
Perinatal suppression of plasma testos-
terone concentrations appeared to be
involved in the changes described. The
effects were elicited by a single maternal
oral dose of TCDD on day 15 of
pregnancy [ED50 approximately 0.16
pg/kg; at this dose, TCDD had no dis-
cernible effect on the mother (242)]. Most
of the effects were found at the lowest dose
level tested (0.064 pg/kg), whereas in other
studies, reproductive toxicity had been
observed with doses of < 0.001 Ipg/kg/day
(247,248). The mechanism of action of
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dioxins and furans may not be primarily
estrogenic or antiestrogenic (e.g., anti-
estrogenic effects of TCDD cannot be
reversed by high estrogen concentrations),
but it is certainly a hormonelike effect.
This necessitates the close surveillance of
humans exposed to TCDD.
Alkylphenol Polyethoxylates
Alkylphenols and related compounds are
present in surface waters and aquatic sedi-
ments (249-251). They are products of
the microbial breakdown of alkylphenol
polyethoxylates (APEs) that are widely
used in industrial surfactants (250,251).
These effective, nonionic surfactants are
used in detergents, paints, herbicides, pesti-
cides, and cosmetics, to name a few major
groups of products. Over 300 million kilo-
grams of APEs are produced annually. After
sewage treatment, approximately 60% of the
APEs are released into the aquatic environ-
ment as short-chain APEs (e.g., nonylphe-
noldiethoxylate [NP2EO]), alkylphenol
carboxylic acids (e.g., nonylphenoxycar-
boxylic acid [NPlEC]), and alkylphenols
(e.g., nonylphenol [NP]; and octylphenol
[OP]) (252-254). Alkylphenols are rela-
tively persistent and bioaccumulate in the
lipids of living organisms (255,256).
NP and OP were shown to be estro-
genic both in vivo and in vitro in mam-
malian systems (202,257). The effects
were estrogen receptor mediated. OP was
more potent than NP, reaching approxi-
mately 1/1000 of the potency of estradiol.
In the trout hepatocyte assay, many other
APEs were also shown to be weakly
estrogenic (111).
Phytoestrogens
Phytoestrogens are natural compounds pre-
sent in plants and are ingested daily in mil-
ligram quantities. The active substances are
isoflavones (genistein and daidzen) and
coumestans (coumesterol) (258). Fungal
metabolites, such as zearalenone, found in
foodstuff (e.g., grain) also belong to the
phytoestrogens. Reproductive disorders in
sheep are well documented after the eating
of red clover containing high amounts of
genistein (259). Some of the food prod-
ucts rich in phytoestrogens include rye,
wheat, cabbage, sprouts, spinach, and soy-
bean. Soybean is by far the richest source
of plant estrogens and is used ubiquitously
in the food industry as a protein source,
including infant milk formula substitutes.
Phytoestrogens may not bioaccumulate or
biomagnify but they are readily metabo-
lized and excreted (260).
Phytoestrogens have been shown to
have estrogenic effects both in vitro and in
vivo (212,258,261). Feeding of rams with
clover that is rich in isoflavone resulted in
decreased sperm counts (262,263). The
effects are receptor mediated and depending
on the dose are either estrogenic or antie-
strogenic in an adult animal (264,265).
Because of these potential antiestrogenic
effects, high doses of isoflavones in the diet
have been proposed as being beneficial for
reducing the risk of hormone-dependent
cancers (266). However, little considera-
tion has been given to neonatal and
childhood life when exposure to phytoe-
strogens would be presumed to have non-
beneficial effects.
Other Xenoestrogens
Bisphenol-A, a plastic monomer that was
released from polycarbonate flasks during
autoclaving, was shown to have an estro-
genic effect on MCF-7 breast cancer cells
(267). Notably, bisphenol-A is used exten-
sively as a plasticizer, e.g., it is used in the
lacquer coating of food cans that are then
heated for sterilization purposes (268).
Other common chemicals used in the plas-
tic industry include the phthalate esters,
butylbenzyl phthalate and di-n-butylphtha-
late, which were shown to act as weak
estrogens on breast cancer cells (203). In
the E-SCREEN assay, di-n-butylphthalate
was not estrogenic (204). Neither of the
phthalate esters had antagonist effects, sug-
gesting that their action may be cumulative
(203). Phthalates are the most abundant
man-made environmental pollutants; and
human intake per day by various routes,
especially through the diet, is measured in
tens of milligrams (201). A food antioxi-
dant, butylated hydroxyanisole (BHA), was
also estrogenic in breast cancer cell assays
(203). However, the estrogenic potency of
BHA and phthalate esters was lower than
that of octylphenol or o,p'-DDT.
Summary
Numerous environmental chemicals, such
as many organochlorine pesticides, PCBs,
alkylphenol polyethoxylates, phthalates,
and phytoestrogens are known to have
estrogenic effects in vertebrates or in assays
in vitro. However, only a few of the tens of
thousands of man-made chemicals have
been tested for estrogenic or other
endocrine activity, and therefore, it is
highly possible that other estrogenic chem-
icals remain unidentified. A major problem
at present is how to fill this gap in our
knowledge rapidly and cost effectively.
Exposure of Humans to
Environmental Chemicals
with Estrogenic Activity and
Their Effects on Male
Reproductive Health
The major routes of exposure to man-made
chemicals are thought to be
* Dietary: pesticides, (including chemicals
used in the formulation of commercial
products), food additives (including
synthetic flavoring substances), contam-
inants (such as PCBs, dioxins, metals,
industrial chemicals, especially those
that are biomagnified in food chains),
packaging and wrapping materials (e.g.,
plastics, food wraps)
* Environmental: from the pollution of
air and water
* Domestic: from contact with house-
hold products, cosmetics, clothing, and
probably many others
* Occupational: inhalation, dermal con-
tact and ingestion of active compounds,
depending on the occupation.
Occupational exposure has not been
considered in any detail in this report,
which is aimed at describing the situation
for the general population. However, valu-
able information on possible association
between exposure to chemicals and effects
on humans may originate from studies in
occupational settings where high exposures
have taken place. Because of better docu-
mentation and higher exposure, such
studies are more likely to reveal adverse
effects of chemicals on humans than are the
studies on the general population (269).
The diet is usually regarded as the most
important source of foreign chemicals.
Very preliminary estimates of some expo-
sures in Denmark are included in
"Appendix A." It should not be overlooked
that the exposure via routes other than
food, such as air, drinking water, and par-
ticularly the skin (e.g., detergents) may be
highly significant. Current knowledge on
actual exposures is rather limited, in partic-
ular with regard to the domestic exposure
to chemical products. A close examination
of all possible exposures to chemicals sus-
pected to be environmental hormones has
not been possible within the constraints of
this report. Humans may be exposed to
xenoestrogens in multiple ways. Direct
administration of synthetic hormones, such
as DES or ethinyl estradiol is obvious, but
the same hormones may be found in meat
and dairy products in some countries
(270). Cow's milk has a high concentra-
tion of endogenous estrogens during late
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gestation, and this milk is also collected for
human consumption. The ratio of estro-
gens in this milk to that in plasma is
generally greater than one (271), and
therefore much higher than in human
breast milk. Occupational exposure in the
pharmaceutical industry is a possibility for a
small minority. Estrogens occur in measur-
able amounts in sewage effluent used for
irrigation (272). Phytoestrogens are ingested
in large amounts, and weakly estrogenic
alkylphenolic compounds are applied to the
skin and ingested daily. Important issues to
consider are the quantity of estrogenic com-
pounds present, their potency, their capabil-
ity to bioaccumulate and biomagnify, and
their additive, synergistic, or antagonistic
effects. Concentrations of organochlorine
contaminants in human reproductive tissue,
adipose tissue, and blood from the general
population (Table Al) and in human breast
milk (Table A2) worldwide are included in
"Appendix 1"[adapted from Thomas and
Colburn (206)].
Organochlorine Pesticides and
Polychlorinated Biphenyls
The daily intake of DDT is now small in
Europe and North America, and it may
not have a significant influence alone.
Chlordecone (Kepone), which is estrogenic,
caused an occupational risk to workers
exposed to high levels of the compound:
exposed men had oligozoospermia,
decreased sperm motility and abnormal
sperm morphology (273).
Exposure to several organochlorine pes-
ticides and PCBs at the same time may
lead to untoward effects, as exemplified by
the suggested association between slight
disturbances of development in children
exposed in utero and contaminants present
in Lake Michigan fish (274-278). The risk
was related to lifetime intake of contami-
nated fish by the mothers and to PCB levels
in maternal serum and milk rather than to
intake during pregnancy. Reproductive dis-
orders have not been described, but the
affected male children have not yet reached
reproductive age. These studies have been
extensively debated, and more investiga-
tions in populations with well-known high
exposures are needed to resolve this issue.
Levels of some PCB congeners were
inversely correlated to sperm motility in
semen samples in which sperm concentra-
tion was < 20 million/ml (279). The small
number of subjects in the study leaves the
significance of the finding open. Severe
poisoning accidents occurred in Yusho,
Japan, and Yu-Cheng, Taiwan, where a
large population ate rice oil contaminated
with PCBs, PCDFs, and polychlorinated ter-
phenyls. Exposed pregnant women had
increased fetal loss and the surviving infants
had low birth weight (280). The exposed
infants were delayed in their developmental
milestones. The behavioral effects were prob-
ably mainly due to exposure in utero, since
the effects were also found in bottle-fed
infants (232). The boys at pubertal age (11
and 14 years of age; n = 23) exposed prena-
tally to very high levels of contaminants
had significantly smaller penis lengths
when compared to controls, whereas 31
boys at prepubertal age (8 and 10 years of
age) did not differ from controls (281).
The plasma levels of PCBs in Yusho were
originally 0.01 to 0.1 ppm while body fat
levels ranged up to 76 ppm. In the normal
population the corresponding figures are
<0.005 ppm and 0.5 to 10 ppm (282).
The reproductive ability of the exposed
males has yet to be ascertained.
Dioxins and Furans. Humans are nor-
mally exposed to dioxin and furan levels far
below those that induce reproductive disor-
ders in animal experiments (206). After
the Seveso accident in Italy in 1976 where
a factory exploded during the production
of 2,4,5-trichlorophenol, TCDD serum
levels on a lipid basis ranged from 1770 to
56,660 ppt (ng/kg) in exposed children
(283), while the background concentration
in human milk fat is approximately 2 ppt
(225). No reproductive disorders in adults
have been described after the accident
(284,285), though the exposed male chil-
dren have not yet been evaluated.
Recendy Found Xenoestrogens
Measurement of human exposure to
alkylphenols, phthalate esters and bisphe-
nol-A is difficult because the data are still
sparse. There is, however, considerable
concern because these compounds are so
ubiquitous in the modern environment.
Some nonylphenol ethoxylates and one
octylphenol ethoxylate were found at con-
centrations of 15 to 29 ng/liter in drinking
water in New Jersey (286). In different
fish species, concentrations of 0.13 to 3.1
mg/kg dry weight of nonylphenol and its
two ethoxylates have been found (256).
Since these compounds have very weak
estrogenicity, it is too early to estimate
whether environmental exposure to them
has any influence on humans, as the level of
exposure of man is not known. However,
for phthalates it is established that human
intake per day is likely to be several
hundreds of micrograms per kilogram per
day, from certain food sources alone
(201). This level of intake would be
likely to result in estrogenic effects based
on data from in vitro (203) and in vivo
(200) studies, though not all phthalates
may be estrogenic.
Phytoestrogens
Large amounts (hundreds of milligrams) of
phytoestrogens such as isoflavones can be
ingested daily by humans, especially in a
vegetarian diet. Antiestrogenic action of
isoflavones was demonstrated in women
who consumed a soy protein-enriched diet
containing 45 mg isoflavones daily for 1
month: the follicular phase was prolonged,
and the midcycle surge of LH and FSH
was suppressed (266,287). This may have
occurred because of phytoestrogen-
induced production of SHBG, which
would reduce bioavailability of endoge-
nously produced estrogens. In post-
menopausal women, dietary soy induced
no significant estrogenic or antiestrogenic
effects (288). SHBG and gonadotropin
levels remained unchanged in these
women, whereas the vaginal epithelium
showed a tendency for a higher percentage
of superficial cells (indicative of estrogenic-
ity). A study of postmenopausal women in
Australia suggested an estrogenic influence
by phytoestrogens on the vaginal epithe-
lium (289). Many infants are fed with soy-
based milk-substitute formulas rich in
phytoestrogens. There are no data avail-
able about the possible endocrine effects in
children, but it is presumed that the
situation would be radically different from
the adult because of the negligible endoge-
nous production of estrogens in infancy
(especially in male infants). Female rats
exposed neonatally to phytoestrogens show
an increased incidence of premature
anovulatory syndrome in adult life. This
syndrome is recognized as a classical conse-
quence of inappropriate exposure to
estrogens in neonatal life (290). Many
phytoestrogens, such as lignans and
isoflavonoids, are metabolized and excreted
in urine similarly to endogenous estrogens
(260). Thus, they may not bioaccumulate
in the body.
Summary
Humans are exposed to environmental
estrogens in multiple ways. Diet, drink-
ing water, air, and the skin are the routes
through which xenoestrogens enter the
body. Several of the known xenoestrogens
have a weak estrogenic activity but are
highly persistent and accumulate in fat.
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Moreover, many of them have additive
effects. Some of these compounds, such as
phthalates, are present in high concentra-
tions in certain food items, whereas
concentrations of pesticides and PCBs are
very low. The level of exposure to pesticides
and other contaminants is rather well mon-
itored, whereas very little is known about
exposure to other xenoestrogens.
Methods for Evaluation of
Estrogenlike Effects, Human
Exposure to Estrogenic
Compounds, and Trends in
Male Reproductive Health
The complexity of our chemical environ-
ment is increasing continuously, and it
may not be possible to forecast all of the
effects of compounds released in nature.
However, we have to use all the available
methods and develop new ones to monitor
possible adverse effects of chemicals and
natural compounds on human and
wildlife. Reproduction is a major concern
because disturbances of this process rapidly
threaten populations as a whole. The male
reproductive system is very sensitive to the
influence of an excess of estrogen; there-
fore, estrogenlike effects in the environ-
ment are a primary suspect for causing the
increased reproductive disorders of men
and wildlife animals.
Test methods are needed to screen
chemicals for estrogenic effects. Further
methods are needed to assess estrogenic
exposure of humans and other species.
Methods to analyze the mechanism of
action of estrogenic compounds are neces-
sary. And finally, it is important to assess
the reproductive toxicity of chemicals and
to predict their effects in the environment,
including the effects on organisms, popula-
tions, communities, and ecosystems.
Epidemiology
The general research question is whether
exposure to environmental estrogens, in par-
ticular during fetal or neonatal life, has
adverse effects on the male reproductive sys-
tem. When designing epidemiological
studies to evaluate this question, one has to
consider both exposure and reproductive
health outcome. Exposure measurements
may sometimes be directly available, e.g.,
controlled DES treatment during pregnancy,
but in most cases such information has to be
obtained retrospectively. This, however, may
raise difficulties of recall bias and recall
uncertainty (often an answer to a general
question such as "have you had hormone
treatment during pregnancy" will be the
only exposure data that can be obtained).
In this situation the so-called ecological
approach may be necessary. Rather than
relating adverse outcomes to exposure for
individuals, this is done for groups. Two
general dimensions are used: temporal and
spatial. Indeed the temporal trends in
selected outcomes have been instrumental
in raising the suspicions and concerns
described in this report. It is hypothesized
that putative exposures do vary consider-
ably along the temporal gradients. Spatial
trends have so far been exploited in only a
few cases, e.g., Danish-Finnish sperm con-
centration and testicular cancer incidence
(16,21,22), which also illustrates that
covariation of outcomes can sometimes be
informative when few if any exposure mea-
surements are available. In general we are
not aware of much hard evidence to
directly support an explanation in terms of
specific exposures of the spatial gradients.
Sources of variation in the spatial gradient
are, for example, ethnic differences, with
the associated difficulties in separating
genetic, cultural, and socioeconomic gradi-
ents from the exposures of our prime inter-
est. In particular, the considerable success
from nutritional epidemiology of migrant
studies (such as Japanese immigrants to
Hawaii or California) might form an inspi-
ration for epidemiological designs for the
problem of environmental estrogens.
Turning to outcomes, the original
focus was on defects of the male reproduc-
tive system. To this we have added specific
estrogen responses (gynecomastia, male
breast cancer). Schematically, there are
advantages and problems (Table 2).
Responses occurring with delay require
a long time span for these kinds of repro-
ductive studies. For both prospective and
retrospective studies this has negative
consequences for both logistics and inter-
pretation (e.g., male breast cancer cases
may have to be related to pregnancies
50-70 years ago).
Epidemiological studies are needed to
monitor the trends in incidence of tes-
ticular cancer and birth defects (cryp-
torchidism, hypospadias), and changes in
semen quality and infertility. Follow-up of
semen quality is very important, since the
sperm concentration has decreased drasti-
cally during the last two generations (5)
and the declining trend appears to be con-
tinuing (11). Risk factors for testicular
cancer have been analyzed in several
case-control studies. Estrogen treatment of
mothers whose sons have developed testic-
ular cancer has remained an equivocal risk
factor. It is unfortunate that there are no
prospective studies yet concerning the tes-
ticular cancer risk among males exposed to
DES. The studies by Bibbo and Gill, and
their co-workers (174,291) preceded the
time when testicular cancer would have
become manifest. Epidemiological studies
of the risk factors for poor semen quality
and infertility are needed. Furthermore,
epidemiological studies should be com-
bined with studies on hormone metabo-
lism when a link between disorder and
hormone effect is sought. In women,
dietary influence on estrogen metabolism
and the risk of breast cancer was analyzed
in large epidemiological studies in which
both exogenous and endogenous hormones
and their metabolites were analyzed metic-
ulously in blood, urine, and feces (292);
this provided the basis for the link between
high levels of free endogenous estrogen
(found in women with Western-type diet)
and increased breast cancer risk. There are
no comparable studies among men concern-
ing reproductive disorders, although if these
disorders are induced in fetal/childhood life
Table 2. Assessment of outcomes.
Outcome Advantages Problems
Hypospadias Inborn: fast ascertainment Not uniformly recorded; no generally
Available in some registries agreed diagnostic criteria
Cryptorchidism Inborn: fast ascertainment Spontaneous descent; no generally
Available in some registries agreed diagnostic criteria
Semen quality Widely available and reasonably uniform Functional importance of sperm
sperm concentration measurements; concentration unknown, other
sperm output probably related to parameters not often uniformly
the Sertoli cell number measured
Fecundity Direct importance Essentially impossible to measure
separately from confounding factors
Testicular cancer Well registered, important Rather rare
Male breast cancer Well registered, important Very rare, occurs late in life
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but are not manifest until adulthood, then
there are large obstacles to deducing any
cause-and-effect relationships. "Time to
pregnancy" analysis and exposure assess-
ment allow the study of fecundity of
exposed males (293).
Ecoepidemiology
Causal relationships between environmen-
tal contaminants and specific disease states
in wildlife are difficult to obtain because
these animals are not living in controlled
conditions. An ecoepidemiologal approach
to circumvent these problems is to evaluate
systematically the relationship between
proposed causal agents and specific out-
comes. The criteria used to develop causal
inference include a) probability, b) time
order, c) strength of association, d)
specificity, e) consistency on replication, f)
predictive performance, and g) coherence
[reviewed by Fox (294)]. This approach is
often more useful in rejecting a causal rela-
tionship than in providing definitive sup-
port. However, the use of this systematic
approach, well-formed sampling designs,
and rigorous statistical analysis can provide
us with data useful in risk assessment.
Continuous monitoring of the wildlife
populations is needed to detect any distur-
bances in reproduction. Furthermore, tim-
ing and magnitude of chemical exposure
should be considered when estrogenic
effects are examined.
Experimental Models for Testing
Estrogenicity and Estrogenic Molecules
Different approaches can be used to assay
estrogenic activity, depending on whether
or not the compound is known to have
such an activity. In the first case, direct
physicochemical analyses, such as gas chro-
matography-mass spectroscopy or high-
performance liquid chromatography
(HPLC), can be used to assess the pres-
ence, and if necessary, the concentration of
a xenoestrogen(s). Many banned chemicals
(e.g., PCBs) can be detected by this
method. Specific immunoassays can be
used when appropriate antibodies are avail-
able. Different approaches must be used
when putative estrogenicity of a com-
pound(s) is screened or the cause of a sus-
pected estrogenic contamination is searched
for. Binding assays and bioassays are com-
monly used for this purpose.
The principle of binding assays is to try
to displace radiolabeled estradiol from its
receptor by increasing molar concentrations
of either unlabeled estradiol (reference
curve) or different purified xenobiotics to
be screened. Biological material used here
is either a total extract or a nuclear extract
of cells or a tissue containing a high con-
centration of estrogen receptor (e.g., the
rabbit or rat uterus, MCF-7 cells). Binding
experiments are very useful, but it should
be remembered that binding of a com-
pound does not necessarily imply its
biologic activity. Moreover, the concentra-
tion of a chemical needed to displace 50%
bound [3H]estradiol is orders of magnitude
higher than that needed to elicit a biologi-
cal response.
There are a number of bioassays avail-
able for assessment of the estrogenicity of a
chemical. These can be divided into two
groups: animal models and in vitro models.
Animal Models. A range of different
species such as chicken, rat, mouse, trout,
and reptiles has been used in estrogenicity
testing. The most widely used rodent
bioassay measures the increase in uterine
weight in the rat (295). However, it is
well known that this bioassay gives a crude
estimate of an estrogen effect, that it is
insensitive, costly, laborious, and cannot
be adopted for large-scale screening.
Moreover, there is no standard procedure
for the uterotropic assays. Instead, different
laboratories use different protocols (multi-
ple doses vs single dose, 24 vs 72 hr, etc.).
Vitellogenesis in male fish, e.g., trout, can
be used to test for the presence of estrogenic
compounds in the aquatic environment.
Mammalian animal models. Various
laboratory or domestic animal species can
be used to address specific aspects of the
possible effects in vivo of estrogenic chemi-
cals. These should be particularly useful for
studies of delayed effects (i.e., where expo-
sure to the chemical(s)occurs in fetal/neona-
tal life and the reproductive consequences
are manifest in adult life) and for studies of
the effects of chronic low-level exposure to
xenoestrogens. For example, possible
effects of these chemicals on Sertoli cell
multiplication can be studied in developing
rats or mice by exposing them during ges-
tation and/or during the first 3 postnatal
weeks of life (the period of Sertoli cell mul-
tiplication extends from day 16 of gesta-
tion to postnatal days 15-18 in the rat).
Sperm output, fertility, and testis size and
morphology can then be evaluated in adult
life and Sertoli cell number determined in
other animals at around day 18 of postna-
tal life. In this way, possible chronic effects
of low-level exposure to xenoestrogens dur-
ing development on adult reproductive
ability can be evaluated in a fairly simple
way. Such studies are ongoing and have
already proved that such effects can be
detected (200). The importance of these
particular studies is that they may provide
reference values of harmful exposure (i.e.,
pg/kg/day) that can then be related to mea-
sured levels of exposure in man.
The other main uses of mammalian
animal models will be in determining the
mechanisms of xenoestrogen-induced dis-
ruption of reproductive development. Mice
and rats have been used already for some
such studies, and probes or antibodies for
some of the key genes that are expressed
during normal reproductive development
are available. Evaluation of the effects of
exposure to xenoestrogens at specific times
during development on expression of these
key genes (or on the effects of the gene
products) will obviously be extremely valu-
able, especially as any changes identified
will be able to be related to consequences
in adult life.
There is also a need for exploitation of
animal models other than rodents, as these
have limitations in terms of direct access to
the developing male fetus (i.e., exposure is
always through the mother). In this respect
there is a place for the use of the fetal sheep
or pig and the developing opossum. In the
former, it is possible to cannulate blood ves-
sels in the fetus at mid-term and to then
directly administer a compound to the fetus
and to monitor consequences in terms of
changes in blood hormone levels (165); for
example, this system could be used to
determine what blood level of xenoestrogen
in the fetus results in reduced secretion of
FSH from the pituitary gland and is thus
likely to reduce Sertoli cell multiplication
(see "Effects of Synthetic Estrogens on the
Testis in Animal Models"). In contrast, the
opossum provides fairly unique direct access
to a fetus that is born before sexual differen-
tiation has occurred. Thus administration of
xenoestrogens to the young at this stage
(either through the skin or orally) could
provide a direct and controlled way of pin-
pointing when and how such exposure
might result in disruption of the normal cas-
cade of male reproductive development; this
would enable identification of critical win-
dows of developmental susceptibility to
estrogens. It is established already that a) the
pathway of development in these animals is
comparable to that in eutherian mammals,
and b) exposure of the young to estrogens is
able to disrupt completely the normal differ-
entiation of the testis and seminiferous cord
formation (296).
Vitellogenesis. Vitellogenin is a yolk
protein produced normally in the liver of
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female fish under estrogen control (297).
Very little, if any, vitellogenin can be
detected in male fish (298). However,
exposure to estrogens activates the vitel-
logenin gene, resulting in increased vitel-
logenin levels in the blood of male fish,
and clear dose-response effects have been
documented (299). Vitellogenesis can be
used both in field studies and in laboratory
in vitro studies (300). It is measured by a
specific radioimmunoassay (301). Sex
reversal could also be used as an end point
for estrogenic effects in an aquatic milieu.
In field studies, caged male rainbow
trout are exposed to water in areas of inter-
est, and their vitellogenin levels are fol-
lowed over time (112). This is a good
screening method for the presence of estro-
genic compounds in different aquatic habi-
tats. Vitellogenin production by superfused
trout hepatocytes can also be used as a sen-
sitive in vitro bioassay for analysis of estro-
genic compounds in the water (111).
Fish reproductive tests. The Office of
Pollution Prevention and Toxics (OPPT)
in the U.S. Environmental Protection
Agency (U.S. EPA) is using two fish repro-
ductive assays: a) fish partial chronic toxic-
ity test that measures effects from adult to
the early life stage, and b) fish whole life
toxicity test that measures effects from egg
to early life stage to adult and then to early
life stage (OPPTS 850.1500).
Reptile egg assays. Reptile sex differen-
tiation is temperature- and estrogen-
dependent (155). Exposure of turtle eggs
to a putative xenoestrogen by spotting or
painting them with the compound results
in a high proportion of feminization or
intersex conditions of hatchlings in a tem-
perature that would normally result in
100% males (99). This assay is suitable for
studies of estrogen exposure in wildlife.
In Vitro Assays. Two complementary
aspects can be studied by in vitro assays:
proliferation of an estrogen-dependent cell
line, and the induction of an estrogen-con-
trolled function. In the first case, cell num-
ber and the incorporation of radiolabeled
thymidine are the parameters measured. In
the second case (induction of function),
there are several possibilities. Prolactin pro-
duction by pituitary cells in response to an
estrogenic compound was an early attempt
to measure estrogenic activity in vitro, but
the assay was abandoned because of its
nonspecificity. For assessment of the estro-
genic activity in the aquatic environment,
the in vitro assay for detecting vitellogenin
in fish is extremely useful (302). At pre-
sent, the most commonly used mammalian
in vitro assays are the MCF-7 cell tests and
the recombinant yeast cell assays. Serum
that is required in the culture of breast-
cancer cell lines must be charcoal-stripped
to remove endogenous estrogens.
MCF-7 cell line. Human breast cancer
cell lines (MCF-7 cells) that are sensitive to
estrogen have been used to screen chemi-
cals for their estrogenic effects (81). The
test -also called the E-SCREEN -is
based on the dose-response relationship
between the proliferation of MCF-7 cells
and the amount of estrogen to which the
cells are exposed during 6 days of culture.
Estradiol is used as a standard. By compar-
ing the effects of a xenoestrogen and estra-
diol, we can present the relative estrogenic
potency of a compound. Soto et al. (81)
use the following concepts to describe
estrogenicity: "Concentration" denotes the
dose at which an estrogenic effect is
detected; proliferative efficiency (PE) mea-
sures the ratio between the highest cell
number in the presence and in the absence
of estrogen; relative proliferative efficiency
(RPE) measures the ratio between the max-
imal cell yield achieved by a xenobiotic and
that of estradiol; relative proliferative
potency (RPP) measures the ratio between
the dose of xenobiotic and that of estradiol
needed to achieve a proliferative effect.
Alkylphenols, pesticides, phytoestrogens,
and synthetic estrogens have been analyzed
using this test (81,212). Some endocrinol-
ogists consider cell proliferation a hallmark
of estrogen action; and if a compound does
not have this property, regardless of what
other end points it influences, it should not
be called an estrogen. The E-SCREEN is
technically an easy method and can be used
for screening and assessment of approxi-
mate estrogenic potency of a compound.
Other hormones and growth factors tested
so far have not influenced this assay (204).
However, the possibility remains that some
compounds may influence these cells
through other than estrogenic pathways
and thereby confound the results.
MCF-7 cells were also used to detect the
estrogenic effect of bisphenol-A that was
released from polycarbonate flasks during
autoclaving (267). Progesterone receptor
induction and [3H]thymidine incorporation
combined with DNA measurement were
used to measure estrogen activity (81). This
approach covers the proliferative effect
(thymidine incorporation) and the change-
of-function effect (progesterone receptor
induction) of the compound studied. This
adds to the technical difficulty and the
expense of the assay.
Estrogen effects on MCF-7 cells can
also be monitored after transient transfec-
tion of cells with reporter plasmids
pTKLUC and pERE-TKLUC by assaying
for luciferase activity (203). The reporter
plasmid pTKLUC contains the herpes sim-
plex virus thymidine kinase (TK) promoter
inserted in the Bgl II site of the luciferase
reporter plasmid pGL2-Basic (Promega).
pERE-TKLUC contains a single copy of
the vitellogenin A2 estrogen response ele-
ment inserted upstream of the TK pro-
moter in pTKLUC.
ZR-75 cell line. Several human estro-
gen-responsive cell lines, such as ZR-75, in
addition to MCF-7 can be used in cell pro-
liferation assays (203).
Recombinant yeast cell lines. The
most sensitive estrogen measurement at the
moment is a recombinant cell bioassay com-
prising a yeast cell line (Saccharomyces cere-
visiae) transformed with plasmids encoding
the human estrogen receptor and an estro-
gen-responsive promoter fused to the struc-
tural gene for ,B-galactosidase (303). This
assay detects 100-fold lower estradiol levels
than the widely used traditional radioim-
munoassays. However, the sensitivity of the
assay to other estrogenic hormones than
estradiol is lower. This bioassay revealed an
8-fold difference in the estrogen levels of
prepubertal boys and girls (303), who were
previously believed to have similar hor-
mone concentrations (304). This has
important implications for future studies
since it is now possible to measure quanti-
tatively increased estrogen levels in prepu-
bertal boys. The assay is simple to perform
once the cell line is established since only
the measurement of P-galactosidase activity
is needed to observe the effect.
Sensitivity of the Assays. The sensitiv-
ity of the assays for measurement of 171-
estradiol is given in the Table 3.
The recombinant yeast cell assay
appears to be the most sensitive of the
assays, although the E-SCREEN may not
be far behind. Both assays detect estradiol
levels that are less than 0.1 pg/ml.
Traditional radioimmunoassays with an
antibody strictly specific for estradiol had a
maximum sensitivity of 2 pg/ml (305).
However, sensitivity can be improved to
less than 0.1 pg/ml (306). In the E-
SCREEN assay, the lowest estradiol level to
produce a maximal proliferative effect is 10
pg/ml, but detectable proliferation occurs
already at 0.3 pg/ml (307). Activity,
significandy different from the unstimulated
control, has been detected at 0.03 pg/ml (C
Sonnenschein and AM Soto, personal
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Table 3. Sensitivities of estrogen assays.
Assay Sensitivity References
Radioimmunoassay (RIA) Traditional RIA: 2 pg/ml Korenman et al. (305)
Improved RIA: 0.3 pg/ml Legan et al. (306)
MCF-7 cell assay (E-SCREEN) 0.03-0.3 pg/mI Soto and Sonnenschein (307)
AM Soto and C Sonnenschein, personal communica-
tion
Recombinant yeast cell assay 0.02-0.2 pg/ml Klein et al. (303); JP Sumpter, personal communication
communication). When the ultrasensitive
estrogen assays are used, extreme care
should be taken in the way the samples (to
be analyzed) are handled, stored (quality of
plastic vials), and processed, because major
problems may be encountered from low
levels of contaminating estrogens, e.g.,
plasticizers leaching from plastic storage
tubes, syringes, cell culture plates, etc.
Complementary to these techniques,
the binding of the compounds to proteins,
such as SHBG and a-fetoprotein (AFP),
should always be studied in order to address
the difficult problem of bioavailability.
In conclusion, although a wide variety
of different assays are used (and probably
always will be!), in general they have pro-
duced very consistent results; that is, a
chemical that is estrogenic in one assay is
estrogenic in all other assays. For example,
alkylphenolic compounds are weakly
estrogenic in molecular assays (257), cell
proliferation assays (81), and in vitro estro-
gen-binding assays (203). There appears to
be no species specificity; i.e., a chemical
that is estrogenic in one animal appears to
be estrogenic in all other species. Again,
alkylphenolic compounds provide a good
example. These chemicals are weakly estro-
genic in fish, birds, and mammals (257).
This is not at all surprising since the struc-
ture of the estrogen receptor is highly con-
served between species.
Limitations of in Vitro Testing.
Absorption and metabolism of a compound
are important for its effects. Because a chem-
ical is, or is not, estrogenic in vitro does not
necessarily mean that it will exhibit this
activity in vivo. It may not be absorbed. It
may be metabolized in the gut to an inactive
or nonabsorbable metabolite. Alternatively, a
chemical that is nonestrogenic in vitro may
be converted to an estrogenic metabolite in
either the gut or the liver. This possibility is
important as it points out the limitation of
in vitro screens (false negatives). Screening of
classes of compounds and identification of
the chemical structure(s) associated with
estrogenicity are obvious ways by which
this limitation could be minimized.
Although some proestrogens are sup-
posed to be metabolized into an active form
in the liver, and thus they are expected to
be inactive in in vitro assays, such com-
pounds (e.g., alkylphenol monoethoxylates,
some PCB congeners, methoxychlor) have
been found to be estrogenic for MCF-7
cells, suggesting that these cells may also
metabolize some chemicals (204,257).
General Reproductive Toxicity Testing
Only a few chemicals have been tested
specifically for estrogenic or other
endocrine activity. However, many chemi-
cals have been tested for their reproductive
toxicity, and thereby indirectly for estro-
genicity, although weak estrogenic activity
most probably does not.appear in these
tests. Current toxicity tests are designed pri-
marily to detect overt teratogenic and
reproductive effects or toxicity in the
adult-they have not been designed to seek
out effects where there is a long lag-phase
between induction and manifestation of the
effect. Moreover, unless such changes were
gross and pathological, they would proba-
bly be dismissed as insignificant, e.g., small
reduction in testis size and sperm count.
Toxicity testing used by U.S. regulatory
agencies and by the National Toxicology
Program includes three test segments
(Segments I-III), Fertility Assessment by
Continuous Breeding (FACB), and either
two-generation or multigeneration tests
(308). Segment I covers fertility and repro-
ductive function in male and female;
Segment II deals with developmental toxi-
cology and teratology; and Segment III
tests perinatal and postnatal toxicity.
Thus, reproductive toxicity testing
belongs to the routine toxicology that has
to be undertaken before a new compound
can be released to the environment. The
problem is that although testing appears
extensive, it may miss important late effects
and actions that occur only when additive
factors are present. The reproductive toxic-
ity tests used in the current safety assess-
ment of various chemicals are discussed in
more detail in "Appendix B".
Testicular Cancer ModeLs
There are no animal models for testicular
germ cell tumors. This necessitates more
intensive search for such a model.
Testicular stromal tumors can be produced
in mice both by gene deletion (309) and
by overexpression of an oncogene under
the control of a testis-specific promoter
(e.g., inhibin alpha promoter connected to
SV 40 large-T antigen). The transgene
approach has been used to produce testicu-
lar somatic cell tumors from which new tes-
ticular cell lines have been developed (K
Kananen, personal communication). Direct
transformation of germ cells with SV 40
large-T antigen has been used to immortal-
ize spermatogonia (310). When a tempera-
ture-sensitive p53 mutant is co-transfected
into these cells they were reported to differ-
entiate through meiosis (311). These
recombinant cell models may give possibil-
ities for detailed analyses of many features
of gene activity and its regulation in specific
testicular cell types. Although the cells are
transformed, most of their characteristic
functions should remain unchanged. Such
approaches may be extremely useful in
improving our understanding of primordial
germ cell development and of the factors
that are involved in arrest of development
resulting in precancerous carcinoma in situ
(CIS) cells.
Brinster and co-workers (312,313)
demonstrated that stem cell spermatogonia
survived a transit to mouse seminiferous
tubules that were either partially or totally
missing their own germ cells. The trans-
ferred spermatogonia produced normal
spermatozoa. Spermatogenic cells survive
poorly in vitro, but spermatogonia are the
most viable (314-316). This raises the pos-
sibility of in vitro experimentation, which
can be continued in vivo by injecting cul-
tured spermatogonia back into the seminif-
erous tubules. Human CIS cells could be
transferred to mouse seminiferous tubules
(which are an immunologically privileged
site) to follow possible carcinogenesis.
Endocrine manipulation of recipient ani-
mals would enable study of the role of hor-
mones in the promotion of tumor growth.
Summary
Multidisciplinary approaches are needed
into studies of environmental effects on
male reproductive health. Epidemiological
methods should be used to follow up the
trends in male reproductive health and to
identify putative association to environ-
mental factors. Similarly, ecoepidemiology
gives valuable information, on concurrent
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changes in wildlife. Experimental studies in
laboratory animals and cell lines provide
direct evidence of the effects of xenobi-
otics. Both physicochemical and biological
methods should be used for the
identification of estrogenic-/endocrine-dis-
rupting compounds in the environment
and for the determination of human expo-
sure to these agents.
General Discussion on the
Association between
Chemicals in the Environment
and Male Reproductive Health
The possibility that exposure of humans
and wildlife to environmental estrogenic
chemicals might result in adverse changes
in reproductive development, function
and/or behavior is not particularly new;
concern was first expressed two decades ago
in relation to DDT. Indeed, the first
demonstration that a range of man-made
chemicals could be estrogenic when admin-
istered to animals stems from 1938 (317).
The issue has resurfaced because of two
new developments. The first is the increas-
ing appearance in the human population of
several adverse changes of the sort that
researchers predicted might occur if human
exposure to environmental estrogens was
widespread. The second has been the dis-
covery of many new environmental estro-
gens to which we are exposed daily. In light
of these developments, the foregoing report
has reevaluated the strength of the available
information to ascertain whether or not
there is real concern for human health
stemming from exposure to environmental
estrogens, or whether the data are more
consistent with a theoretical, but unlikely,
effect on the human. The following step-
wise conclusions have been reached:
* All of the best evidence available points
with some certainty to a rising tide in
Europe and many other countries of
human male reproductive disorders
involving sperm counts (and probably
sperm quality), testicular cancer, mal-
formation of the external genitalia, and
possibly testicular maldescent.
* There are insufficient data to prove or
disprove that these adverse changes in
male reproductive health are the result,
wholly or partially, of exposure to envi-
ronmental estrogens. In addressing this
issue, we have identified alarming gaps
in our knowledge of the route and lev-
els of human exposure to nonpesticide
environmental chemicals. Many of these
chemicals have not been evaluated for
their reproductive toxicity; even where
such studies have been performed, their
design and intent were such that they
may have failed to exclude delayed
effects of the sort that can be induced
by estrogen (or other hormone) expo-
sure during development.
* If the above changes in male reproduc-
tive health do result from fetal and/or
neonatal exposure to environmental
estrogens, then we will not know what
the current prevalence in male children
is for another 20 to 40 years. This is
due to the delay between induction and
manifestation of many of the effects,
e.g., lowered sperm counts or the devel-
opment of testicular cancer in adult
life. The indications are that these
problems are still increasing in inci-
dence in the general population.
* Based on what is known about the
widespread imprinting effects of steroid
hormones (androgens and estrogens as
well as antagonists of these hormones)
when there is exposure during
fetal/neonatal development, it is possi-
ble that there are other adverse health
consequences in man of such exposures
of which we are currently unaware, e.g.,
permanent changes to the immune sys-
tem, growth, etc.
* There is enough evidence from a variety
of sources to suggest that environmental
estrogens have the capacity to induce
adverse minor and major reproductive
defects in man, but there are inadequate
data on the level of actual human expo-
sure to these chemicals, which means
that no accurate risk assessment can be
made. There are also insufficient animal
data to permit such an assessment.
* Determination of whether environmen-
tal estrogens do exert harmful effects in
man will probably have to rely on
weight of evidence rather than estab-
lishment of precise cause and effect. To
provide this evidence as accurately as
possible, future work should address
the problem at several levels, including
epidemiology, laboratory animal
studies, wildlife studies, more complete
identification of estrogenic chemicals
(i.e., screening), and accurate assess-
ment of the routes and levels of human
exposure to these chemicals.
* There are substantial differences in the
incidence of the reproductive defects,
referred to previously, in different coun-
tries/races and these also appear to show
possible relationships to the incidence of
other hormone-dependent diseases of the
reproductive system (breast, prostate).
The etiology of these differences should
be explored to ascertain to what extent
they reflect ethnic/genetic, lifestyle, or
environmental influences.
* There is an urgent need for a clearer
understanding of the hormonal envi-
ronment of the fetus during the period of
male sexual differentiation and develop-
ment, especially of what mechanisms are
present to protect the fetus from mater-
nal estrogens, e.g., ox-fetoprotein, steroid-
metabolizing enzymes, etc. Because of
the inaccessibility of the human fetus at
this stage, these studies will probably
have to be undertaken in animals.
* Investment of resources in obtaining the
information necessary to assess whether
environmental estrogens pose a health
risk to man will have major spin-off in
terms of our understanding of fetal and
neonatal determinants of disease, the
routes and importance of human expo-
sure to nonpesticide environmental
chemicals and of the etiology of geo-
graphic and ethnic differences in disease.
Suggestion for a Strategy to
Strengthen the Evaluation of
Hazards of Estrogens or
Xenoestrogens
Several lines of evidence have indicated
adverse trends in male reproductive health
over the last few decades. Clinical and
experimental research has demonstrated
that the reproductive disorders reported
may be interrelated and may have a com-
mon origin in fetal life or childhood.
Studies of wildlife and human epidemiol-
ogy suggest that environmental factors are
involved in the origin of reproductive disor-
ders. Common environmental contami-
nants such as alkylphenols and phthalate
esters, and natural factors such as phytoe-
strogens, have been shown to be endocrine-
disrupting agents, many of them being
estrogenic. Our hypothesis is that the
adverse trends in human male reproductive
health is, at least in part, associated with
exposure to environmental estrogenic com-
pounds during early development. Testing
of this hypothesis necessitates a multidisci-
plinary research approach, including epi-
demiological and experimental studies,
examination of wildlife, and analyses of
environmental contaminants and human
exposure to them. Extensive international
collaboration that combines the existing
strengths of various institutions and inves-
tigators is probably required if this complex
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Figure 8. Suggestion for a research strategy to strenghten the evaluation of hazards of estrogens or xenoestrogens.
health problem is to be addressed in the
most accurate and effective way.
Research Strategy
The proposed research strategy is illus-
trated schematically in Figure 8 and is
expanded upon in the relevant sections
below. There are three fundamental com-
ponents to this strategy (boxed in Figure 8).
The first component centers on the col-
lection and evaluation of epidemiological
evidence for male reproductive disorders in
man and animals. The intention of this
approach is to define the scale of male repro-
ductive disorders, to establish geographical
differences in their distribution and to assess
whether there is an increase in -incidence of
such disorders in groups with known expo-
sure to estrogens or xenoestrogens.
The second and third components of
the strategy are designed to identify xenoe-
strogens using a variety of in vitro screen-
ing methods and then to evaluate whether
their administration to laboratory animals
results in biochemical and biological
effects (in vivo screening). This approach
would be complemented by studies on the
environmental distribution of these chemi-
cals and by assessment of the routes and
level of human exposure. This informa-
tion, in conjunction with the relevant
epidemiological evidence, should enable
some form of risk assessment to be made
for man and for wildlife.
Epidemiological Studies in Man
In epidemiological studies, trends in male
reproductive health must be followed up
further in different geographic areas and in
populations with different ethnic and racial
backgrounds. In addition, every attempt
should be made to use some of the existing
data or cohort studies, if these are appro-
priate, although in some instances collec-
tion of new data is essential.
Incidence of Male Reproductive
Disorders in Man. There are geographic
and racial variation in semen quality and
other aspects of male reproductive function.
Semen quality, testis size, levels of sex hor-
mones and gonadotropins as well as pres-
ence of cryptorchidism and gynecomastia
may all be indicators of abnormal male
reproductive function. The aim of the
study is to examine geographic and racial
differences and to establish reference values
for semen quality, blood levels of sex
hormones and gonadotropins, testis size,
and prevalence of gynecomastia and cryp-
torchidism, since these conditions may pro-
vide us with information on environmental
and genetic influences on male reproductive
development and function. Furthermore,
such studies may be starting points for
future prospective studies on secular trends
in male reproductive function.
In order to obtain comparable groups
of individuals, well-defined types of men
should be investigated, such as army
recruits and semen donor candidates. The
study should involve men from the United
States, France, Finland, Denmark, United
Kingdom, and possibly Taiwan or Japan,
with the final selection of countries to be
determined by the study groups.
The following parameters should be
assessed:
* semen quality: volume, density, mor-
phology, computerized motility assess-
ment; to ensure a standardization of the
methods, the laboratories involved in the
project should circulate relevant samples
or videotapes
* serum levels of testosterone, estradiol,
FSH, and LH
* morphometric measurements: weight,
height, testis size
* cryptorchidism
* gynecomastia
* time to pregnancy if the men have
reached an age when they have wished
to become fathers
The rest of serum and semen samples
should be stored in the freezer for possible
future analysis for, e.g., environmental pol-
lutants or other relevant parameters.
Denmark and Finland provide an inter-
esting comparison. The incidence of testic-
ular cancer in Denmark is remarkably
higher than in Finland (22). Conversely,
semen quality seems to be markedly better
in Finland compared to Denmark (16).
The incidence of testicular cancer is
increasing in both countries, whereas less is
known about semen quality. The incidence
of cryptorchidism in Denmark in 1960 is
known from a careful study of 2701 new-
borns (60). Additional information is
available from the doctors' and midwives'
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notes of 17,767 newborn males during the
period 1957 to 1960. No information on
possible increase in the incidence of cryp-
torchidism in Denmark is available and
neither is there information on the inci-
dence of other minor malformations of the
male external genitalia. There are no large
studies on the incidence of cryptorchidism
in Finland. According to the hypothesis
that testicular cancer, poor semen quality
and developmental anomalies in the male
reproductive tract are interrelated, we pos-
tulate that the incidence of cryptorchidism
is higher in Denmark than in Finland and
that the prevalence of genital malforma-
tions is increasing in newborns.
Follow-up Data on Humans Exposed
to EstrogensiXenoestrogens. There are sit-
uations in which exposure of pregnant
women to estrogens or estrogenic com-
pounds have been clearly identified. DES
treatment in the United States and some
countries of Europe or contamination of
foodstuffs with PCBs and PCDFs in Japan
and Taiwan are such examples.
These situations are true experimental
models and maximum effort should be
made to collect existing data on the off-
spring of these women. The following are
the possibilities:
* Obtain additional information from
men born to mothers who participated
in the well-designed DES trial made in
the United States in the 1950s (167).
There have been more than 300 men
in the follow-up studies of these
cohorts (174).
* Obtain information from other men
born to exposed mothers.
A possibility would be to study brothers
ofwomen known to be exposed to DES, as
there is probably an increased possibility
that they also were exposed to DES. The
size of the study group and a paired control
group would have to be defined carefully.
* New case-control studies should be
done especially for testicular cancer,
since, e.g., the DES-exposed males have
now reached the age at which the inci-
dence of testicular cancer peaks.
* Taiwanese boys prenatally exposed to
PCBs are now in puberty (281). It is
proposed to obtain all the available data
on the reproductive tract disorders
from these men, and later semen analy-
ses when available.
More information is needed on the
incidence and trends for genital defects in
various countries.
* Attention should be mainly accorded to
cryptorchidism, hypospadias, and male
breast cancer. This information could
be obtained from many, if not all, of
the countries in the EU.
* Information from the newborn cohort
established in the 1960s in Denmark
could also be used to analyze the trends
for genital malformations through a new
study. The Bristol-coordinated European
cohort study which involves large num-
bers of children in several Western and
Eastern European countries will give
additional data on these trends.
Risk factors may be shared among
many disorders. Mothers of men with tes-
ticular cancer were reported to have an
increased risk for breast cancer (190), sug-
gesting common risk factors, such as a
high estrogen exposure. In national cancer
registries, it is possible to analyze the asso-
ciation between testicular cancer and
mother's breast cancer in large patient
groups, and such a study is ongoing for
example in Denmark.
Occupational Studies. Studies on the
offspring ofwomen occupationally exposed
to xenoestrogens. Comparison between
population groups in so-called ecological
studies may suffer from various weaknesses,
including confounding bias. Also, if the
main effect on male reproductive function
is due to prenatal exposure, it may be very
difficult to determine the causative expo-
sure in any detail because it happened in
the distant past. These problems do not
indicate that such studies should not be
carried out; but it would be important to
supplement this evidence with studies of
more specific exposures, such as those that
occur in certain occupations.
Among the industrial chemicals so far
identified as xenoestrogens are certain addi-
tives to plastic materials (e.g., alkylphenols,
phthalates, bisphenol-A) and some pesti-
cides. It would therefore be of interest to
find female occupational groups with
known exposures to such compounds. One
group of particular interest is greenhouse
workers. Because of the enclosed space of
greenhouses, pesticide exposure invariably
occurs, partly because of percutaneous
absorption. Prospective and cross-sectional
studies of the male offspring of the female
greenhouse workers could then be carried
out with emphasis on cryptorchidism and
other indicators of adverse effects on repro-
ductive organs.
Epidemiological Studies in
Domestic Animals
There is a lack of information on possible
secular trends in male reproductive function
among domestic animals. Such animals
might serve as good models for evaluation
of the environmental impact on human
male reproduction, although it should be
kept in mind that, for breeding of many of
these species, individuals with the best
reproductive function have been highly
selected. Nevertheless, if any adverse trends
are still evident, this would provide power-
ful supporting data for the human studies
and might open up new possibilities for
identifying causal agents.
The species that might be of interest are
the bull, pig, stallion, and dog. The indica-
tors of male reproductive studies are, as in
humans, cryptorchidism, hypospadias ,and
semen quality. It is well known that dogs
develop spermatocytic seminoma and not
the classical, premeiotic germ cell-derived
seminomas and nonseminomas. It remains
to be seen whether such tumors occur
among the other species. Available retro-
spective data (e.g., databases for artificial
insemination stations) on reproductive
function in these animals should be ana-
lyzed. New, prospective studies should be
initiated, if suitable studies can be designed
and the archival data warrant such investiga-
tion. The overall importance of these analy-
ses is that they may indicate whether adverse
changes in male reproductive function are
unique to man or more prevalent in man.
Wildlife Studies
If environmental estrogens are currently
present in biologically significant back-
ground concentrations, a survey of wildlife
would provide important supportive infor-
mation concerning possible human risk.
One extremely useful biomarker of estro-
gen exposure is the synthesis of the hepatic
protein vitellogenin. This is normally syn-
thesized in the liver of egg-laying females
after estrogen stimulation. Synthesis of this
protein is usually correlated with seasonal
reproductive activity in females but it is
not found in males. Numerous laboratory
studies, with a variety of wildlife species,
have demonstrated that vitellogenin syn-
thesis is stimulated in males after exoge-
nous estrogen treatment. Recent evidence
(112) suggests that both caged male trout
in English rivers receiving sewage effluent
and males of native fish species from vari-
ous English rivers and from the river Seine
in Paris exhibit elevated plasma vitellogenin
levels. These data suggest that environmen-
tal estrogens exist in these rivers at biologi-
cally significant levels. Thus, a survey of
male fish, amphibians, reptiles, and birds
living in wetland areas would provide a
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definitive measure of estrogen exposure in
this environment.
Fish would provide a very important
model system as they transport large quan-
tities of water through gills that are highly
vascular. Second, various species feed at dif-
fering trophic levels of the food chain, mak-
ing a comparison among levels possible.
Additionally, other species such as frogs,
salamanders, turtles, and alligators or croco-
diles could be used, depending on the eco-
logical knowledge base for such species and
the specific questions to be addressed. For
example, many fish and amphibian species
are short lived and are limited to specific
water bodies whereas other fish, turtles, and
alligators are long lived and may migrate
between various wetland areas.
We would propose that a series of
rivers, lakes, and marshlands be examined
in Europe and North America. If possible,
a few common species from similar genera
should be examined to minimize inter-
species variation. However, as the relative
sensitivities of various species are unknown,
this survey should examine species that
occur in large numbers. Detailed sampling
should be designed and similar protocols
used. In addition to vitellogenin, plasma
androgens and estrogens should be exam-
ined to ensure that natural estrogens are
not elevated in those males that exhibit a
positive response for plasma vitellogenin.
These data would also provide supporting
evidence of abnormal reproductive activity
as previous studies have demonstrated
abnormal steroidogenesis following expo-
sure to various contaminants.
The limitation of this study, as pre-
sented, is the need for antibodies that rec-
ognize vitellogenin from the various species
of interest. Vitellogenin is a large, globular
protein, approximately 400 to 500 kD,
with a complex, three-dimensional struc-
ture. Currently, a universal antibody that
would cross-react with the vitellogenin of
all oviparous species is not available but a
number of laboratories are presently devel-
oping and screening possible candidates.
Collaboration with these laboratories
should be fostered. However, if a universal
assay is not possible, other methods such as
polyacrylamide gel electrophoresis (SDS-
PAGE) can be used to detect plasma vitel-
logenin, although this technique would
provide poor quantification of plasma con-
centrations as compared to a validated
radioimmunoassay. An additional limita-
tion of this survey involves the specificity of
vitellogenin as an estrogen-induced prod-
uct. A survey for vitellogenin will not detect
possible antiandrogens or antiestrogens in
the environment. Additional assays for
other biomarkers may be required,
although the plasma steroid analyses per-
formed simultaneously with vitellogenin
assays may provide clues to reproductive
abnormalities due to other mechanisms of
endocrine disruption.
Surveys need to be performed on a
series of wetlands that represent a contin-
uum in water quality. Sites with known
contamination will serve as positive con-
trols, whereas other localities with reduced
input of manmade chemical contaminants
can serve as negative controls. One point of
caution should be made concerning the
negative control localities-areas perceived
as being pristine, such as arctic and antarc-
tic regions, are known to have animal and
human populations with elevated body
burdens of various persistent environmen-
tal contaminants. Thus, it is important
that representative species be examined
from each test locality for persistent conta-
minants (e.g., DDE, total PCBs, dioxin).
These measurements of contaminant load
should not be used as a measure of possible
estrogenic contamination, but rather as a
general measure of possible environmental
pollution. Initial surveys should examine as
many male fish as possible (n=-100 males/
wetland). Blood samples would be col-
lected rapidly for analysis of vitellogenin,
androgens, and estrogens. Specific body
characteristics should be noted such as size,
body weight, and other descriptive mor-
phometric characteristics. For alligators or
other wildlife having phallic structures,
measurements of size and developmental
abnormalities should be noted.
Experimental Studies -in VWo and
in Vivo Screening
The action of estrogenic chemicals, espe-
cially during fetal development in most
species, is, in part, determined by their rel-
ative binding with intracellular targets and
extracellular binding proteins. Estrogenic
chemicals with relatively poor binding to
extracellular proteins, such as SHBG and
AFP, would be expected to have a dispro-
portionate effect on developing estrogen
target tissues. This is the case for DES.
Experiments are proposed to evaluate the
micropharmacokinetics of a selected group
of priority environmental agents with estro-
genic activity with regard to distribution
within both the maternal and fetal com-
partments. Care must be given as to selec-
tion of the appropriate animal model with
special regard to endogenous estrogen levels
and binding components. As an example,
an early step would be to study the relative
binding in vitro of selected chemicals to
SHBG, AFP, and the estrogen receptor.
To understand the etiology of estrogen-
associated developmental abnormalities
that may be related to later disease or dys-
function, it is crucially important to study
the ontogeny of estrogen responsiveness in
target tissues associated with reproduction
in appropriate animal models. In addition
to whole-animal studies, experiments
should be attempted in organ and cell cul-
tures of fetal genital and gonadal tissues;
additionally, studies with transgenic mice
would be illustrative. These studies should
certainly include or emphasize the
ontogeny and regulation of the estrogen
receptor and related signaling molecules.
This information would help to predict
which chemicals would most likely alter
sexual development and provide strategies
for prevention.
Estrogenic chemicals can alter male
reproduction through chronic or acute
mechanisms. Long-term exposure to these
chemicals during fetal/neonatal life can
alter the expression of various other hor-
mones, leading to impaired development
of the testis such that the capacity for
sperm production in adult life is irre-
versibly reduced. Direct effects on the
adult testis that interfere with sperm pro-
duction are also possible, although less
likely. On the other hand, hormonally
active xenobiotics can alter a process or
expression of a gene during a short window
of susceptibility that has long-lasting con-
sequences. Characterization in detail of
these later consequences is recommended.
There are a few key genes involved in the
development of the reproductive tract and
gonads, and these provide important targets
for study. For example, the effect of estro-
gen on the expression, regulation, and
structure of SRY, Wilm's tumor gene (WT-
1), MIS, MIS receptor, growth factor
receptors and their ligands, estrogen recep-
tor, genes for steroidogenic and steroid-
metabolizing enzymes, and homeotic genes
and related genes should be determined.
The class of chemicals called environ-
mental estrogens comprises a diverse group
of molecules. Studies to determine the
metabolism, distribution, bioaccumulation,
and excretion of representative members of
this functional class in adult, pregnant, and
fetal systems (both in vivo and in vitro) are
proposed. This also includes identification
of their active estrogenic forms. These data
are important to make accurate exposure
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estimates for susceptible target tissues in the
human fetus.
The incidence of testicular cancer in
humans is still increasing while its etiology is
still unknown. A plausible hypothesis is that
estrogenic exposure early in testicular devel-
opment is associated with later germ cell
neoplasia in humans. Studies to elucidate
molecular and morphological markers for
testicular development are needed. The cell
type at risk for neoplastic transformation
should also be studied and the process deter-
mined. Creative application of modern mol-
ecular biological and cell biological
techniques should be considered to establish
the malignant cell lines. Targeting germ
cell-specific gene promoters for transgenic
approaches to specific cell transformation
and the development of new animal models
to study should be encouraged. Studies on
the physiology and pathophysiology of
estrogens in developing and adult male
germ cells are needed to evaluate the role of
estrogens in testicular neoplasia. Attention
should be given to new experimental mod-
els, such as the pig and nonhuman primates.
In order to improve the safety assessment
of environmental chemicals, it should be
assured that future toxicological testing used
for the generation of safety data adequately
takes into account the possible detrimental
effects on male reproduction of chemicals
possessing estrogenic and/or otherwise
endocrine-disrupting activity. This probably
necessitates the development of new test
strategies. It is anticipated that the goal can
be achieved by combining modifications of
existing protocols for reproductive toxicity
testing with the introduction of new in vitro
and in vivo assays. The strategy should be
based on insight into the mechanisms of
action as currently known and emerging
from future research activities. The develop-
ment of improved methods should be an
international collaborative effort to obtain
worldwide acceptance of their possible use in
regulatory safety assessments.
The exposure to possible xenoestrogens
should be considered in far more detail
than currently practiced in such studies.
Methods should be elaborated that address
the following questions:
* What chemicals are man (and wildlife)
exposed to, by which routes, and to
what degree?
* Do these chemicals actually get absorbed
(they will not cause effects if they are not
absorbed)?
* What are the concentrations of these
chemicals in man (and wildlife)? Do
any of them accumulate?
* How are these chemicals distributed in
the body? Are they mobilized (redis-
tributed) in certain states, such as
pregnancy?
* How are they metabolized? Is it the
metabolites, rather than the parent
compounds, that are of concern? For
example, alkylphenol polyethoxylates (a
group of surfactants) are not estrogenic,
but their degradation products are.
* If humans (and wildlife) are exposed
simultaneously to a mixture of estro-
genic, and/or antiestrogenic, anti-
androgenic, or otherwise endocrine
disrupting compounds, rather than to
an individual chemical, would the over-
all effect be diminished or enhanced
(additivity, synergism, antagonism)?
Presently we do not have adequate
answers (or even preliminary answers in
some cases) to any of these questions,
mainly because we do not know what
chemicals are of the greatest concern.
A major emphasis should be placed on
how to identify priority compounds that
justify examination (in addition to those
already identified as estrogens). The aim
would be to test for estrogenic activity of
the chemicals to which man (and probably
wildlife) is exposed the most.
The usefulness of various sources of
information should be explored, such as
existing product registers and OECD data
on high-volume chemicals. In addition,
advice and help may be obtained from
industry, which may be able to assist in
identifying the more important chemicals.
Collectively, these approaches should
enable identification of the major man-
made chemicals. These chemicals could
then be screened to determine whether
they possess any endocrine-disrupting
activity. If no effect is observed, the
significance of the compound (as far as this
context is concerned) is likely to be trivial.
If effects are observed, more detailed
studies, including dose-response studies on
animals, should be undertaken. If the
results of these studies raise concern, further
metabolic studies, such as accumulation in
the body and access to the fetus, would pro-
vide further information and enable a better
extrapolation to the human situation.
Conclusions
Male reproductive health has received
remarkably little attention considering
that subfertility affects 5% or more of
men and that prostatic hypertrophy or
cancer is a major problem for older men.
It is now evident that several aspects of
male reproductive health have changed
dramatically for the worse over the past 30
to 50 years. The most fundamental change
has been the striking decline in sperm
counts in the ejaculate of normal men;
recent evidence from Paris indicates that
this decrease amounts to about 2% per year
over the last two decades. The result is that
many otherwise normal men now have
sperm counts so low that their fertility is
likely to be impaired. Over the last half-
century, the incidence of testicular cancer
has increased progressively in many coun-
tries to become now the most common
cancer in young men. Other disorders of
the male reproductive tract may also be
increasing in incidence, with several
European countries reporting a progressive
rise in hypospadias (a malformation of the
external genitalia) and an apparently emerg-
ing trend toward an increasing incidence of
testicular maldescent.
These observations suggest that male
reproductive health has declined progres-
sively since the Second World War as a
result of changes in environmental or
lifestyle factors. While the etiologies under-
lying these apparent changes are currently
unclear, both clinical and laboratory
research suggests that all of the described
changes in male reproductive health appear
interrelated and may have a common origin
in fetal life or childhood. This means that
the increase in some of the disorders seen
today originated 20 to 40 years ago, and
the prevalence of such defects in male
babies born today will not become mani-
fest for another 20 to 40 years or more.
Trends in the reproductive health of
species other than man also raise the possi-
bility of environmental factors as partial
etiologic contributions in a decline noted
in male reproductive health of wildlife. For
example, wild panthers in the United States
have been reported to have an increase in
undescended testes and a decrease in semen
quality, whereas male alligators in some
lakes in Florida have been shown to have
abnormalities in their sex hormone levels
(tending toward femaleness) and to have
smaller than normal genitalia. Male fish in
some parts of the United Kingdom have
been shown to express a femalelike
response when studied in a relatively nat-
ural setting. Earlier studies of fish-eating
birds in the United States demonstrated
nests containing male hatchlings that were
apparently feminized. A recent report of
lactating male fruit bats suggested that the
males were, in some way, exposed to a
female sex hormone. Recent laboratory
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studies showed that when estrogenic forms
of PCBs were painted on turtle eggs, the
male hatchlings were sex-reversed to
females. Taken together, this growing body
of evidence suggests that environmental
factors that resemble female sex hormones
may be having an adverse effect on the
reproductive capacity and well being of
diverse species.
It has been well established that expo-
sure of the male fetus to supranormal levels
of estrogens can result in many, if not all,
of the reproductive defects referred to ear-
lier. Experiments in which potent synthetic
estrogens, such as DES, were given to preg-
nant laboratory animals have demonstrated
that prenatal exposure to synthetic estro-
gens results in a spectrum of adverse effects
on the male offspring including unde-
scended testes, testicular cancer, decreased
semen quality, epididymal cysts, hypospa-
dias, and poor fertility. Men similarly
exposed in utero to DES have been
reported to display related abnormalities
such as cryptorchidism, lower sperm
counts, cysts of the epididymis, and ini-
tially decreased fertility. The wealth of
experimental results and associated clinical
reports suggests strongly that prenatal
exposure to exogenous estrogens may play
an etiologic role in the trends observed in
human male reproductive health.
The growing number of reports
demonstrating that common environmen-
tal contaminants and natural factors pos-
sess estrogenic activity presents the
working hypothesis that the adverse trends
in human male reproductive health may
be, at least in part, associated with expo-
sure to estrogenic environmental chemicals
during fetal and childhood development.
The reproductive health trends in men are
consistent with this hypothesis. While
exposure levels to estrogenic chemicals are
not at all well known for humans, the large
number of chemicals in numerous environ-
mental categories suggests adequate avail-
ability. For example, environmental
chemicals reported to be estrogenic
include, but are not limited to, some ubiq-
uitous chlorinated hydrocarbons, such as
PCBs and DDT; some products of deter-
gent and surfactant manufacture, such as
the alkylphenols; and some products
released from plastics such as bisphenol-A
and some phthalates. Many other com-
pounds in our natural and synthetic envi-
ronment demonstrate estrogenic activities
and more are being discovered as the
search continues. Although not the subject
of this report, in considering and evaluat-
ing the possible role of estrogenic chemi-
cals in male reproductive disorders, it
should not be forgotten that many chemi-
cals may have a detrimental effect on male
reproductive health through mechanisms
other than an estrogenic effect.
The reproductive health trends for
men, the emerging data from wildlife, the
well-controlled experimental data with
developmental exposure to estrogens, and
the less well-studied, but consistent, data
on human cohorts, as well as the growing
knowledge concerning hormonally active
environmental chemicals, all point in the
same direction. We conclude that these
issues, taken in toto, indicate the need for a
vigorous research effort to understand the
extent of the problem, its underlying etiol-
ogy, and the development of a strategy for
prevention and intervention. Since the
health research issues involved are complex
and multifactorial and since these issues
apparently involve research needs in many
disciplines, countries and, indeed, species,
this report outlines a multinational, inter-
disciplinary research effort involving acade-
mic, government, and industrial scientists
and comprising field and clinical studies,
epidemiological research, and basic and
applied laboratory research with a compre-
hensive view to the relationships that will
evolve. We consider that this approach will
optimize the existing strengths of various
institutions and investigators on a world-
wide basis and will be the most cost-effec-
tive use of fiscal and intellectual resources.
There are many research needs in this
area; a detailed description of these needs
and strategies to fill them are considered in
the full report. In addition to key basic,
clinical, and epidemiological studies, the
highest priorities go to investigations to fill
crucial data gaps necessary to make
informed decisions about the risk these
chemicals may pose to human health. The
most pressing areas of need are reliable esti-
mates of exposure of humans to estrogenic
chemicals at different ages including fetal
life, and of how the exposures relate to
adverse effects on the reproductive system;
use of animal models to identify what lev-
els of exposure to estrogenic chemicals do,
and what levels do not, impair reproduc-
tive development; more penetrating studies
of the molecular events that lead to
impaired spermatogenesis and testicular
cancer; improved studies on the structural
and analytical chemistry of chemicals with
special emphasis on the prediction of estro-
genic activity from the molecular structure
of a chemical; and the development of
rapid in vitro and in vivo test systems for
the detection of estrogenic potency of envi-
ronmental chemicals and the harmoniza-
tion of these screening tests with improved
techniques for quick, reliable analysis of this
chemical class. The proposed high-priority
research will help provide the information
necessary for appropriate risk assessments.
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Appendix A: Toxicological Evaluations of
Pesticides and Environmental Chemicals
Regulatory Requirements for
Safety Data on Pesticides and
Other Chemicals
There is a principal difference between
pesticides and other environmental chemi-
cals. Pesticides are approved by the authori-
ties for use in the production of food crops.
This means that in a number of cases
residues are accepted in food. However, the
pesticide residues in foods are very closely
regulated. This, of course, does not imply
that pesticide residues are accepted in other
media such as drinking water and air.
For the environmental pollutants, their
presence in food is not intended but may
be caused by many different factors, of
which the contamination of food chains
and migration/formation during storage
and production are significant. It should be
emphasized that although the uses of vari-
ous highly persistent compounds such as
PCBs and many chlorinated pesticides
(e.g., DDT) have been severely restricted
or banned for a number of years in many
Western countries, they can still be found
in foods, in particular in fat from fish and
domestic animals. As a consequence of
their persistence in the food chain, these
compounds are also present in human tis-
sues. Concentrations of organochlorine
contaminants in human reproductive tis-
sue, adipose tissue, and blood from the
general population worldwide, as well as
the concentrations in human breast milk
fat, are presented in Tables Al and A2,
respectively [adapted from Thomas and
Colborn (1)].
Approval by regulatory agencies of a
pesticide demands that the health risk asso-
ciated with exposure to the compound be
evaluated by the regulating authorities. In
Denmark, pesticides are approved for use
by the Danish Environmental Protection
Agency; and residues in foods are regulated
through the establishment of maximal
residue limits (MRL) for each single pesti-
cide by the Danish National Food Agency.
A substantial part of these evaluations takes
place within the framework of the
European Union. In brief, the MRLs are
based on three parameters:
* A toxicological evaluation of the pesti-
cide in question, which results in the
establishment of an acceptable daily
intake (ADI) for humans
* An evaluation of effects and residues of
the pesticide in vegetable and animal
food commodities after controlled
application trials using the principles of
Good Agricultural Practice (GAP)
* An evaluation of the possible intake of
pesticide residues from treated food
crops. In establishing the MRL for each
food commodity, exceeding the ADI is
not accepted.
Data from toxicological investigations
are a substantial part of the assessment of a
pesticide. The toxicological studies should
identify possible adverse health effects of
the compound and establish the dose at
which such effects are likely to occur, and
in particular identify a dose level where
adverse effects are absent. The require-
ments for toxicological investigations have
been developed since the early 1960s, espe-
cially during the international cooperation
within the Codex Alimentarius of the
FAO/WHO. ADIs and suggestions of
MRLs are established at yearly meetings in
a committee of independent experts, the
so-called Joint FAO/WHO Meetings on
Pesticide Residues (JMPR). A similar
expert group, the Joint FAO/WHO Expert
Committee on Food Additives establishes
tolerable daily intakes of contaminants in
foods. In the United States, U.S. EPA
establishes reference doses (RfD) for pesti-
cides and environmental chemicals using
principles similar to those ofJMPR.
The majority of the toxicological data
used in the risk assessment are generated in
studies performed according to interna-
tionally accepted standards (guidelines),
which for each type of study state the mini-
mum requirements for an acceptable per-
formance. In addition, regulatory agencies
also require that, to be used in decision
making, the investigations are performed
according to Good Laboratory Practice
(GLP) involving quality control and qual-
ity assurance. The different types of toxico-
logical investigations required for the
evaluation of a pesticide involve studies on
acute effects, including effects on skin and
mucous membranes, and more important
long-term studies on chronic effects,
including carcinogenicity following
repeated, daily exposure. Studies on effects
on reproduction over a minimum of two
generations are also required, as well as
special studies on teratogenicity and
embryo/fetotoxicity, and on effects on the
genetic materials. In addition, studies on
absorption, biotransformation, bioaccumu-
lation, distribution, and excretion are also
required. In these studies, effects on
macromolecules, such as DNA, enzymes,
and other biochemical parameters are
often included.
The toxicological data that are used in
the risk assessment are usually generated
from animal experiments and in vitro
investigations. When human data are avail-
able, for example from occupational or
accidental exposure, these of course are
considered highly valuable.
From the toxicological data a no
observable effect level (NOEL) or a no
observable adverse effect level (NOAEL) is
identified as the highest daily dose level
that does not produce observable effects or
adverse effects in the most sensitive animal
species. In establishing the ADI for
humans the NOEL is reduced by a
(un)safety factor, which takes into account
the uncertainties of the results of the inves-
tigation, the extrapolation from animals to
humans, and the variations in sensitivity
and life-style within the human population.
When the toxicological background mater-
ial is considered sufficient, a safety factor of
100 is normally used (a factor of 10 for dif-
ferences between species and 10 for differ-
ences within species). Additional safety
factors are occasionally used, for example,
when the biological effect is considered to
be particularly serious or when uncertainty
exists in the evaluation of the consequences
of a finding. Safety factors of 1000 or even
higher have occasionally been used.
When a clear NOAEL cannot be estab-
lished on the basis of the available data, a
lowest observed adverse effects level
(LOAEL) is sometimes identified and used
to establish an ADI. In this case, a safety
factor larger than 100 is always used (the
numerical value depends on the quality of
the data and the severity of the effect).
The ADI covers the intake during the
whole lifetime, including childhood, and is
defined as the daily intake of the com-
pound that-on the basis of all relevant
information at that time-is considered
not to result in adverse health effects. ADI
is expressed in milligrams per kilogram of
body weight (bw). The use of "considered
not to" and "on the basis of all relevant
information at that point in time" under-
lines that the toxicological investigations
have their inherent limitations, that a zero-
risk does not exist, and that the ADI may
change in the light of new knowledge. ADI
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Table Al. Concentration of organochlorine contaminants in human reproductive tissue, adipose tissue, and blood from the general population worldwide.a
Geographic location/year Number of samples Quantification analysis
of sample/chemical (% positive) Units/mean SD Range Tissue Case informationb and detection limits
Norway, Oslo No history of
(1981-1982) exposure
ppb (pg/kg) Maternal
HCB 15(100) 2 2 serum/wet Caesarean 0.001 mg/kg (HCH)
20(90) 1 1 Normal delivery
PCBs 15 (93.3) 10 4 Caesarean 0.002 mg/kg (PCBs)
20(100) 10 7 Normal delivery
p,p'-DDE 15 (100) 19 21 Caesarean 0.002 mg/kg (DDE)
20(100) 10 8 , Normal delivery
P-HCH 15(73.3) <1 Caesarean 0.001 mg/kg (bHCH)
20(30) <1 Normal delivery
Umbilical
HCB 12 (83.3) 2 1 cord serum Caesarean
20(85) 1 2 . Normal delivery
PCBs 12 (75) 5 4 Caesarean
20(65) 3 1 Normal delivery
p,p'-DDE 12(100) 10 9 Caesarean
20(100) 3 2 Normal delivery
,B-HCH 12 (16.6) <1 Caesarean
20(10) <1 Normal delivery
Yugoslavia ppb (pg/l) No history of GLC-ECD
(1985-1986) Geometric Maternal exposure
1-HCH 14(100) 1.69 1.0-3.6 serum Nonpregnant
14 (100) 1.45 1.1-2.8 At delivery
y-HCH 14(100) 1.77 1.2-3.6 Nonpregnant
14(100) 2.72 0.9-5.4 At delivery
p,p'-DDE 14 (100) 9.31 6.1-14.4 Nonpregnant
14 (100) 7.57 2.8-11.7 At delivery
p,p'-DDT 14(100) 5.87 3.2-9.7 Nonpregnant
14(100) 3.62 1.0-8.2 At delivery
PCBs 14(100) 2.86 1.8-3.9 Nonpregnant
14(100) 2.01 1.1-4.65 At delivery
Yugoslavia, No history of GC-ECD
North Adriatic ppb(Mg/l) exposure
area (1989) Median
HCB 10)100) 2 1.0-4 Blood Samples taken
oa-HCH 10 (80) 2 1.0-2 from lactating
P-HCH 10(80) 18 13.0-31 mothers
p,p'-DDE 10 (100) 6 4.0-13
PCB 10 (100) 7 6.0-?
India, Bombay No history of GC-ECD
(1987) Ppfm Amniotic fluid exposure
PCBs 26(100) 0.131 0.026 0.001-1.162
Male professionals
(1986-1987) ppm.
PCBs 60(100) 0.837 0.01 0.005-3.33 Blood
India, Lucknow Placental No history of GLC-ECD
(1979-1980) ppb tissue exposure
HCH 27 (100) 39.9 10.7-97.9 Liveborn
9(100) 35.7 17.2-62.4 Stillborn
a-HCH (Lindane) 27 (100) 17.1 4.1-95.6 Liveborn
9(100) 13.4 5.5-26.1 Stillborn
Aldrin 27 (<100) 8 0.0-85.3 . Liveborn
9 (<100) 31.7 0.0-83.3 Stillborn
p,p'-DDE 27 (100) 18.3 2.8-93.0 Liveborn
9(100) 12.4 4.7-22.3 Stillborn
p,p'-DDT 27 (100) 13.8 2.0-46.3 Liveborn
9(100) 38.5 5.4-80.0 Stillborn
DDT total 27(100) 39.8 7.6-162.2 Liveborn
9 (100) 60.8 21.9-93.2 Stillborn
(continued)
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Table Al. (continued)
Geographic location/year Number of samples Quantification analysis
of sample/chemical (% positive) Units/mean SD Range Tissue Case informationb and detection limits
India, Delhi and Faridabad No history of GLC-ECD
(1987) ppb (ng/gI exposure
HCB 7 (42.9) 12.19 8 0-64 Adipose/wet U.S. EPA Manual,
1980
HCB 4(100) 280 280 59-830 Adipose/wet
Poland, Pobnan No history of GC-ECD
(1981) ppm (P9}gL exposure
HCB 36 (86.1) 0.029 0.025 0.004-0.117 Testicular
a-HCH 36(100) 0.018 0.014 0.004-0.058 Testicular
)-HCH 36 (72.2) 0.124 0.09 0.049-0.571 Testicular
y-HCH 36 (69.4) 0.022 0.02 0.004-0.083 Testicular
A-HCH 36 (97.2) 0.055 0.053 0.011-0.254 Testicular
E-HCH 36 (38.8) 0.094 0.045 0.039-0.177 Testicular
p,p'-DDE 36 (97.2) 0.072 0.045 0.015-0.216 Testicular
Heptachlor epoxide 36 (8.3) 0.131 0.047 0.083-0.194 Testicular
Massachusetts, New Bedford No history of
(1985-1986) pp exposure
PCBs 391 5.9 0.0-60.9 Blood Males
449 5.7 0.0-154.2 Blood Females
Michigan Children, 4 year GLC-ECD
(1980-1981) ppb old-no history (Webb-McCall
(ng/mIl of exposure method)
PCBs 205 (52.2) 4.18 3.29 1.00-19.40 Blood Fish exposure 3 ng/ml
80 (48.8) 4.82 4.81 1.00-23.30 Blood Farm exposure 3 ng/ml
PBBs 205(12.7) 2.44 1.5 1.00-6.40 Blood Fish exposure 1 ng/ml
80 (21.3) 2.95 2.66 1.00-9.50 Blood Farm exposure 1 ng/ml
DDT 202 (69.8) 4.36 3.87 1.00-21.40 Blood Fish exposure 1 ng/ml
79(77.2) 4.24 4.47 1.00-143.2 Blood Farm exposure 1 ng/ml
Missouri No history of HRGC-HRMS
(1987)
_Wt exposure
2,3,7,8-TCDD 50(100) 54.4 125.8 2-745 Adipose/whole
50(100) 0.519 1.314 0.013-8.290 Serum/whole
Texas, El Paso
(1984-1985) No history of U.S. EPA, 1974
exposure Manual
ppb of Analytical
Methods
Aldrin 112(34) 4.6 8.6 0.0-46.8 Blood
BHC 112 (24) 2.5 2 0.0-16.5 Blood
p,p-DDE 112 (99) 7.1 4.3 0.0-34.6 Blood
Heptachlor 112 (19) 3.1 3 0.0-9.9 Blood
Texas,
Gulf Coast
(1979-1980)
HCB
p,p-DDE
2,4,5,2',4',5'-HCBP
2,3,4,2',4',5'-HCBP
7(85.7)
7(100)
7(100)
7(100)
ppm
0.021
3.849
0.184
0.645
No history of
exposure
0.0-0.043
0.843-6.527
0.098-0.267
0.211-1.625
Germany, Munich
T4CDD
P5CDD
H6CDD
H7CDD
OCDD
T4CDF
P5CDF
28 (100)
28 100)
28 (100)
28)100)
28 (100)
28 (100)
28 (100)
8
16.4
94.7
106.7
373.2
2.5
35.2
2.6-1 8.0
7.7-40.4
35.7-178.2
35.1-246.0
116.5-789.1
0.7-12.8
7.6-93.3
Adipose
Adipose
Adipose
Adipose
No history of
exposure
Adipose
Adipose
Adipose
..
..
,,
,,
GLC-ECD
0.005 ppm (86%)
0.004 ppm (96%)
0.005 ppm (92%)
0.005 ppm (96%)
HRGC/HRMS
(continued)
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Table Al. (continued)
Geographic location/year Number of samples Quantification analysis
of sample/chemical (% positive) Units/mean SD Range Tissue Case informationb and detection limits
Germany, Munich (continued)
H6CDF 28 (100) 41.5 15.8-146.0
H7CDF 28 (100) 14.2 3.8-45.6
OCDF 28 (100) 4 1.2-13.5
T4CDD 28 (100) 16.4 1.0-88.9 Liver/fat
P5CDD 28 (100) 20.2 7.3-58.7
H6CDD 28 (100) 166.8 56.4-615.1
H7CDD 28 (100) 1002.4 95.5-3463.1
OCDD 28 (100) 4416.2 472.7-15259
T4CDF 28 (100) 5 5 0 9-45 3
P5CDF 28 (100) 173.7 36.7-643.0
H6CDF 28 (100) 389.5 40.8-1800.7
H7CDF 28 (100) 218.9 12.2-757.0
OCDF 28 (100) 29.7 4.3-65.8
Pakistan, No history of GC/MS
Quetta ppb (W/I) exposure
(1987) 21(66.6) 0.396 0-1.88 Blood
xc-HCH 21(90) 1.99 0-7.16
,B-HCH 21(100) 9.26 0.53-18.98
4,4'-DDE 21(76.2) 0.94 0-4.83
4,4'-DDT
Spain, agrarian
area (1985-1987) ppm (ml/kg) Adipose/ext. No history of GLC-ECD
HCB 87(100) 2.99 2.24 lipid exposure
p,p'-DDE 87 (100) 6.27 5.67
Lindane 87(100) 0.083 0.05
)-HCH 87 (100) 3.06 5.18
p,p'-DDD 87 (62) 0.079 0.079
p,p'-DDT 87(100) 1.5 0.89
Dieldrin 87 (100) 0.072 0.068
Australia, Sidney No history of GLC-ECD
(1985-1986) ppmWnAigL exposure
292 (99.3) 3.72 0.0-26.30 Adipose/wet 0.001 ppm (81%)
DDT 292 (99.3) 0.13 0.0-0.16 0.001 ppm (81-102%)
Dieldrin
Canada, Ontario No history of GC/MS
(1984) ppb (ng/gI exposure
141(100) 84 56 18-373 Adipose 1.4 ng/g
HCB 141 (100) 84 82 14-530 3.0 ng/g
)-HCH 141 (100) 33 27 2-107 1.1 ng/g
Heptachlor 141 (100) 3237 2602 138-12167 1.2 ng/g
epoxide 141 (99.3) 47 41 0-235 0.9 ng/g
p,p'-DDE 141 (100) 84 80 7-369 1.7 ng/g
Dieldrin 141 (92.2) 11 13 0-98 1.8 ng/g
p,p'-DDT 141 (100) 2136 1473 197-11209 " 00lng/g
Mirex
PCB
Israel,
Jerusalem
(1984-1985)
p,p'-DDT
p,p -DDE
o,p'-DDT
29
14
29 (100)
14(100)
29
14
29
ppb (ng/g)
3.09
0.4
16.1
10.55
7.111
5.83
2.61
6.81
0.99
11.82
8.17
6
8.6
3.51
0.0-28.8
0.0-3.5
2.9-43.4
2.1-32.1
0.0-21.6
0-0-32 2
0.0-15.4
Blood
.,
,,
,,
,,
,,
,,
No history of
exposure (males
5-year history of
infertility=
Study group)
Study group
Control group
Study group
Control group
Study group
Control group
Study group
GC-MS
(continued)
Environmental Health Perspectives * Vol 104, Supplement 4 - August 1996780
MALE REPRODUCTION AND ENVIRONMENTAL CHEMICALS
Table Al. (continued)
Geographic location/year Number of samples Quantification analysis
of sample/chemical (% positive) Units/mean SD Range Tissue Case informationb and detection limits
o,p-DDE 14 1.27 2.04 0.0-6.4 " Control group
29 2.28 2.42 0.0-9.8 " Study group
Lindane 14 1.13 0.671 0.0-3.0 " Control group
29 3.65 3.71 0.0-15.9 " Study group
Dieldrin 14 2.69 2.47 0.0-7.1 " Control group
29 (100) 8.31 3.83 3.0-15.8 ' Study group
Heptachlor 14 (100) 11.64 3.67 17.0-21.7 " Control group
epoxide 29 11.21 13.48 0.0-64.2 " Study group
14 7.94 14.69 0.0-47.3 " Control group
Total PCBs
Japan No history of GC-ECD
(1986-1988) ppgm exposure
,-HCH 23(100) 0.84 0.44 0.37-2.02 Adipose/fat
p,p'-DDE 23 (100) 2.4 2.5 11.04-0.52
Heptachlor 23 (91.3) 0.07 0.06 0.00-0.25
epoxide 23 (100) 0.67 0.48 0.13-2.16
Chlordane 20(85) 0.08 0.08 0.00-0.27
Dieldrin
Japan, Tokushima ppb (ng/g) No history of GC-ECD
(1984-1985) Geometric exposure
Chlordane 22(100) 0.51 1.6 0.18-1.16 Blood Male subjects 0.01 ppb
21(100) 0.46 1.7 0.12-1.12 " Female subjects
Japan No history of GC-MS
(1985) ppt(pg/g) exposure
2,3,7,8-TCDD 13 (92.3) 9 6-18 Adipose/wet (Cancer patients)
1,2,3,7,8-PCDD 13 (100) 15 3-36
1,2,3,4,7,8-HCDD 13 (69.2) 8 5-14
1,2,3,6,7,8-HCDD 13 (92.3) 70 26-220
1,2,3,7,8,9-HCDD 13(76.9) 12 4-44
1,2,3,4,6,7,9-HCDD 13 (69.2) 28 14-63
1,2,3,4,6,7,8-HCDD 13 (92.3) 77 29-180
08CDD 13 (92.3) 230 26-1100
PCDDs total 410 160-1400
2,3,7,8-T4CDF 13(100) 9 3-12
2,3,4,7,8-P5CDF 13(100) 26 4-71
1,2,3,4,7,8-/1,2,3,4,7,9-H6CDF 13 (84.65) 15 4-24
1,2,3,4,7,9-H6CDF 13 (84.6) 14 3-28
2,3,4,6,7,8-H6CDF 13 (23.1) 8 4-16
PCDFs total 63 7-120
Abbreviations: GC-ECD, gas chromatography-electron capture detector GLC-ECD, gas-liquid chromatography-electron capture detector GC-MS, gas chromatography-mass
spectrometry HRGC-HRMS, high-resolution GC-MS. aAdapted from Thomas and Colborn (1). bGeneral information regarding the subjects analyzed.
is not a danger-limit, but rather a safe value
for an acceptable exposure to the pesticide
in question. Exposures that lead to exceed-
ing the ADI on a short-term basis are not
expected to result in any health hazard.
GAP is defined as the nationally autho-
rized safe method for application of a pesti-
cide that under local conditions, such as
climate, is found necessary for effective crop
protection. The MRL is based on field
spraying trials and subsequent determina-
tions of residues. These investigations
include different methods of application,
including those using the highest dosages
and used in such a way that the lowest possi-
ble amount of residue is produced. The
MRL is never established at a level higher
than needed even if the established ADI
value would allow a higher residue content.
In practice, this means that the intake of
most pesticides by the general population is
well below the ADI. In the evaluation of the
health risk, the possible total intake of the
pesticide is calculated as if the concentration
in all the food in which it can be present is
at the MRL for each single food item. This
means that exceeding the MRL in one single
sample does not automatically result in
exceeding the ADI, as many samples nor-
mally are without detectable residues.
The toxicological evaluations of conta-
minants and industrial chemicals are in
principle performed following the same
principles that are used for the pesticides.
However, as exposure to such compounds is
not intended, but in many cases is unavoid-
able, tolerable daily intakes (TDIs) are
established rather than ADIs.
For many environmental chemicals the
toxicological database is less comprehen-
sive than for most pesticides. This is true
for many chemicals that were introduced
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Table A2. Human breast-milk fat concentrations worldwide compared with the lowest observed endocrine or reproductive effect levels in animal studies. a
Human data Animal data
Average levels in
Chemical and units human breast milk fat High levels, location Doses, exposure route Impairment
Dieldrin 0.05 ppm 1.78 ppm 20 mg/kg/bw. Induced testoserone,
Heptachlor and its epoxide
Chlordane (oxychlordane
and trans-nonachlor)
Total DDT
0.05 ppm
0.08 ppm
1.00 ppm
0.25 ppm
Australia
1.00 ppm
Iraq
1.00 ppm
Uruguay
2.50 ppm
Spain
0.48 ppm
Italy
>2.00 ppm
Mexico and Iraq
Single injection to ten 3-
week-old rats
250 ,umole/kg/bw.
Single injection to 3-
week-old rats
0.16 mg/kg wt/day.
Dietary exposure to pregnant mice
throughout gestation
>100 ppm
Guatemala
2 ppm.
Dissolved in corn oil and
injected into yolk of gull embryos
16ax- and 16p-hydroxylases
Induced testosterone,
1 6a- and 16P-hydroxylases
Elevation of plasma cortico-
sterone concentrations, when
measured on day 400 in both male
and female offspring.
Caused feminization
(a thickened ovarylike cortex
in left testis).
300 ,umole/kg/bw.
Single injection to 3-
week-old rats.
50 mg/kg/bw (ppm).
Dietary exposure to weaned
rats for 13 weeks.
8 mg/kg (ppm).
ip daily in glycerine-
suspension to adult male
rats for 10 days.
8 mg Aroclor 1254/kg
(ppm). Dissolved in 0.2
ml peanut oil. Lactating
dams were exposed via
their diet on days 1,3,5,7,
and 9 of lactation
0.064 jig/kg (ppb)-
Dietary exposure to pregnant
rat on day 15 of gestation
Induced testosterone,
16ax- and 16p-hydroxylases.
Caused reduction in testes weight.
Caused reduction in testes weight,
degeneration of seminiferous
tubules and affected both
spermatocytes and spermatids
Males exposed only during
lactation exhibited reduced
fertility as adults. Specifically,
decreased number of implants
and decreased number of embryos
when mated normal females
Male offspring had decreased
sperm counts when exposed
perinatally in utero and via lactation
aAdapted from Thomas and Colborn) (1).
in the society before the stricter regula-
tions of new chemicals were enforced in
many countries during the 1970 to 1980s.
Toxicological Summaries on
Pesticides and Other
Chemicals Implicated as
Environmental Hormones
The following summaries on the most
important toxicological properties of vari-
ous compounds that have been implicated
as environmental hormones are mainly
based on the monographs prepared by the
expert groups of the JMPR and on the
reviews performed by the U.S. EPA as
published in the IRIS database (U.S. EPA's
Integrated Risk Information System). In
addition, valuable information can be
found in the Environmental Health
Criteria (EHC) documents published by
the International Programme on Chemical
Safety (IPCS). These monographs are pub-
lished under the joint sponsorship of the
United Nations Environment Programme,
the International Labour Organisation,
and the World Health Organization. Most
attention has been paid to those com-
pounds that have not already been dis-
cussed in "Environmental Chemicals with
Known Estrogenic Effects" and "Exposure
of Humans to Environmental Chemicals
with Estrogenic Activity and Their Effects
on Male Reproductive Health."
Preliminary estimates of dietary intakes
are included (unpublished data). It is antici-
pated, but not necessarily true for all of the
compounds, that diet is the major route of
exposure for the general population. It is
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o,p'-DDT
HCB 0.10 ppm
1-HCH 1.00 ppm
y-HCH 0.05 ppm
Total PCB 1.00 ppm
7.00 ppm
Greece
6.50 ppm
Chile
0.89 ppm
Italy
3.6 ppm
Canada
(Hudson Bay)
1.45 ppb
Vietnam
(1 970s)
2,3,7,8-TCDD 2.00 ppt
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known that the drinking water in Denmark
meets the general limit standard of 0. 1
fg/liter, and that for most of the com-
pounds the levels of exposure are expected
to be very low. However, for some of the
herbicides, recent analysis of groundwater
samples has in some cases revealed the pres-
ence of 2,4-dichlorophenoxyacetic acid
(2,4-D) and atrazine near the limit value.
For pesticides and PCBs these prelimi-
nary estimates of dietary intakes are based
mainly on the results and experiences of
more than 30 years of pesticide control of
Danish and imported foodstuffs. The
results have been continuously published
(in Danish) in reports from the Danish
National Food Agency. The latest report
was published in 1994, covering the results
of the samples analyzed in 1993 (2). The
latest sales statistics of the chemicals were
published 1994 (3).
Herbicides
The exact exposure to the herbicides
described later in this section is not known.
To a limited extent, the herbicides have
been included in the Danish pesticide con-
trol program since the early 1980s. When
analyzed, these herbicides were found to be
almost absent in food samples during the
1970s in spite of considerable use.
Herbicides are used on plant food crops
only very early in the growth season and
are therefore less likely to be present in the
final product. This view is supported by
the observations of other countries. MRLs
for the herbicides in fruits and vegetables
have been set at the limit of detection, typ-
ically 0.05 mg/kg. The above-mentioned
observations lead to the assumption that
the average herbicide concentration in all
fruits and vegetables, after rinsing, peeling,
and preparating for consumption, is at least
1000 times lower than the MRL, e.g., less
than 0.05 fg/kg. In Denmark the yearly
intake of fruits and vegetables has been esti-
mated at 60 kg per capita for each food cat-
egory. This would correspond to an intake
of less than 0.006 mg of each herbicide per
person per year.
2,4-Dich1orophenoxyacetic Acid.
2,4-Dichlorophenoxyacetic acid and
derivatives are currently being used as
herbicides. The dietary intake estimate of
less than 0.006 mg/person/year would
correspond to a daily intake of less than
0.0000003 mg/kg bw/day for a 60-kg per-
son. If it is assumed that drinking water
contains 2,4-D at a level near the limit
value of 0.1 fg/liter, and the daily consump-
tion is set at 2 liters for a 60-kg person, a
daily intake of 0.000003 mg/kg bw/day
can be estimated. 2,4-D was most recently
evaluated by JMPR in 1975 when an ADI
of 0 to 0.3 mg/kg bw was established (4).
An RfD for noncarcinogenic effects of
2,4-D has been established by the U.S. EPA
(5) at 0.01 mg/kg bw/day based on a no
effect level of 1.0 mg/kg bw/day in rat sub-
chronic bioassays. At 5.0 mg/kg bw/day,
hematologic, hepatic and renal toxicities
were observed. The safety factor was 100.
Histopathological examinations correlated
well with kidney organ weight changes
showing cortical and subcortical pathology.
Increases in ovarian weights and T4 levels
were not considered to be treatment
related. Increases were also noted in thy-
roid/pituitary weights at high dose levels;
however, no histopathological changes were
found (5). Chronic toxicity and reproduc-
tion studies of 2,4-D exposure indicated no
adverse effects at dietary levels up to 500
ppm in dogs (approximately 14.5 mg/kg
bw/day), up to 1250 ppm in rats (approxi-
mately 62.5 mg/kg bw/day) (6), or at levels
of 1000 ppm in drinking water (50-100
mg/kg bw/day) in pregnant rats (exposed
through gestation and for 10 months fol-
lowing parturition) or their offspring
(exposed for up to 2 years after weaning)
(7). 2,4-D does not accumulate in the
mammalian organism. Further toxicological
information on 2,4-D exposure can be
found in EHC 29 (8) and EHC 84 (9).
2,4,5- Trichlorophenoxyacetic Acid.
For 2,4,5-trichlorophenoxyacetic acid
(2,4,5-T), the dietary intake estimate of
less than 0.006 mg/person/year would cor-
respond to a daily intake of less than
0.0000003 mg/kg bw/day for a 60-kg per-
son. The most recent evaluation of 2,4,5-T
by JMPR is from 1981 when an ADI of 0
to 0.03 mg/kg bw was established (10).
An RfD for noncarcinogenic effects of
2,4,5-T was established by the U.S. EPA at
0.01 mg/kg bw/day and is based on a no
effect level of 3 mg/kg bw/day in a 2-year
feeding study in rats and a three-generation
reproduction study in rats. At 10 mg/kg
bw/day, increased urinary coproporphyrin
was observed in the chronic study and a
tendency toward reduced neonatal survival
was seen in the three-generation reproduc-
tion study. The safety factor was 300 (5).
Other studies have also shown effects
on reproduction in mice, rats, hamsters,
and monkeys. A NOEL of 8 mg/kg
bw/day for reduced fetal body weight was
reported for NMRI mice (11). Fetal mor-
tality was observed after administration of
2,4,5-T at 40 mg/kg bw/day (highest dose)
to pregnant hamsters. Cleft palate was
induced in A/JAX mice at 15 mg/kg
bw/day; lower doses were not tested. Other
strains of mice were less sensitive. Higher
doses (approximately 200 mg/kg bw/day)
induce frank teratogenic effects in rats. A
qualitative association between 2,4,5-T
exposure and human birth defects has been
suggested. Terata and fetotoxic effects have
not been observed in monkeys up to a dose
of 40 mg/kg bw/day (5). 2,4,5-T does not
accumulate in the mammalian organism.
Alachlor. For alachlor, the dietary
intake estimate of less than 0.006 mg/per-
son/year would correspond to a daily intake
of less than 0.0000003 mg/kg bw/day for
a 60-kg person. Alachlor has not been
evaluated by JMPR.
An RfD for noncarcinogenic effects of
alachlor was established by the U.S. EPA at
0.01 mg/kg bw/day based on a no effect
level of 1 mg/kg bw/day in a 1-year dog-
feeding study. At 3 mg/kg bw/day, hemo-
lytic anemia was observed; and in an earlier
study using higher dose levels, changes
indicative of liver toxicity were recorded.
The safety factor was 100. No signs of tes-
ticular toxicity were observed in any of
these studies (5).
In a 2-year chronic toxicity/carcino-
genicity study of alachlor in rats, a NOEL
for systemic toxicity was found at 2.5
mg/kg bw/day. At 15 mg/kg bw/day, molt-
ing of retinal pigmentation, increased
mortality rate in females, and abnormal
disseminated foci in the liver of males were
seen. In an earlier 2-year feeding study in
rats, 14 mg/kg bw/day and higher dose lev-
els resulted in degenerative ocular and
hepatic changes as well as other pathologi-
cal gross and microscopic findings in the
thyroid, kidneys, brain, spleen, heart,
prostate, and ovaries (5).
In a three-generation reproduction
study of alachlor in rats using dietary levels
of 0, 3, 10, and 30 mg/kg bw/day, no sig-
nificant adverse effects on the reproductive
performance of adult rats were observed at
any dose tested. Compound-related effects
were seen on kidneys (increased weights
and pathological changes in parents and
progeny) in the high-dose males and
females. Lower ovary weights were noted in
the high-dose females of each parental gen-
eration and in pups from the third genera-
tion. The NOEL for systemic toxicity was
10 mg/kg bw/day (5).
In a developmental toxicity study in
rats, soft stools, hair loss, anogenital stain-
ing, and maternal death were observed
after 400 mg/kg bw/day, whereas the
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NOEL for maternal toxicity was 150 mg/kg
bw/day. Based on a slight decrease in mean
fetal body weight and a slight increase in
mean postimplantation loss, the NOEL
and LOAEL for developmental toxicity
were 150 and 400 mg/kg/day, respectively.
In the rabbit, the NOEL for developmen-
tal toxicity was found to be equal to or
greater than 150 mg/kg bw/day (5).
Amitrole. No residues of amitrole have
been detected in food after recommended
use (12). The previously mentioned pre-
liminary dietary intake estimate of less than
0.006 mg/person/year would correspond
to a daily intake of less than 0.0000003
mg/kg bw/day for a 60-kg person.
Amitrole was evaluated for acceptable
daily intake by JMPR in 1993, when a
temporary ADI of 0 to 0.0005 mg/kg bw
was established based on a no effect level of
0.5 mg/kg bw/day in a long-term toxicity/
carcinogenicity study in rats. At a dose
level of 5 mg/kg bw/day, an increase in the
incidence of thyroid tumors and an increase
in (mainly benign) pituitary tumors were
observed. Due to the noncompleteness of
the available reproduction study, a safety
factor of 1000 was used (13).
In mice, rats, and sheep, but not in
Syrian hamsters, dogs, or cattle, amitrole
affects the thyroid. In the rat, a no effect
level was established at 2 ppm in the diet
for 6 to 13 weeks (equivalent to 0.1 mg/kg
bw/day) based on increased iodine uptake
(shortly after injection), increased thyroid
weight, and histopathological changes of
the thyroid (goiter and clearly activated
thyroids). The mechanism involves inhibi-
tion of thyroid peroxidase, resulting in
decreases in circulating levels of T4 and T3,
which stimulate the pituitary to increase
secretion of thyroid-stimulating hormone
(TSH), which in turn may cause thyroid
hypertrophy, hyperplasia, and neoplasia.
Long-term toxicity/carcinogenicity
studies have been performed in mice, rats,
and golden hamsters. In the mouse, liver
and thyroid tumors were observed after
administration of 1000 mg/kg bw/day by
gavage. In a special carcinogenicity study,
in which pups were treated for a period of
90 weeks at a level of 500 ppm in the diet, a
slight increase in liver tumors was observed.
In another 18-month carcinogenicity study
in mice, levels of 0, 1, 10, or 100 ppm in
the diet did not increase the incidence of
tumors. At 100 ppm an increase in thyroid
weight was observed.
In the rat, 100 ppm in the diet for 24
months produced an increase in the inci-
dence of thyroid tumors and an increase in
(mainly benign) pituitary tumors. At this
dose level the thyroid weight was increased
throughout the study. There was no effect
with 10 ppm in the diet. Amitrole was con-
sidered not to be teratogenic in the rat at
dose levels up to 1000 mg/kg bw/day.
Slight maternal toxicity and fetal and
embryotoxicity (reduced fetal body weight/
litter, reduced skeletal ossification and
increased incidence of enlarged and/or dark
fetal thyroids) were seen after dose levels of
500 and 1000 mg/kg bw/day.
In the hamster, up to 100 ppm of amit-
role in the diet produced no evidence of
carcinogenicity, and no effect was observed
on the thyroid.
In the rabbit, embryo and fetotoxicity
were observed after a dose level of 40 mg/kg
bw/day. The no effect level was considered
to be 4 mg/kg bw/day.
No adequate reproduction study is
available. From a limited study in rats at
dietary concentrations ranging from 25 to
1000 ppm, effects on reproductive capabil-
ity were observed at a dose level of 500 ppm
and above. Reduction of liver weight and
thyroid hyperplasia was observed at the
lowest level studied, 25 ppm (equivalent to
1.3 mg/kg bw/day).
Amitrole does not accumulate in the
mammalian organism. Additional toxico-
logical information can be found in EHC
158 (12).
Atrazine. For atrazine, the preliminary
dietary intake estimate of less than 0.006
mg/person/year would correspond to a
daily dietary intake of less than 0.0000003
mg/kg bw/day for a 60-kg person. If it is
assumed that the drinking water contains
atrazine at a level near the limit value of
0.1 fg/liter, and the daily consumption is
set at 2 liters for a 60-kg person, a daily
intake of 0.000003 mg/kg bw/day can be
estimated. Atrazine has not been evaluated
by JMPR.
An RfD for noncarcinogenic effects of
atrazine was established by the U.S. EPA at
0.035 mg/kg bw/day based on a no effect
level of 3.5 mg/kg bw/day in a 2-year rat
feeding study. Mean body weights were
significantly depressed in males and females
receiving 25 and 50 mg/kg bw/day. The
absolute weight of liver and kidney in
males receiving 50 mg/kg bw/day was sig-
nificantly lower than that in controls. The
safety factor was 100 (5). Acinar hyperpla-
sia of the mammary gland and epithelial
hyperplasia of the prostate were increased
in males receiving 50 mg/kg bw/day when
compared to controls. In females receiving
25 or 50 mg/kg bw/day, there were
increases in the incidences of mammary
fibroadenomas and adenocarcinomas.
In beagle dogs administered atrazine for
1 year in the diet, a dose level of 4.97
mg/kg bw/day was without toxicity. At a
level of 33.65 mg/kg bw/day, clinical signs
and pathological changes related to cardiac
toxicity were found (5).
Atrazine is able to induce hormonal
imbalances in rodents. Most work has been
directed toward the effects of atrazine on
the pituitary-gonadal axis. Steroid hormone
metabolism was found to be impaired by
atrazine. At 120 mg/kg bw/day for 7 days,
atrazine increased the wet weight of the
anterior pituitary (hyperemia and hypertro-
phy) and reduced the activities of several
steroid-metabolizing enzymes in the rat.
The deethylated metabolite of atrazine was
equally potent. Prenatal treatment with
atrazine or deethylatrazine (16 mg/kg bw,
sc) did not alter pituitary metabolism in
male pups, but atrazine increased 5-a-
steroid reductase activity in the female
pups. Treatment pre- and postnatally with
atrazine and its metabolite decreased 3-ax-
hydroxysteroid dehydrogenase activity, and
atrazine decreased 5-a-steroid reductase
activity in the male pups. Both compounds
decreased the number of androgen-specific
binding sites in the prostate. Neither com-
pound had any effect on female pituitary
androgen metabolism. In vitro studies have
demonstrated inhibition of rat pituitary
androgen metabolism by atrazine (14).
In a three-generation reproduction
study with atrazine in rats, body weights
were significantly lower for high-dose ani-
mals (34.97 mg/kg bw/day) throughout
the study. Body weight gains were also
significantly depressed at the high dose.
The NOEL for parental toxicity was 3.5
mg/kg bw/day. At 34.97 mg/kg bw/day an
equivocal decrease in body weights of the
second generation male pups was observed.
Therefore, the NOEL for reproductive
toxicity was also 3.5 mg/kg bw/day (5).
Several developmental toxicity tests have
been performed in rats and rabbits. In these
studies, embryotoxicity and fetotoxicity
have been observed only at dose levels
where maternal toxicity was also evident. In
addition, developmental toxicity studies in
rats of two metabolites of atrazine, hydroxy-
atrazine and diaminochlortriazine, did
not reveal a specific potential concerning
embryo- or fetotoxicity (5).
Atrazine does not accumulate in the
mammalian organism.
Metribuzin. For metribuzin the
dietary intake estimate of less than 0.006
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mg/person/year would correspond to a
daily intake of less than 0.0000003 mg/kg
bw/day for a 60-kg person. Metribuzin has
not been evaluated by JMPR.
An RfD for noncarcinogenic effects was
established by the U.S. EPA at 0.025
mg/kg bw/day based on a no effect level of
2.5 mg/kg bw/day in a 2-year dog-feeding
study. At 37.5 mg/kg bw/day mortality,
decreased body weights and liver and kid-
ney effects were observed. The safety factor
was 100 (5).
In a 2-year chronic toxicity/carcino-
genicity study in rats, the NOEL was
5.0 mg/kg bw/day. Following a dose level
of 15.0 mg/kg bw/day, decreased body
weight gain and pathologic changes in the
liver, kidneys, uterus, and mammary glands
were observed.
Metribuzin was not carcinogenic to
rats. Enlarged thyroids were reported in
male rats administered 25 and 75 mg/kg
bw/day for 3 months (5). Metribuzin
was not carcinogenic in a 2-year mouse
study. At 480 mg/kg bw/day, changes
were observed in hematological parameters
and liver weight. The NOEL was 120
mg/kg bw/day.
Studies on developmental toxicity in
rats and rabbits have not revealed terato-
genicity at doses up to 100 or 15 mg/kg
bw/day, respectively. In a three-generation
reproduction study in rats, a NOEL of 15
mg/kg bw/day for reproductive effects and
maternal toxicity was established (5).
Metribuzin does not accumulate in the
mammalian organism.
Trifluralin. For trifluralin, the dietary
intake estimate of less than 0.006 mg/
person/year would correspond to a daily
intake of less than 0.0000003 mg/kg
bw/day for a 60-kg person. Trifluralin has
not been evaluated by JMPR.
An RfD for noncarcinogenic effects of
trifluralin was established by the U.S. EPA
at 0.0075 mg/kg bw/day based on a no
effect level of 0.75 mg/kg bw/day in a 1-
year dog-feeding study. At 3.75 mg/kg
bw/day, increased liver weights and an
increase in methemoglobin were observed.
The safety factor was 100 (5).
At higher dose levels administered to the
dog for 6 months (10 mg/kg/day), enlarged
livers, discolored kidneys, corneal vascular-
ization, hemolytic anemia, and increased
alkaline phosphatase concentrations were
seen (5).
Several subchronic and chronic bio-
assays in the mouse and rat have produced
NOELs that are higher than the one
observed in the dog (5). In a 3-month
feeding study in rats, the pituitary weight
relative to the body weight was decreased
after 40 mg/kg bw/day.
In two two-generation reproduction
studies in the rat, the lowest NOEL for
reproductive effects was identified at 32.5
mg/kg bw/day. At 100 mg/kg bw/day
reduced litter size was seen. In the parents,
increased kidney weights and renal lesions
of the proximal tubules were observed after
doses of 32.5 mg/kg bw/day. Teratology
studies in rats showed no malformations,
whereas fetotoxicity (decreased mean fetal
body weight) was observed after doses of
1000 mg/kg bw/day, a dose level that also
produced maternal toxicity. However, in
another teratology study in rats, reduced
skeletal maturity and increased vascular
fragility were reported after doses of 20
mg/kg bw/day. In the rabbit, no terata were
observed, whereas fetotoxicity (decreased
fetal weight and increased number of fetal
runts) was seen at a maternally toxic dose
of 500 mg/kg bw/day (5).
In one 2-year chronic bioassay of
trifluralin using F344 rats, significant
increases were found in the incidences of
bladder papillomas and renal pelvis carci-
nomas at the highest dose level tested in
female and male rats. In addition, a
significant increase in the incidence of fol-
licular cell tumors of the thyroid gland
(adenomas and carcinomas combined)
occurred at the highest dose tested in male
rats. Four other rodent chronic bioassays of
trifluralin in the diet have been performed.
These included a 2-year study in Sprague-
Dawley rats, a 78-week study in Osborne-
Mendel rats, a 78-week study in B6C3F1
mice, and a 2-year study in B6C3F1 mice.
Trifluralin did not produce significant
increases in the incidence of tumors in any
of these studies (5).
Fungicides
Benomyl (and Its Prineipal Metabolite
Carbendazim). Benomyl is widely used as
a fungicide together with carbendazim. In
both instances the active principle is
methyl-2-benzimidazolecarbamate and
MRLs are expressed as carbendazim.
The main source of exposure for the
general population is the residue of benomyl
and carbendazim in food crops. Dietary
exposure analysis in the United States and
the Netherlands yielded an expected mean
daily intake of about one-tenth the ADI for
benomyl and carbendazim (0.001-0.002
mg/kg bw/day) (15). In 1993, residues were
found in 1 of 72 samples of apples and 1 of
30 samples of bananas in Denmark. The
detection limit is 0.1 mg/kg, which is also
the MRL in most crops. However, in some
fruits the MRL is 2 mg/kg. Considering that
residues were found in only a few samples
and that intake of residues primarily will
originate from fruits, it is assumed that the
average concentration in all fruits, after
rinsing, peeling, and preparing for con-
sumption, is at least 1000 times lower than
the MRL, e.g., less than 0.002 mg/kg. In
Denmark the yearly intake of fruits has been
estimated at 60 kg per capita. This implies
an intake of less than 0.120 mg of carben-
dazim per person per year corresponding to
a daily intake of less than 0.000006 mg/kg
bw/day for a 60-kg person.
In 1983, JMPR established an ADI of
0 to 0.02 mg/kg bw for benomyl. In 1985,
an ADI was established of 0 to 0.01 mg/kg
bw for carbendazim. These ADI values
were based on no effect levels for benomyl
of 30 mg/kg bw/day for teratology studies
in the rat and 125 mg/kg bw/day for
chronic studies in the rat. The no effect
level for carbendazim was 2.5 mg/kg
bw/day in subchronic dog studies (16-18).
An RfD for noncarcinogenic effects of
benomyl was established by the U.S. EPA
at 0.05 mg/kg bw/day based on a no effect
level of 5 mg/kg bw/day in a three-genera-
tion reproduction study in rats. At 25
mg/kg bw/day, decreased pup weaning
weights were observed. The safety factor
was 100 (5).
Toxicological monographs on benomyl
and carbendazim have also been published
by IPCS (15,19).
In the reproductive system, benomyl
and its metabolite carbendazim cause, after
an initial testicular swelling, a decrease in
testis and epididymis weight in adult male
rats, a reduction in caudal sperm reserves, a
decrease in sperm production, and a
decrease of male fertility. At higher doses,
there is generalized disruption of all stages
of spermatogenesis. Benomyl does not
affect copulatory behavior, seminal vesicles,
sperm mobility, or related reproductive
hormones. The lowest benomyl concentra-
tion shown to induce statistically signi-
ficant spermatogenic effect in male rats was
45 mg/kg bw/day. The NOEL for these
effects was 15 mg/kg bw/day (15,19). The
testicular effects of benomyl treatment in
the adult rat were shown to be reversible
after a recovery period of 70 days.
In one study in which prepubertal male
rats (33 days of age) were administered 200
mg benomyl/kg bw/day for 10 days, no
effects on sperm parameters and testicular
histopathology were induced (15).
Environmental Health Perspectives * Vol 104, Supplement 4 * August 1996 785
TOPPARI ET AL.
Several studies in rats and mice have
demonstrated teratogenicity of benomyl
and carbendazim. A NOEL of 30 mg/kg
bw/day for benomyl has been established
in the rat (5).
Benomyl and carbendazim caused liver
tumors in two strains of mice that have a
high spontaneous rate of liver tumors,
whereas carbendazim did not produce
tumors in a mouse strain with a low spon-
taneous incidence of tumors. Carcino-
genicity studies with both compounds in
the rat were negative (10,20).
Benomyl and carbendazim do not accu-
mulate in the mammalian organism.
Ethylenebisdithiocarbamates:
Mancozeb, Maneb, Metiram, and Zineb.
Ethylenebisdithiocarbamates (EBDCs) are
fungicides primarily used in the production
of fruits and vegetables. Residues are fre-
quently found at levels below the MRLs,
which typically are between 0.5 mg (the
detection limit) and 2 mg/kg. If a concen-
tration of 1 mg/kg is used as an average
MRL for fruits and vegetables, and it is
assumed that the average concentration in
all fruits and vegetables, after rinsing, peel-
ing and preparing for consumption, is at
least 100 times lower than the MRL, an
intake of less than 1.2 mg per person per
year can be obtained from 60 kg of fruits
and 60 kg of vegetables. This would corre-
spond to a daily intake of less than 0.00006
mg/kg bw/day for a 60-kg person.
These compounds were evaluated for
acceptable daily intake by JMPR in 1993.
A group ADI of 0 to 0.03 mg/kg bw was
established for each compound alone or in
combination because of a) the similarity
of chemical structure of the EBDCs;
b) the comparable toxicological profiles of
the EBDCs based on the toxic effects of
ethylenethiourea (ETU), which forms part
of the terminal residue to which con-
sumers of products treated with the
EBDCs are exposed; and c) the fact that
parent EBDC residues cannot be differen-
tiated using presently available analytical
procedures (13).
These compounds are rapidly absorbed,
extensively metabolized, and rapidly
excreted (90%) within 24 hr in rodents.
ETU is the major metabolite.
The data on mancozeb would support
an ADI of 0 to 0.05 mg/kg bw, based on a
no effect level of 4.8 mg/kg bw/day in a rat
long-term toxicity/carcinogenicity study
using a safety factor of 100.
In the rat, mancozeb affects the thy-
roid. In a 13-week study in rats, the no
effect level of mancozeb was 125 ppm in
the diet, equal to 7.0 mg/kg bw/day, based
on increased serum TSH and decreased T4
values at 250 ppm in the diet.
Mancozeb was not carcinogenic in the
mouse in two long-term toxicity/carcino-
genicity studies. At the highest dose used,
1000 ppm in the diet (equivalent to 130
mg/kg bw/day) decreased body weight and
decreased T3 and T4 values were recorded.
In a two-year long-term toxicity/carcino-
genicity study in the rat, a no effect level of
125 ppm in the diet, equivalent to 4.8
mg/kg bw/day, was observed. At 750 ppm
in the diet, decreased body weight gains,
decreased T3 and T4 values, increased
thyroid weights, thyroid follicular cell
hypertrophy, hyperplasia, and nodular
hyperplasia were seen. Increased incidences
of thyroid follicular cell adenomas and/or
carcinomas were noted at this dose level.
In two 2-generation reproduction
studies, the overall no effect level was
observed at 120 ppm in the diet, equiva-
lent to 7.0 mg/kg bw/day. At 150 ppm
decreased body weights were seen and at
1200 ppm microscopic changes were
observed in the thyroid, kidney, and pitu-
itary gland. Other changes found were
increased relative weights of liver, kidney
and thyroid; decreased gestation and lacta-
tion, body weight, and feed consumption;
decreased premating body weight and
feed consumption.
Several teratogenicity studies in rats and
rabbits have produced embryo and fetotox-
icity only at dose levels where maternal
toxicity was clearly evident. At a high dose
level of 512 mg/kg bw/day, teratogenic
effects were seen (13).
The data on maneb would support an
ADI of 0 to 0.05 mg/kg bw, based on the
no effect level of 5.0 mg/kg bw/day for
thyroid effects in rat studies using a safety
factor of 100.
In the rat, dog, and monkey, maneb
affects the thyroid. In a 13-week study in
rats, the no effect level of maneb was
80 ppm in the diet equal to 5.0 mg/kg
bw/day, based on an increase in absolute
thyroid weight and thyroid follicular cell
hyperplasia at 400 ppm. In two studies in
dogs, follicular cell hyperplasia in the thy-
roid was observed after 400 ppm in the
diet for 13 weeks and 1000 ppm in the diet
for 52 weeks, respectively. The overall no
effect level was 200 ppm, which is equiva-
lent to 6.4 mg/kg bw/day. In the monkey
an increased thyroid weight was observed
after 300 ppm in the diet for 6 months,
while 100 ppm in the diet, equivalent to
7.3 mg/kg bw/day, was without effect.
Maneb produced hepatocellular adeno-
mas in the mouse in a 79-week long-term
toxicity/carcinogenicity study at a dose
level of 2400 ppm in the diet. A no effect
level was established at 60 ppm in the diet,
equivalent to 11 mg/kg bw/day, whereas
decreased body weight and decreased
thyroxin levels were observed at 240 ppm.
In a 31-month long-term toxicity/car-
cinogenicity study in the rat, a no effect
level of 300 ppm in the diet, equivalent to
20 mg/kg bw/day, was observed. At 1000
ppm in the diet decreased body weight,
decreased T4 values, and increased thyroid
weights were seen. There was no evidence
of carcinogenicity.
In two two-generation reproduction
studies, the no effect level was observed at
75 ppm in the diet, equivalent to 5.6
mg/kg bw/day. At 300 ppm, increased
organ to body weight ratios for liver and
kidney, and follicular cell hyperplasia of
the thyroid were seen.
Two teratogenicity studies in rats pro-
duced embryo fetotoxicity (increased early
resorptions, increased postimplantation
losses and a decrease in viable fetuses) only
at dose levels at which maternal toxicity
was clearly evident (13).
The data on metiram would support an
ADI of 0 to 0.03 mg/kg bw based on a no
effect level of 2.5 mg/kg bw/day for thy-
roid effects in dogs and the no effect level
of 3.1 mg/kg bw/day in the long-term rat
study, using a safety factor of 100.
In the mouse, rat, dog, and monkey,
metiram affects the thyroid. In two 13-
week studies in rats, the no effect levels
of metiram were 80 and 100 ppm in the
diet, equivalent to 5.8 and 6.0 mg/kg
bw/day, respectively, based on decreased
serum T4 and an increase in absolute thy-
roid weight at 300 and 960 ppm, respec-
tively. In dogs, follicular cell hyperplasia of
the thyroid was observed after 1000 ppm
in the diet for 52 weeks. The no effect level
was 80 ppm, equivalent to 2.5 mg/kg
bw/day. In the monkey, decreased serum
T3 and T4 levels, increased thyroid
weights, and minimal follicular cell hyper-
plasia of the thyroid were observed after 15
and 75 mg/kg bw/day administered by
gavage for 26 weeks, whereas 5 mg/kg
bw/day was without effect.
Metiram was not carcinogenic to the
mouse in an 88-week long-term toxicity/
carcinogenicity study at dose levels up to
1000 ppm in the diet. A no effect level was
established at 300 ppm in the diet, equal to
24 mg/kg bw/day, whereas decreased body
weight was observed at 1000 ppm.
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In a 111-week long-term toxicity/car-
cinogenicity study in the rat, a no effect
level of 80 ppm in the diet, equivalent to
3.1 mg/kg bw/day, was observed. At
320 ppm in the diet, muscular atrophy
was observed. There was no evidence
of carcinogenicity.
In a three-generation, two litter per
generation reproduction study in rats, no
adverse effects were revealed on reproduc-
tive parameters. The no effect level was
observed at 40 ppm in the diet, which was
equivalent to 1.8 mg/kg bw/day. At 320
ppm decreased parental body weight and
food consumption were recorded in the Fo
and F1 generations.
Metiram was not teratogenic in rats
and rabbits at any dose tested during criti-
cal periods of organogenesis. The no effect
levels for embryo/fetotoxicity were 80
mg/kg bw/day in the rat based on slight
decreases in litter size and weight after dose
levels of 160 mg/kg bw/day, and 40 mg/kg
bw/day in the rabbit, based on decreases in
mean fetal weights at 120 mg/kg bw/day.
At both these dose levels maternal toxicity
was evident (13).
In the rat and dog, zineb affects the
thyroid. Dietary administration of zineb to
rats for 6 weeks indicated a no effect level
of 500 ppm, equivalent to 25 mg/kg
bw/day, based on morphological changes
of the thyroid gland and reduced iodine
uptake at 5000 ppm. Rats treated by gav-
age for 4 weeks exhibited slight hyperplasia
of the thyroid at a dose level of 1000
mg/kg bw/day, resulting in a no effect level
of 250 mg/kg bw/day. In a limited study in
dogs, follicular cell hyperplasia of the thy-
roid was observed after 10,000 ppm in the
diet for 52 weeks, whereas 2000 ppm had
no effect.
Zineb was not carcinogenic when given
to mice at a dose of 460 mg/kg bw/day
from postnatal day 7 until weaning, fol-
lowed thereafter with dietary administra-
tion of 1300 ppm until 18 months of age.
In a two-year study in rats, dietary levels of
500 ppm and higher revealed goitrogenic
effects. At or above 1000 ppm renal con-
gestion, nephritis, and nephrosis increased
mortality and diminished growth rate.
There was no evidence of carcinogenic
potential. Neither of these two studies is
considered adequate for the study of long-
term toxicity/carcinogenicity according to
the modern standard.
Treatment of rats with zineb at doses of
50 to 960 mg/kg bw/day suggested adverse
effects on the reproduction. Sterility,
decreased fertility, and resorption of fetuses
were observed. From the limited data avail-
able, a dose level of 50 mg/kg bw/day
appeared to be without significant adverse
reproductive effects.
Zineb was not teratogenic in mice at
dose levels up to 2000 mg/kg bw/day dur-
ing critical periods of organogenesis, nor
were maternal or embryo/fetotoxicity
observed. The no effect level for terato-
genicity and embryo/fetotoxicity was 630
mg/kg bw/day in the rat. At the maternally
toxic dose level of 2000 mg/kg bw/day,
zineb was teratogenic, resulting in a sig-
nificant increase in hydrocephalus and
skeletal anomalies (13).
Hexachlorobenzene. The use of hexa-
chlorobenzene (HCB) as a seed dressing to
prevent fungal disease on grains was dis-
continued in most countries in the 1970s.
HCB continues to be released into the
environment as a byproduct and contami-
nant in many other chlorinated chemicals
including chlorinated solvents. HCB is
highly stable in the environment and accu-
mulates in the food chains. Humans are
almost exclusively exposed through the
diet, especially meat, fish, and poultry; and
HCB accumulates in human adipose tis-
sue. In Denmark 0.1 ppm of HCB was
found in the fat from mothers' breast milk
in 1986 (21). Typical concentrations found
in various foodstuffs of animal origin are
around 0.01 mg/kg fat. Similar values are
found for fish. From the continuous sur-
veillance ofHCB in food, a maximal intake
of less 0.73 mg per person per year has been
estimated. This corresponds to an intake of
less than 0.000033 mg/kg bw/day.
In 1978, JMPR withdrew the previous
ADI of 0 to 0.0006 mg/kg bw/day (22).
An RfD for noncarcinogenic effects was
established by the U.S. EPA at 0.0008
mg/kg bw/day based on a no-effect level of
0.08 mg/kg bw/day in a 130-week chronic
feeding study in rats. The study involved
feeding male and female rats diets contain-
ing HCB for 90 days prior to mating and
until 21 days after parturition (at weaning),
whereafter the offspring that had been
exposed to HCB and metabolites in utero
and from maternal nursing received the
compound in their diets for the remainder
of their lifetime (130 weeks). At a dose
level of 0.3 mg/kg bw/day, liver changes
were observed. At higher doses increases in
pup mortality, hepatic toxicity including
increased liver porphyrin levels, and severe
chronic nephrosis (males only) were
observed. The safety factor was 100 (5).
HCB-induced porphyria has been reported
for all species examined, except the dog.
Long-term dietary exposure of humans
to HCB caused an epidemic of porphyria
cutanea tarda (PCT) in Turkish citizens
who accidentally consumed bread made
from grain treated with HCB. In children
less than 1 year of age, pink sore disease
was observed along with 95% mortality. In
addition to the PCT-associated symptoms
of skin lesions, hypertrichosis, and hyper-
pigmentation, the exposure caused neuro-
toxicity and liver damage. Follow-up
studies reported PCT symptoms, reduced
growth and arthritic changes in the
appendages of children who were directly
or indirectly (i.e., through breast milk)
exposed. Accurate exposure data (dose and
duration) are lacking (5). HCB is a potent
inducer of hepatic microsomal enzymes.
Several studies have indicated that HCB
affects the immune system.
A number of investigations have indi-
cated that repeated exposure to HCB can
affect male reproduction in various species,
but only at relatively high doses. Thus, 30
mg/kg bw/day for 21 days reduced serum
testosterone levels in male mice, probably
due to induction of hepatic microsomal
enzymes. Decreased fertility was observed
in male rats after 250 mg/kg bw/day for 5
days. Histologic changes in the testes, lead-
ing to retarded maturation has been noted
in the pig after 50 mg/kg bw/day for 90
days. In female monkeys HCB caused
degenerative changes in the reproductive
tissues. In female rats HCB produced ele-
vated serum progesterone levels and no
estrogenic effects were observed.
In a four-generation rat reproduction
study, reduced litter sizes, increased num-
ber of stillbirths, and reduced pup survival
were observed after a dose of 4 mg/kg
bw/day. A NOAEL was established at
1 mg/kg bw/day.
Oral administration ofHCB has induced
tumors in the liver, thyroid, parathyroid,
and kidney in three rodent species.
HCB was negative in most in vitro and
in vivo mutagenicity assays (5).
Tributyltin Compounds. Tributyltin
compounds were previously used in large
quantities in marine antifouling paints on
ships, boats, and mariculture pen nets.
However, their use is now restricted in
most countries.
Exposure to tributyltin compounds is
not well documented; however, the dietary
exposure is expected to be indeed very low.
In 1991, JMPR established an ADI of
0 to 0.0005 mg/kg bw for tributyltin com-
pounds (fentin compounds) based on a
no-effect level of 0.5 mg/kg bw/day in
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short-term rat studies with respect to
general, as well as specific, effects on the
immune system (23,24).
An RfD for noncarcinogenic effects of
tributyltin compounds was established by
the U.S. EPA at 0.00003 mg/kg bw/day
based on a no effect level of 0.025 mg/kg
bw/day in a chronic feeding study in rats.
At 0.25 mg/kg bw/day, an effect on host
resistance to T spiralis was reported. The
safety factor was 1000 (5).
In a parallel lifetime carcinogenicity/
chronic toxicity study in rats, the only
observed immunological alterations were
an increase of IgM and a decrease of IgG
titers in the females at a dose of 2.5 mg/kg
bw/day after 12 and 24 months of treat-
ment. No effect was observed after a dose
of 0.25 mg/kg bw/day (5,24). Similar
immunological effects have been observed
in short-term rat studies. In a 4-week feed-
ing study, thymic atrophy was reported at
dietary concentrations as low as 1 mg/kg
bw/day. In a companion study, rats fed 1
or 4 mg/kg bw/day in the diet for at least
6 weeks displayed impaired cell-mediated
immunity (5).
Short-term studies suggest that trib-
utyltin decreases the activity of the pitu-
itary-thyroid axis. Structural effects were
observed in the pituitary and thyroid
glands, and changes in circulating hor-
mones were observed. However, in long-
term studies most of these effects seemed
to be absent. The mechanism of action is
not known (5,24).
Tributyltin was found to be fetotoxic
and teratogenic in mice and rats at a level
at which overt maternal toxicity was also
observed (18 mg/kg/day), with no effects
observed at 9 mg/kg/day (5).
One carcinogenicity study in rats
reported increased incidences of benign
tumors of the pituitary gland (not dose
related) and adrenal medullary tumors
(pheochromocytomas) at a high dose. These
tumor types appear usually at high and vari-
able background incidences, and the signi-
ficance of the finding is questionable (24).
Dicarboximides (Vinclozolin). Vin-
clozolin (3-(3,5-dichlorophenyl)-5-ethenyl-
5-methyl-2,4-oxazolidinedione) is used as a
fungicide on fruits, vegetables, vines, and
ornamental plants and grasses. Residues
slightly above the Danish MRLs of 1 to 2
mg/kg are occasionally found in some
fruits and vegetables. If a concentration of
2 mg/kg is used as an average MRL for
fruits and vegetables and it is assumed that
the average concentration in all fruits and
vegetables, after rinsing, peeling, and
preparing for consumption is at least 100
times lower than the MRL, an intake of
less than 2.4 mg per person per year can be
obtained from 60 kg of fruits and 60 kg of
vegetables. This would correspond to a
daily intake of less than 0.00012 mg/kg
bw/day for a 60-kg person.
Vinclozolin was evaluated for accept-
able daily intake by JMPR in 1986 (25),
where a temporary ADI of 0 to 0.04 mg/kg
bw was estimated based on a no effect level
of 7 mg/kg bw/day in a 6-month dog feed-
ing study. A safety factor of 200 was used.
The ADI was made temporary as 3,5-
dichlorophenylcarbamoyl-2-propionic acid
was identified as a major plant metabolite
that had not been fully evaluated with
respect to its toxicity, and additional
studies were requested. In 1988 (26)
JMPR established an ADI of 0 to 0.07
mg/kg bw for vinclozolin and all metabo-
lites containing the 3,5-dichloroaniline
moity, as additional data ensured the low
acute toxicity and absence of mutagenicity
of this plant metabolite. The safety factor
was 100.
An RfD for noncarcinogenic effects of
vinclozolin was established by the U.S.
EPA at 0.025 mg/kg bw/day based on an
estimated no effect level of 2.5 mg/kg
bw/day from the same dog study used by
JMPR. The safety factor was 100 (5).
After absorption vinclozolin is rapidly
and extensively biotransformed and
excreted as conjugated metabolites. The
major metabolite found in rat urine was
N-(3,5-dichlorophenyl)-2-methyl-2,3,4-
trihydroxybutanoic acid amide (25).
Vinclozolin has a low order of acute
toxicity and was negative in a number of in
vitro and in vivo mutagenicity assays.
In a 6-month feeding study, groups of
dogs were given daily dosages of vinclo-
zolin equal to 0, 7.0, 20, 41, and 135
mg/kg bw/day (males) or 0, 7.4, 21, 41,
and 141 mg/kg bw/day (females). Hemo-
lytic anemia was observed in high-dose
males and females, while other clinical
chemistry parameters were not affected.
Dose-related increases in absolute and rela-
tive weights of adrenals were noted in ani-
mal feed with dose levels of 20 mg/kg
bw/day or higher. Other organ weight
changes were noted, including decreased
relative pituitary weights in females at dose
levels of 21 mg/kg bw/day or higher. Upon
microscopic examination, changes related
to the anemia observed at the highest dose
were recorded and, in additition, atrophy/
stromal proliferation of the prostate
(males) and vacuolization of the zona
fasciculata of the adrenals (males and
females) were seen. The no effect level was
7.0 mg/kg bw/day.
Vinclozolin did not show carcinogenic-
ity in long-term studies in rats and mice
after doses as high as 278 mg/kg bw/day
(rats) and 912 mg/kg bw/day (mice). In
the long-term mouse study, increases in
absolute and relative weights of the liver
were noted in females at the two highest
dose levels, 287 and 912 mg/kg bw/day.
Increased liver and testes weights were seen
in male mice at the highest dose level of
818 mg/kg bw/day. After a complete
microscopic examination no toxicologically
significant differences were observed
between treated and control animals. The
no effect level was 87 mg/kg bw/day. In
the long-term rat study, absolute weights
of several organs were decreased at the two
highest dose levels. The incidence of
macroscopic and microscopic findings were
randomly distributed among all test groups
and did not appear to be related to treat-
ment with vinclozolin. The no effect level
was 27 mg/kg bw/day.
Special studies in mice and rabbits did
not reveal any teratogenic potential of vin-
clozolin. In the mouse study it was found
that mice receiving 6000 ppm or higher in
their diets did not have any implantations.
The no effect level was 1 10 mg/kg bw/day.
In a three-generation rat reproduction
study, no effects were observed on alter-
ation in fertility, gestation length, litter
size, sex ratio of pups, fetal birth weight,
weight gain of pups, or survival of pups.
No treatment-related malformations or
developmental defects were noted, and no
treatment-related pathological findings
were seen in either parent rats or pups at
necropsy. The NOAEL was estimated
to be higher than the highest dose tested,
152 mg/kg bw/day (25).
In contrast, recent reproduction/toxicity
studies conducted in rats have shown
Leydig cell tumors and atrophic ventral
prostate and seminal vesicles after chronic
exposure of adult male rats to vinclozolin.
In addition, anogenital distance in male
offspring was reduced to a femalelike size
(27). Subsequently, another toxicological
study (28) showed strong demasculinizing
effect of vinclozolin in the male offspring
of mice treated with 100 or 200 mg/kg
bw/day from gestational day 14 to postna-
tal day 3; in addition to the femalelike
anogenital distance many other abnormali-
ties were observed, such as retention of
nipples, hypospadias, epididymal granulo-
mas, maldescent of the testis, and frequent
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presence of vaginal pouch. These findings
suggested that vinclozolin possesses anti-
androgenic activity. Recent biochemical
studies have demonstrated that the demas-
culinizing effects of vinclozolin may be
attributed to two intermediary metabolites,
2-(3,5-dichlorophenyl)-carbamoyl)oxy-
2-methyl-3-butenoic acid (MI) and
3', 5'-dichlo-2-hydroxy-2-methylbut-3-
enanilide (M2), which inhibit the andro-
gen receptor function, although in certain
conditions these metabolites may act as
agonists (29,30).
Insecticides
A number of the insecticides mentioned
below are no longer approved for use.
However, several of the compounds are
very persistent and can be found in the
environment as general background pollu-
tion. Therefore, residues may still be found
in foods. In addition, residues may be con-
tained in foods imported from countries
where some of the compounds are still in
use. In particular, the organochlorine pesti-
cides are bioaccumulating in the food
chains and are found widely distributed in
fat-containing foods of mammalian or
marine origin. In contrast to this environ-
mentally based contamination of foods, it
is characteristic that the development of
several different types of new insecticides
during the last few years has resulted in a
shift to more specific and limited uses of
the single approved insecticide. This means
that residues of each single insecticide
are not widespread but rather found in a
limited number of crops.
f-HCH, dieldrin, heptachlor, hep-
tachlor epoxide, and lindane (y-HCH) are
included in the Danish pesticide control
program. With a few exceptions they are
never found in fruits and vegetables,
including cereals. Typical concentrations in
fat of animal and marine species is about
0.01 mg/kg of fat. The intake from heavy
consumption of animal fat and fish is esti-
mated at less than 0.7 mg per person per
year. This would correspond to a daily
intake of less than 0.00003 mg/kg bw/day
for a 60-kg person.
Chlordane and oxychlordane, methoxy-
chlor, mirex, and toxaphene are not
included in the Danish pesticide control
program. These compounds are not used
in Denmark. Therefore, the knowledge on
exposure is rather limited. From concentra-
tions reported in human mothers' milk
(21), it seems reasonable to assume, that
the exposures to these compounds are not
higher than to the previously mentioned
insecticides. Thus, a daily intake of less
than 0.00003 mg/kg bw/day for a 60 kg
person is assumed.
Carbaryl. Carbaryl is approved as an
insecticide for use on plants and fruit trees.
Food is considered the major exposure
route for carbaryl. Residue findings ranging
from trace to 0.05 mg/kg food have been
reported. In United States the intake in
1969 was estimated at 0.003 mg/person/
day (31). The MRL for cereals is 0.5
mg/kg. Assuming a concentration of 0.5
mg/kg as an average for fruits and vegeta-
bles, and assuming that the average con-
centration in fruits and vegetables after
rinsing, peeling, and preparing for con-
sumption is at least 100 times lower than
the MRL, an intake of less than 0.6 mg per
person per year can be obtained from
60 kg of fruits and 60 kg of vegetables.
This would correspond to a daily intake of
less than 0.00003 mg/kg bw/day for a
60-kg person.
Carbaryl was last evaluated by JMPR
for acceptable daily intake in 1973. An
ADI of 0 to 0.01 mg/kg bw has been estab-
lished based on the following no effect
levels: 10 mg/kg bw/day in the rat; 1.8
mg/kg bw/day in the dog; and 0.06 mg/kg
bw/day for cholinesterase (ChE) inhibition
in humans (31,32).
An RfD for noncarcinogenic effects was
established by the U.S. EPA at 0.1 mg/kg
bw/day based on a no effect level of 9.6
mg/kg bw/day in a chronic feeding study
in rats. At a dose of 15.6 mg/kg bw/day,
kidney and liver toxicity was seen. The
safety factor was 100 (5).
Carbaryl has been shown to affect mam-
malian reproduction and perinatal develop-
ment adversely in a number of species.
Effects include impairment of fertility,
decreased litter size, and reduced postnatal
viability. Malformations have also been
observed. Adverse reproductive and devel-
opmental effects were noted only at doses
that caused maternal toxicity. Data indicate
that the reproductive and developmental
processes of mammals are not especially
sensitive to carbaryl compared with the
susceptibility of the adult organism (31).
In the mouse, doses of carbaryl up to
35 mg/kg bw/day for 5 days did not affect
weights of testes and accessory sex glands
or uptake of progesterone by the prostate
gland. However, at 68 mg/kg bw/day,
increased hepatic androgen hydroxylase
activity was indicated (31).
There are conflicting data about effects
of carbaryl on sperm counts and changes in
sperm morphology in plant workers. No
adverse effect on reproduction have been
reported (31).
The results of numerous carcinogenicity
studies in mice and rats have mainly been
negative. However, these studies are old
and do not meet modern standards. In
the majority of genotoxicity assays, car-
baryl did not have any DNA-damaging
properties (31).
Malathion. The use of malathion is
rather limited in food crops. No residues
were reported in 1993 when a limit of 1
mg/kg food was used. If it is assumed that
residues are present in 1/12 of fruits and
vegetables and assuming that the average
concentration in the food items after rinsing,
peeling and preparing for consumption is at
least 1000 times lower than 1 mg/kg, an
intake of less than 0.01 mg per person per
year can be obtained from 10 kg of fruits
and vegetables. This would correspond to a
daily intake of less than 0.0000005 mg/kg
bw/day for a 60-kg person.
Malathion was last evaluated by JMPR
for acceptable daily intake in 1966. An ADI
of 0 to 0.02 mg/kg bw was established (33).
An RfD for noncarcinogenic effects was
established by the U.S. EPA at 0.02 mg/kg
bw/day based on a no effect level of 0.16
mg/kg bw/day in a subchronic human
feeding study. At a dose of 0.34 mg/kg
bw/day, depression of red blood cell
cholinesterase activity was seen. The safety
factor was 10 (5).
In a 2-year chronic toxicity/carcino-
genicity study in rats, a NOEL of 5 mg/kg
bw/day was observed. At a dose of 50
mg/kg bw/day, decreased brain cholin-
esterase and body weight were reported.
In a reproduction study in rats, reduced
number of live pups and reduced pup body
weight were seen at a dose of 240 mg/kg
bw/day, the only dose tested. No terato-
genic effect was seen in the rat after ip
injection of 900 mg/kg bw/day (5).
Methomyl. Methomyl is approved for
use on apples, pears, and some berries.
Residues found in GAP trials are from 0.5
to 1.0 mg/kg raw food. In considering the
reduction after rinsing, peeling, and prepar-
ing for consumption, it is assumed that the
average concentration in fruits is at least
1000 times lower than 1 mg/kg, and that
only 1/6 of fruits are contaminated. This
would correspond to an intake of less than
0.01 mg of methomyl per person per year.
The daily intake would then be 0.0000005
mg/kg bw/day for a 60-kg person.
Methomyl was evaluated by JMPR for
acceptable daily intake in 1989. An ADI of
0 to 0.03 mg/kg bw was established (34).
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An RfD for noncarcinogenic effects was
established by the U.S. EPA at 0.025
mg/kg bw/day based on a no effect level of
2.5 mg/kg bw/day in a 2-year feeding
study in dogs. At 10 mg/kg bw/day, kidney
and spleen toxicity was seen. Histopatho-
logic changes were observed in the liver
and bone marrow at 50 mg/kg bw/day.
The safety factor was 100 (5).
The NOEL observed in the dog study
is further supported by lifetime studies in
rats and mice, and a three-generation
reproduction study in rats where higher
NOELs were seen (5).
Dicofol In 1993 Dicofol residues were
found in a limited number of apples, citrus
fruits, and berries at levels below the
reporting limit of 1 mg/kg. If it is assumed
that residues are present in 50% of fruits
and assuming that the average concentra-
tion in fruits after rinsing, peeling, and
preparing for consumption is at least 100
times lower than 1 mg/kg, an intake of less
than 0.3 mg per person per year can be
obtained from 60 kg of fruits. This would
correspond to a daily intake of less than
0.000015 mg/kg bw/day for a 60-kg person.
Dicofol was evaluated by JMPR for
acceptable daily intake in 1992. An ADI of
0 to 0.002 mg/kg bw was established based
on the no effect level of 0.22 mg/kg
bw/day in a rat long-term study. At 2.2
mg/kg bw/day, histopathological changes
in the liver and vacuolation of adrenal
cortical cells were observed (35).
Dicofol is structurally related to DDT,
and therefore tends to accumulate in the
mammalian organism, however at a rate
much less than that of DDT and its
metabolites.
Dicofol primarily affects the liver in
experimental animals. It is an inducer of
the hepatic mixed-function oxidase (MFO)
activity in rats and mice. In the rat, an
increase in the incidence of thyroid follicu-
lar cell hypertrophy in one study could not
be reproduced in other studies. In the dog,
a NOEL was found to be 0.82 mg/kg
bw/day (1-year study) based on liver
changes and reduced cortisol response to
ACTH at 5.7 mg/kg bw/day (35).
Dicofol increased the incidence of liver
adenomas in male mice at high doses, but
not in female mice. Dicofol was not
carcinogenic in the rat.
In a two-generation reproduction study
in rats, the NOEL was 0.5 mg/kg bw/day
based on increased incidences of ovarian
stromal cell hyperplasia and hepatocellular
changes at 2.5 mg/kg bw/day. Viability of
offspring was reduced at higher doses. The
NOEL for reproductive parameters was
2.1 mg/kg bw/day.
Dicofol was not teratogenic in mice, rats
or rabbits. Embryotoxicity and fetotoxicity
were observed at maternally toxic dose
levels (35).
Methoxychlor. The dietary intake of
methoxychlor has been estimated at less than
0.00003 mg/kg bw/day for a 60-kg person.
Methoxychlor was last evaluated by
JMPR for acceptable daily intake in 1977.
An ADI of 0 to 0.1 mg/kg bw was estab-
lished (20).
An RfD for noncarcinogenic effects was
established by the U.S. EPA at 0.005
mg/kg bw/day based on a no effect level of
5.01 mg/kg bw/day in a rabbit teratology
study. At 35.5 mg/kg bw/day, excessive
loss of litters due to maternal toxicity was
seen. The safety factor was 1000 (5).
Teratology studies in rats as well as a
three-generation reproduction study in rats
and a 2-year chronic rat study all showed
no effect levels higher than that observed
for the rabbit.
Methoxychlor is considered to have
estrogenic activity. Kupfer and Bulger (36)
found that both methoxychlor and metabo-
lites have estrogenlike activity with several
metabolites having proestrogen activity.
Gray et al. (37) investigated the effects
of methoxychlor on the pubertal develop-
ment and reproductive function in the male
and female rat by dosing rats from gesta-
tion, weaning, lactation, through puberty
with either 25, 50, 100, or 200 mg/kg
bw/day of methoxychlor. In females, an
acceleration of vaginal opening, abnormal
estrous cycle, inhibition of luteal function,
and a blockage of implantation was
observed. In males, an inhibition of somatic
growth and accessory sex gland weight, ele-
vated pituitary and serum prolactin levels,
and a suppression of testicular Leydig cell
function were found. Some of these effects
occurred at levels as low as 25 mg/kg
bw/day. These observations are consistent
with the earlier reports that methoxychlor
mimics estrogen both in vivo and in vitro.
Goldman et al. (38) investigated the
subchronic effects of methoxychlor on the
rat (Long-Evans hooded) reproductive sys-
tem by dosing for 8 weeks with 25 or 50
mg/kg of methoxychlor by oral gavage. No
effect was observed on the pituitary weight,
serum LH, FSH, or prolactin levels and the
pituitary LH or FSH concentrations.
Pituitary prolactin levels were increased at
both dose levels. There was an increase in
GnRH levels in the mediobasal hypothala-
mus at the high-dose level. The authors
determined that the reproductive effects of
methoxychlor are mediated in part by an
increase in prolactin release, which in turn
influences the hypothalamic levels of
GnRH. This may be considered an
early effect of methoxychlor on the rat
reproductive system.
Cummings and Gray (39) found that
methoxychlor affects the decidual cell
response of the rat uterus, suggesting a
direct effect of the compound on the
uterus with no effects on uterine weight,
serum progesterone levels, or corpora lutea
maintenance. Long-term exposure to
methoxychlor reduced fertility and induced
fetotoxicity. The effects of reduced fertility
and fetotoxicity were noted in a three-gen-
eration reproduction study. Although the
available data from these three studies are
limited, it is apparent that methoxychlor at
1000 ppm produced reproductive effects in
the form of reduced fertility index, reduced
litter size, and reduced viability index.
Bal (40) reported inhibition of sperma-
togenesis, degeneration of spermatogonia
and spermatocytes, and cytoplasmic vacuo-
lation in the epithelium of the epididymis
in male rats after the administration of 100
to 200 mg/kg bw/day methoxychlor. A
decrease in seminal vesicle and caudal epi-
didymal weight and caudal sperm count as
well as delayed puberty were observed in
neonatal rats administered 25 to 200
mg/kg bw/day methoxychlor for one gen-
eration, indicating that the endocrine func-
tion of the testes and pituitary gland were
affected (37). Cooke and Eroschenko (41)
also noted that the development of the
neonatal male rat reproductive tract was
inhibited by methoxychlor administration,
as shown by a decrease in serum testos-
terone levels and decreased DNA content of
the seminal vesicles, bulbourethral glands,
and the ventral prostate. Rats fed 2000
ppm methoxychlor for 90 days exhibited
decreased prostate size and cell content
(42). Goldman et al. (38) hypothesized
that part of methoxychlor's effects on male
reproductive function may be mediated by
a prolactinemic effect, since administration
of 25 or 50 mg/kg/day methoxychlor to 21-
day-old male rats caused an increase in
serum prolactin levels and an increase in
hypothalamic gonadotropin-releasing
hormone levels.
Several chronic oral carcinogenicity
bioassays have been conducted with
methoxychlor, the results of which have
been equivocal.
A number of studies show that meth-
oxychlor does not accumulate in the body
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to any appreciable degree, but accumula-
tion of methoxychlor in fat has been
observed following administration of very
high dietary levels. Methoxychlor is metab-
olized in the liver to readily excretable polar
compounds. The results of several studies
indicate that methoxychlor does not induce
hepatic microsomal enzymes (5).
Lindane (y-Hexachlorocyelohexane or
y-HCH). The intake of lindane has been
estimated at less than 0.00003 mg/kg
bw/day for a 60-kg person.
Lindane tends to accumulate in body
fat of mammalian species. More than 90%
of the intake of lindane is estimated to
originate from foods. Studies of the total
diet in the United States estimated the
intake up to 0.00005 mg/kg bw/day in
1970 and up to 0.000003 mg/kg bw/day
in 1980 (43).
Lindane was last evaluated by JMPR
for acceptable daily intake in 1989. An
ADI of 0 to 0.008 mg/kg bw was estab-
lished based on the following no-effect lev-
els: 0.75 mg/kg bw/day in the rat; 1.6
mg/kg bw/day in the dog (34,43).
An RfD for noncarcinogenic effects was
established by the U.S. EPA at 0.0003
mg/kg bw/day based on a no effect level of
0.33 mg/kg bw/day in a chronic feeding
study in rats. At 1.55 mg/kg bw/day, kid-
ney and liver toxicity was seen. The safety
factor was 1000 (5).
In a 2-year bioassay in dogs, a NOEL
for liver effects was determined to be 1.6
mg/kg bw/day. Lindane is a well-known
inducer of the liver MFO system. Lindane
induced hyperplastic nodules and/or hepa-
tocellular adenomas in mice, especially in
males given high doses in long-term
studies. Lindane did not increase the inci-
dence of liver tumors in rats (43).
Lindane had no teratogenic effect in
mice, rats, dogs, and pigs. Fetotoxic and/or
maternal toxic effects were observed with
doses of 10 mg/kg bw/day and above. A
dose of 5 mg/kg bw/day was considered a
no effect level. In a three-generation repro-
duction study in rats, lindane had no effect
on reproduction or maturation at doses up
to 5 mg/kg bw/day. At 2.5 mg/kg bw/day,
liver changes indicative of MFO enzyme
induction occurred in the offspring of the
third generation. The no effect level in this
study was 1.25 mg/kg bw/day (43).
When given to pregnant mice at various
stages of pregnancy, lindane (3.6-10.4
mg/kg bw/day) caused reproductive failure
and fetotoxicity. The effects were partly
corrected by co-administration of estrogen,
while progesterone had no effect. When
estrogen and progesterone were simul-
taneously given to pregnant mice that were
fed lindane during early pregnancy, the
fetal development became normal. It thus
appeared that lindane caused a hormone
deficiency, resulting in reproductive and
developmental failure (44).
/3-Hexachlorocyclohexane. f-Hexa-
chlorocyclohexane (P-HCH) is a byprod-
uct in the manufacture of lindane. 3-HCH
has been found in the air over oceans at
0.004 to 0.13 ng/m3. P-HCH is the most
persistent HCH isomer; bioconcentration
takes place in invertebrates, fish, birds, and
man. In mammals the compound is stored
in adipose fat (45).
Food is the main exposure route for the
general population. Total dietary studies
from United Kingdom in 1966 to 1967
found 0.003 mg/kg, in 1975 to 1977
0.0005 mg/kg, and in 1981 <0.0005
mg/kg of total diet. The average daily
intake in the United States in 1982 to
1984 ranged from less than 0.0000001 to
0.0000004 mg/kg bw/day for various age
groups (45).
,B-HCH is included in the Danish
pesticide control program. As mentioned
above, the intake has been estimated at
less than 0.00003 mg/kg bw/day for a
60-kg person.
No ADI or RfD has been established
for f-HCH. The most sensitive organ to
the toxicity of P-HCH is the liver. In the
rat, hypertrophy and proliferation of
smooth endoplasmic reticulum and
increased activity of microsomal enzymes
were seen after a dose 2.5 mg/kg bw/day
for 90 days. After 12.5 mg/kg bw/day,
changes in the gonads (testicular atrophy)
were reported, but associated hormonal
changes showed no consistent endocrine
effect. There were no adverse effects
reported after 0.1 mg/kg bw/day. In a
long-term study, liver enlargement and his-
tological changes were seen at 0.5 mg/kg
bw/day (45). In a two-generation repro-
duction study in rats, parental liver effects
were also reported. No effects on reproduc-
tion were seen after 0.1 mg/kg bw/day,
whereas 0.5 mg/kg bw/day resulted in
increased mortality and infertility. The
parental animals at 2.5 mg/kg bw/day
showed decreased weight of ovaries and
increased weight of adrenal glands and
uterus in females. In males, the testes
showed a reduced number of Leydig cells.
A weak estrogenlike effect after a dose of 25
mg/kg bw/day for 5 days has been described
in female mice and rats. The uterus was the
target organ, and there were no clear effects
on endocrine control systems. P-HCH
did not displace 17,-estradiol from its
receptors. The mechanism of the effect
is unclear.
Positive or marginally positive tumori-
genic responses, characterized as benign
hepatomas or hepatocellular carcinomas,
have been observed in two strains of
mice (45).
DDT and Its Metabolites, DDE and
DDD. The use of DDT in the Western
world is now severely restricted. However,
it is still extensively used in some develop-
ing countries against malaria. Technical
DDT contains mainly the p,p'-isomer
(75-80%); o,p'-DDT constitutes 10 to
25% of the technical product. The DDT
metabolite DDE is more persistent than
the parent compound, and is therefore the
form ofDDT normally found in foods and
human tissues. Following the severe restric-
tions in the use of DDT in the late 1960s,
a dramatic decline has occurred in the con-
tamination of foods and humans. For
example, levels in herring have declined
from 5 to 7 mg/kg fat in 1973 to 0.5 to 1
mg/kg fat in 1993 (2). In 1986, DDE lev-
els in human milk in Denmark ranged
from 0.29 to 1.21 mg/kg fat (21).
DDT and its metabolites are included
in the Danish pesticide control program.
In 1993, the typical levels found in animal
and fish lipids were about 0.02 mg/kg. It
has been estimated that an individual who
consumes a large amount of fish is exposed
to less than 2.5 mg of DDT and its
metabolites per year. This corresponds to
less than 0.0001 mg/kg bw/day.
JMPR in 1984 established an ADI at 0
to 0.02 mg/kg bw/day for any combination
ofDDT, DDD, and DDE (17).
An RfD for noncarcinogenic effects was
established by the U.S. EPA at 0.0005
mg/kg bw/day based on a no effect level of
0.05 mg/kg bw/day in a 27-week rat feed-
ing study. At 0.25 mg/kg bw/day, liver
lesions (hepatocellular hypertrophy) were
observed. The safety factor was 100 (5).
In a three-generation rat reproduction
study, offspring mortality increased at all
dose levels, the lowest of which corre-
sponds to about 0.2 mg/kg bw/day. Three
other reproduction studies (rat and mouse)
showed no reproductive effects at much
higher dose levels (5).
Nine feeding studies, including two
multigenerational studies, have been
conducted in mice. Only one of these
studies, conducted for 78 weeks, showed
no indication of DDT tumorigenicity.
However, both hepatocellular adenomas
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and carcinomas were observed in six mouse
studies. Benign and malignant lung tumors
were observed in two studies in which mice
were exposed both in utero and throughout
their lifetime. Doses leading to the increased
tumor incidence ranged from 0.15 to 37.5
mg/kg bw/day. Three studies using rats
and doses from 25 to 40 mg/kg bw/day
produced an increased incidence of benign
liver tumors. Another study was negative,
as were three additional assays in which
lower doses were given (5).
Studies of DDT exposure in hamsters
have not shown an increased tumor inci-
dence. Unlike mice and humans, hamsters
accumulate DDT in tissue but do not
metabolize it to DDD or DDE. Studies of
DDT in dogs and monkeys have not
shown a carcinogenic effect. However, the
length of these studies was insufficient to
assess the carcinogenicity ofDDT (5).
p,p'-DDE exposure increased the inci-
dence of liver tumors including carcinomas
in males and females of two strains of mice
and in hamsters. In the rat, a dose-depen-
dent, but not statistically significant,
increase in thyroid tumors in females was
not considered convincing evidence of
carcinogenicity (5). DDE was mutagenic
in mouse lymphoma cells and Chinese
hamster (V79) cells, but not in Salmonella.
p,p'-DDD induced an increased inci-
dence of lung tumors in male and female
mice, liver tumors in male mice, and
thyroid tumors in male rats (5).
Chlordane, Heptachlor, and Hepta-
chlor Epoxide. At one time, these insecti-
cides were widely used in the United State,
but now the use of chlordane is suspended,
and that of heptachlor restricted. Technical
chlordane contains a mixture of various
chlordane isomers and heptachlor (chlori-
nated cyclodienes). Oxychlordane and hep-
tachlor epoxide are persistent metabolites
of chlordane and heptachlor, respectively.
Levels of heptachlor/heptachlor epoxide
in human milk fat in the 1 970s ranged from
0.10 to 0.35 ppm in Europe and America,
whereas chlordane and oxychlordane levels
are low and mostly below the detection
limit in Europe (21). As mentioned earlier,
the intakes have been estimated at less than
0.00003 mg/kg bw/day for a 60-kg person
for each of these compounds.
Chlordane was evaluated by JMPR in
1986 when an ADI of 0 to 0.0005 mg/kg
bw was established (25). An RfD for non-
carcinogenic effects of chlordane has been
established by the U.S. EPA at 0.00006
mg/kg bw/day based on a no effect level of
0.055 mg/kg bw/day in a rat chronic
bio-assays. At 0.273 mg/kg bw/day,
regional liver hypertrophy was observed in
females. The safety factor was 1000 (5).
In a 24-month chronic toxicity study in
the mouse, a NOEL of 0.15 mg/kg bw/day
was observed based on hepatocellular
swelling and necrosis in males and
increased liver weight in males and females
at 0.75 mg/kg bw/day (5). Chlordane has
been studied in four mouse and four rat
long-term carcinogenesis bioassays. Dose-
related incidences of liver carcinoma con-
stitute the major finding in mice. In the
rat, chlordane produced a significant
increase in adenomas of the liver of male
rats. Although no tumors were observed in
female rats, hepatocellular swelling was
significantly increased. Other studies in the
rat have been negative (5).
Most studies have found chlordane
not to be genotoxic. No adequate studies
on reproduction and teratology are avail-
able (5).
Heptachlor was evaluated by JMPR in
1991 when an ADI of 0 to 0.0001 mg/kg
bw was established for heptachlor and hep-
tachlor epoxide combined (23). An RfD
for noncarcinogenic effects was established
by U.S. EPA at 0.0005 mg/kg bw/day
based on a no effect level of 0.15 mg/kg
bw/day in a 2-year chronic feeding study in
rats. At 0.25 mg/kg bw/day, increased liver
weight was seen in males. The safety factor
was 300 (5).
In an inadequate three-generation repro-
duction study, no effects were observed
after 0.5 mg/kg bw/day (5).
Heptachlor induced hepatocellular car-
cinomas in male and female mice in two
studies. No indication of treatment-related
increase of tumors has been reported in
chronic studies with rats.
Most studies have indicated that
heptachlor is not mutagenic.
Heptachlor epoxide was evaluated by
JMPR in 1991 when an ADI of 0 to
0.0001 mg/kg bw was established for
heptachlor and heptachlor epoxide com-
bined (23). An RfD for noncarcinogenic
effects was established by the U.S. EPA at
0.000013 mg/kg bw/day based on a lowest
effect level of 0.0125 mg/kg bw/day in a
60-week chronic feeding study in dogs.
The effect seen was increased liver-to-body
weight in both males and females. The
safety factor was 1000 (5).
A NOEL of 0.025 mg/kg bw/day was
established from a two-generation repro-
duction study in dogs. At 0.075 mg/kg
bw/day, liver lesions were observed in
pups. Reduced pup survival was seen after
0.175 mg/kg bw/day. In a three-generation
reproduction study in rats the NOEL was
0.25 mg/kg bw/day. At 0.5 mg/kg bw/day,
increased pup mortality was recorded (5).
Heptachlor epoxide has induced liver
carcinomas in two strains of mice of both
sexes. In rats no significant carcinogenic
effect was seen.
Most studies have indicated that
heptachlor epoxide is not mutagenic.
Dieldrin. Dieldrin is the major
metabolite of aldrin. Both compounds
have been severely restricted or banned
since the early 1970s in a number of coun-
tries. Dieldrin accumulates in the mam-
malian organism. Aldrin is rarely found in
food. Dieldrin levels in food (total diet
study, United Kingdom) have been declin-
ing from 0.004 mg/kg in 1966 to 1967 to
0.0005 mg/kg in 1981 (46). In 1986,
dieldrin levels in human milk in Denmark
ranged from less than 0.01 to 0.04 mg/kg
fat (21). The intake has been estimated
at less than 0.00003 mg/kg bw/day for a
60-kg person.
JMPR in 1977 established an ADI at 0
to 0.0001 mg/kg bw/day for the combined
total of dieldrin and aldrin (22).
An RfD for noncarcinogenic effects was
established by the U.S. EPA at 0.00005
mg/kg bw/day based on a no effect level of
0.005 mg/kg bw/day in a 2-year feeding
study in rats. At 0.05 mg/kg bw/day,
increased liver weight and liver lesions
(parenchymal cell changes including focal
proliferation and focal hyperplasia) were
observed. The safety factor was 100 (5).
Liver toxicity of dieldrin has also been
observed in the mouse, hamster, dog, and
monkey in chronic feeding studies (46).
In most of the reproduction studies
(over one to six generations) carried out
with aldrin or dieldrin on mice and rats,
the major effect was an increased mortality
rate in pups not yet weaned. Reproductive
performance was only affected at doses
causing maternal intoxication. It was con-
cluded, that 0.1 mg/kg bw/day was a
NOAEL in the rat (46).
Dieldrin was carcinogenic in seven
strains of mice when administered orally.
Dieldrin increased the incidence of
hepatomas and hepatic carcinomas. It also
produced significant increases in the inci-
dence of pulmonary adenomas, pulmonary
carcinomas, and lymphoid tumors. How-
ever, in the rat, seven studies with four
strains of rats fed 0.1 to 285 ppm dieldrin
and varying in duration of exposure from
80 weeks to 31 months did not produce
positive results for carcinogenicity (5).
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Although positive in a few assays in
vitro for clastogenic activity, most studies
in vitro and in vivo on the genotoxicity of
aldrin and dieldrin have yielded negative
results (46).
Mirex. Mirex was commonly used in
the United States in the 1960s and 1970s
to control fire ants; it was also used in plas-
tics, rubber, paints, paper, and electrical
goods, but its use is now banned. The
intake has been estimated at less than
0.00003 mg/kg bw/day for a 60-kg person.
An RfD for noncarcinogenic effects was
established by the U.S. EPA at 0.0002
mg/kg bw/day based on a no effect level of
0.07 mg/kg bw/day in a chronic feeding
study in rats. The effects seen at at a dose
level of 0.7 mg/kg bw/day were liver hyper-
trophy and thyroid cystic follicles.
Histologic examinations revealed dose-
related changes in the parathyroid gland,
kidney, liver, spleen, and thyroid. The
safety factor was 300 (5). Effects of mirex
on the liver and thyroid have been reported
in many other studies.
Effects on the testis have been reported.
Histologic evaluation of the testis revealed
hypocellularity, decreased spermatogenesis,
and luminal nucleated and giant cells, all of
which are characteristic of testicular degen-
eration. Reproductive and developmental
effects (decreased fertility, fetal cataracts,
edema) have been reported in several
studies. Perinatal and postnatal exposure to
mirex resulted in significantly decreased
pup survival (5).
Mirex is an inducer of liver microsomal
mixed function oxidases.
Toxaphene (Camphechlor). Toxa-
phene is a mixture of several hundred poly-
chlorinated terpenes. Toxaphene is a global
pollutant spread by long-range air trans-
portation. Although hardly used in
Sweden, it was detected in two pooled
human milk samples; the level calculated
from 22 peaks was 0.1 ppm in the milk fat.
The intake has been estimated at less
than 0.00003 mg/kg bw/day for a 60-kg
person. Toxaphene was evaluated by JMPR
in 1973. No ADI was established (22). No
RfD has been established by U.S. EPA.
Dietary toxaphene administered to
mice at doses higher than 50 ppm caused
dose-related increased incidences of hepa-
tocellular carcinomas and adenomas in
both sexes (5).
In rats receiving toxaphene at doses of
556 and 1112 ppm for males and 540 and
1080 ppm for females for 80 weeks, a sta-
tistically significant dose-related increased
incidence of thyroid tumors (adenomas
and carcinomas) was seen in both male and
female rats.
Toxaphene was mutagenic in bacteria,
but negative in a modified dominant lethal
assay of male mice (5).
Nematocides
Aldicarb. The intake of aldicarb through
foods is estimated to be very low and
insignificant. Aldicarb does not accumulate
in the body.
In 1992 JMPR established an ADI at
0.003 mg/kg bw based on a no effect level
of 0.025 mg/kg bw in humans. The no
effect level was based on decrease of acetyl
cholinesterase (Ache) activity in erythro-
cytes at 0.05 mg/kg bw (35).
An RfD for noncarcinogenic effects was
established by the U.S. EPA at 0.001
mg/kg bw/day based on a no effect level of
0.01 mg/kg bw/day in acute oral exposure
studies in humans. Essentially all hazards
from aldicarb exposure are associated with
cholinesterase inhibition. At 0.025 mg/kg
bw/day, clinical signs of acetylcholinester-
ase inhibition were observed. The safety
factor was 10 (5).
Available evidence both from experi-
mental animals and from humans exposed
to aldicarb suggests that neurobehavioral
effects are short lasting with no accumula-
tion of effects over time. Thus, the doses
producing effects following repeated daily
exposure are comparable to those following
a single dose. Also, a comparable degree of
cholinesterase inhibition is seen at the same
dose levels, whether delivered in one acute
dose or by subchronic or chronic dosing (5).
The results of a 2-year feeding study in
the rat demonstrated that the exposed ani-
mals did not differ significantly from con-
trols for any of a number of toxicological
parameters, except the inhibition of
cholinesterase. Therefore, the NOAEL for
systemic toxicity is greater than or equal to
0.3 mg/kg bw/day (5).
In two multigeneration reproduction
studies in rats, the lowest NOEL for feto-
toxicity was found at 0.3 mg/kg bw/day.
No reproductive effects were noted at any
dose tested. Decreased body weight of sec-
ond-generation pups was observed at 0.7
mg/kg bw/day. Reduced pup viability was
observed at lactation day 4 at higher doses.
Developmental toxicity studies in rats
and rabbits revealed no congenital malfor-
mations but showed feto/embryotoxicity at
maternally toxic doses. The lowest NOEL
for developmental effects was 0.125 mg/kg
bw/day in the rat and 0.25 mg/kg bw/day
in the rabbit.
Aldicarb was not found to induce signi-
ficant increases in tumor incidence in mice
or rats in feeding studies or mice in a skin-
painting study. In the feeding studies there
were, however, significant changes in the
incidence of pituitary tumors in female rats
and fibrosarcomas in the male mouse (5).
Aldicarb has not been shown to be
genotoxic in any of a variety of in vitro and
in vivo genotoxicity assays (35).
1,2-Dibromo-3-chloropropane. No
information on exposure to 1,2-dibromo-
3-chloropropane (DBCP) is available.
DBCP has not been evaluated by
JMPR and an oral RfD is not available
from the U.S. EPA.
An inhalation RfD for noncarcinogenic
effects was established by the U.S. EPA at
0.0002 mg/m3 based on a no effect level of
0.17 mg/m3 in a 13-week, subchronic rab-
bit inhalation study. At 1.7 mg/m3 testicu-
lar effects were observed. The safety factor
was 1000 (5). In that study, the average
sperm count as well as the percentage of
live sperm of the rabbits was significantly
less than those of the controls after 7 weeks
of exposure, and remained decreased for the
duration of the exposure period and
through week 42 after the exposure. To
assess the effects of DBCP on fertility,
exposed male rabbits were mated to unex-
posed female rabbits at weeks 14 and 41 of
the study. DBCP did not affect the libido
of the exposed male rabbits during week
14; however, the five males exposed to 17
mg/m3 DBCP were infertile. During week
41 (27 weeks postexposure), all rabbits
exposed to lower concentrations of DBCP
produced normal litters, and two of the five
males exposed to 17 mg/m3 regained fertil-
ity (i.e., increased sperm count) and pro-
duced normal litters. The FSH serum levels
were also significantly elevated at 14 weeks
in the males exposed to 1.7 mg/m3 DBCP.
Increased FSH serum levels were consistent
with a marked decrease in sperm count,
whereas serum levels of testosterone were
unchanged. The only gross lesion observed
under macroscopic examination was the
small size of the testes. A histopathologic
examination revealed changes in the repro-
ductive system. These effects included
atrophy of the testes, epididymides, and
accessory sex glands including the prostate.
The testes weight was significantly decreased
to 50% of control values (week 14) in the
group exposed to 1.7 mg/m3 and to 75% of
control values (week 8) in the group exposed
to 17 mg/m3. Severe testicular atrophy was
characterized by nearly complete or complete
loss of spermatogenic cells in seminiferous
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tubules. Following the recovery period,
tubular regeneration was observed in the
testes of the affected rabbits (5).
A number of occupational studies on
exposure to DBCP demonstrated this com-
pound to be a potent testicular toxicant in
humans. The azoospermic men had ele-
vated FSH, but normal LH and testos-
terone levels. Testicular biopsy showed
atrophy of seminiferous epithelium and
tubules lined by Sertoli cells only. Few reli-
able exposure data are available from any of
these studies. Limited follow-up studies of
affected worker populations indicate that
paternal exposure to DBCP sufficient to
produce oligoospermia or azoospermia did
not detectably increase the rate of congeni-
tal malformations or impair the health sta-
tus of offspring conceived during or after
DBCP exposure (5).
DBCP is, however, a potential mutagen
capable of inducing a dominant-lethal
effect in mice.
Chronic inhalation carcinogenesis
bioassays in rats and mice have established
DBCP as a carcinogen, with high inci-
dences of tumors appearing in the nasal
cavity and on the tongues of rats and in the
nasal cavity and lungs of mice (5).
Industrial Chemicals and
Environmental Poliutants
Bisphenol-A. Bisphenol-A is used as a plas-
tic monomer in the manufacture of epoxy,
polycarbonate, and polyester-styrene
resins. Little is known about exposure to
bisphenol-A. Recently, bisphenol-A was
found to be released from the epoxy-lac-
quer coating in food cans. Concentrations
from 0.004 to 0.023 mg per kg of food
have been detected in canned food (47).
A tolerable daily intake of bisphenol-A
was established at 0.05 mg/kg bw by the
EU Scientific Committee for Food and a
specific limit for migration of bisphenol-A
from food packaging materials has been set
at 3 mg per kg of food (48).
An RfD for chronic oral exposure of
bisphenol- A was established at 0.05 mg/kg
bw/day by the U.S. EPA (5).
In both evaluations an LOAEL of 1000
ppm in the diet (corresponding to 50
mg/kg bw/day) of rats in a 103-week
chronic oral bioassay was used applying a
safety factor of 1000. Groups of 50 rats of
each sex were fed diets containing 0, 1000,
or 2000 ppm of bisphenol-A. All treated
groups of rats had reduced body weights.
Food consumption was also reduced.
In the same study, male mice (50/
group) were fed diets containing 0, 1000,
or 5000 ppm of bisphenol-A and female
mice (50/group) were fed 0, 5000, or
10,000 ppm of bisphenol-A. Male mice at
5000 ppm and female mice at 5000 and
10,000 had reduced body weights. At 1000
and 5000 ppm, there was an increase in the
number of multinucleated giant hepatocytes
in male mice. This effect was not consid-
ered adverse, and an NOAEL in mice was
established at 130 mg/kg bw/day (5).
The only toxic effect seen in beagle
dogs fed 1000 to 9000 ppm of bisphenol-A
in the diet for 90 days was an increase in
mean liver weight in the high-dose group.
In a two-generation feeding study of
bisphenol-A (100-9000 ppm) in rats,
decreases in body weight in the parent gen-
eration at 9000 ppm and in the F1 genera-
tion at greater than or equal to 1000 ppm
were observed. In mice, a dose level of
1250 mg/kg bw/day was associated with
fetotoxicity and maternal toxicity, but
there was no significant increase in the
incidence of malformations at any dose
level. In rats, dose levels of less than or
equal to 1280 mg/kg/day were not toxic
and did not cause malformations to the
fetus (5).
Polychlorinated Biphenyls. The poly-
chlorinated biphenyls (PCBs) are a series of
209 congeners. They were marketed under
various trade names (Aroclor, Clophen A,
and Kanechlor). Within each series there
were different average chlorine contents in
the mixtures. PCBs had diverse uses in
electrical transformers and other electrical
appliances (49), but their use has been
severely restricted in most countries since
the 1970s and 1980s. Waste containing
>50 ppm PCBs should be treated as haz-
ardous waste and destroyed by combustion
(50). Many of the PCB congeners are very
stable in the environment and accumulate
in marine, avian, and mammalian species.
Foodstuffs, in particular fatty fish, meat,
and dairy products, are important sources
of human exposure to PCBs. Until
recently, most analytical procedures for
PCBs in food and human tissue have mea-
sured total PCBs and do not reflect differ-
ences in composition. Modern analytic
techniques are now able to provide con-
gener-specific information, but so far only
a limited database has emerged.
The biological effects caused by the var-
ious congeners differ, not only in potency
but also qualitatively. Several non- and
mono-ortho-substituted PCB congeners
induce effects similar to those caused by
chlorinated dioxins and dibenzofurans, i.e.,
the toxicity is probably mediated through
interaction with the Ah receptor, and they
are potent inducers of certain cytochrome
P450 isozymes (CYPlAl and CYP1A2).
The toxicity of such PCB congeners can be
expressed in terms of TEFs, that is,
expressed as a fraction of the toxicity of
TCDD (51,52). Other PCB congeners
presumably act by different mechanisms
and are potent inducers of a different set of
cytochromes (CYP2B1 and CYP2B2). In
addition, there are PCB congeners that are
intermediate in this respect, i.e., they elicit a
mixed spectrum of effects. Our knowledge
of possible interactions between the various
groups of PCBs is still very limited (50).
PCB levels in foods (herring and cod
liver) and human milk have declined in the
Nordic countries since the 1970s (2,50).
PCB levels in fish now seem to have stabi-
lized at 10% of the levels found in the
beginning of the 1970s. In fact, the levels
in herring are now below 0.1 mg/kg. It has
been estimated that the intake of PCBs
from heavy fish consumption is less than
25 fg per person per day, corresponding to
0.0004 mg/kg bw/day for a 60-kg person.
A Nordic group of experts concluded
that the present database does not allow a
traditional risk assessment to be performed,
i.e., it was not possible to recommend a
tolerable daily intake of either total PCB
or any individual congener. Furthermore,
the evaluation suggested that the present
exposure of Nordic populations is of the
same order of magnitude as that at which
subtle health effects may occur in children
exposed in utero and possibly through
breast-feeding (see "Exposure of Humans
to Environmental Chemicals with
Estrogenic Activity and Their Effects on
Male Reproductive Health"). Further
studies would be necessary to clarify
whether such effects actually occur (50). In
addition, when the concentrations of the
dioxinlike PCBs are taken into account,
the joint risk from PCBs in mothers' milk
and certain other foods appears to be of
similar importance as the dioxin content.
Most of the animal studies with PCB
mixtures have been performed using com-
mercial mixtures that differ in composition
from the PCB mixtures to which humans
are exposed through food. Although ani-
mal feeding studies demonstrate the car-
cinogenicity, immunotoxicity, and
reproductive toxicity of commercial PCB
preparations, it is not known which of the
PCB congeners in such preparations are
responsible for these effects.
PCBs (Aroclor 1260, Kanechlor 500
and Clophen A 60, mixtures containing
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more highly chlorinated biphenyls) have
produced hepatocellular carcinomas in
three strains of rats and two strains of mice.
Aroclor 1254 (lower chlorine percentage)
only produced hepatocellular adenomas in
mice and rats (5). Most genotoxicity assays
of PCBs have been negative.
PCB exposure has been reported to
cause several effects on different processes
in reproduction and the development of
the embryo/fetus/offspring. Most effects
are specific to fertility and to the develop-
ment of offspring. In addition, teratogenic
effects, such as hydronephrosis and cleft
palate, have been produced in mice. Effects
seen on male reproduction include decreases
in fertility, matings and pregnancies; testic-
ular spermatozoa concentration; ventral
prostate weight; and seminal vesicle weight.
The underlying cause of some of the repro-
ductive effects of PCBs may be alterations
in hormonal levels and/or receptor affini-
ties/levels. Decreased levels of gonadal hor-
mones can be explained by enhanced
metabolism of steroids, which are the nor-
mal substrates for microsomal enzymes
induced by PCBs (50). In addition, effects
on the thyroid gland and its function have
frequently been reported (52).
Perinatal toxicity and long-term neu-
robehavioral effects of Aroclor 1016 have
been evaluated in infant monkeys. Aroclor
1016 was administered to groups of eight
adult female rhesus monkeys via the diet at
levels of 0.007 and 0.028 mg/kg bw/day
for approximately 22 months. Exposure
began 7 months prior to breeding and con-
tinued until offspring were weaned at age 4
months. No exposure-related effects were
seen in the mothers, who all had uncom-
plicated pregnancies. Mean birth weights
of the infants in the 0.028 mg/kg bw/day
dose group were lowered. Effects occurring
in the offspring of these monkeys consisted
of hairline hyperpigmentation at greater
than or equal to 0.007 mg/kg bw/day, and
decreased birth weight at 0.028 mg/kg
bw/day. The results of neurobehavioral
tests in the monkey offspring at 14 months
and 4 to 6 years of age demonstrated
adverse learning deficits at the 0.028
mg/kg/day maternal dose. However, evalu-
ation of these data is complicated by possi-
ble inconsistencies in the outcome of the
learning tests. Learning was impaired and
facilitated on different problems; perfor-
mance was improved in the low-dose
group, and no significant differences were
seen between either test group and the con-
trol group. There is some evidence to sug-
gest that deficits in learning are related to
decreased brain dopamine, which has
been observed in monkeys orally exposed
to Aroclor 1016 (5). The issue of male
reproductive effects was not addressed in
these studies.
In the rat, Aroclor 1016 produced
elevated serum levels of adrenal cortical
hormones, and Aroclor 1016 was immuno-
toxic in mice.
Aroclor 1016 (3.8 mg/kg bw/day for
237 days) adversely affected reproduction
in mink. The investigators noted that the
adverse effects on reproduction did not
appear to be due to an effect on spermato-
genesis, since PCB-treated male mink have
had acceptable levels of reproduction
when mated to untreated females in other
studies (5).
In rhesus monkey infants whose mothers
were or had been exposed to Aroclor 1248
during gestation and lactation, behavioral
testing showed hyperactivity and retarded
learning ability at 6 to 24 months of age.
However, at 44 months of age the monkeys
were hypoactive and at 4 to 6 years of age
they showed impairment in learning and
memory tests. These effects were reported
at doses of about 0.006 mg Aroclor
1248/kg bw/day to the mothers (50).
Adult female rhesus monkeys fed 0, 0.1
and 0.2 mg/kg bw/day of Aroclor 1248 for
up to 14 months showed skin changes,
such as hyperpigmentation and alopecia,
characteristic signs of PCB intoxication.
Increased menstrual duration was noted. In
a breeding trial a highly increased rate of
abortion was observed, and liveborn infants
showed clinical signs of PCB toxicity and
died at weaning. Thymic atrophy was a
common lesion in such infants. The study
included three recovery breeding periods
after dosing: at 22 months, 36 months,
and 55 months after the initiation of
Aroclor 1248 dosing, respectively. Results
of this prolonged recovery period revealed
impairment of reproductive function in
female rhesus monkeys lasting for more
than 4 years after dosing ceased. In the
groups of infants for which birth weight
data are available, a significant reduction in
mean birth weight for PCB-exposed
infants was evident. Severe immunological
deficiencies have also been observed in
monkeys after PCB exposure.
Studies of individual congeners and
PCB mixtures of higher chlorine content
in animals indicate, in general, that PCBs
are readily and extensively absorbed (75-
>90%) in rats, mice, monkeys, and ferrets.
A study of a PCB mixture containing 54%
chlorine provides direct evidence of
absorption of PCBs in humans after oral
exposure, and indirect evidence of oral
absorption of PCBs by humans is available
from studies of ingestion of contaminated
fish by the general population. PCBs dis-
tribute preferentially to adipose tissue and
concentrate in human breast milk due to
its high fat content (5).
The estrogenic activity of hydroxylated
PCB metabolites has been discussed in the
"Environmental Chemicals with Known
Estrogenic Effects."
Two episodes of ingestion of PCB-con-
taminated rice oil have been reported: the
Yusho incident of 1968 in Japan and the
Yu-Cheng incident of 1979 in Taiwan (see
"Exposure of Humans to Environmental
Chemicals with Estrogenic Activity and
Their Effects on Male Reproductive
Health"). There is strong evidence indicat-
ing that the health effects seen in Yusho
victims were due to ingestion of polychlori-
nated dibenzofurans, rather than to PCBs
themselves (5).
Polychlorinated Dibenzo-p-dioxins
and Dibenzofurans. Polychlorinated
dibenzo-p-dioxins and polychlorinated
dibenzofurans consist of 75 and 135 dif-
ferent congeners, respectively. The most
toxic and well-studied congener is TCDD.
These compounds are not used commer-
cially but are formed as unwanted byprod-
ucts in a variety of chemical and thermal
processes, such as production of chlori-
nated compounds, incineration processes,
paper and pulp bleaching, and emissions
from steel foundries and from motor vehi-
cles (53). These chemical and thermal
processes lead to continuous formation
and release of PCDDs and PCDFs into
the environment.
Although many of the PCDD/PCDFs
are emitted into the environment, only
congeners with chlorine substitution, at
least in positions 2, 3, 7, and 8, are found
in biological material. These stable,
lipophilic substances accumulate in food
chains. The stable PCDD/PCDFs share a
common mechanism of action. They have
been shown to act via a cytosolic receptor,
the Ah receptor. The Ah receptor regulates
a number of cellular proteins, such as
cytochrome P4501A1 (CYP lAI), and
most of the toxic responses following
TCDD exposure are believed to be medi-
ated through the Ah receptor. To express
the combined toxicity of the PCDD/
PCDF mixtures to which humans are
exposed, the concept ofTCDD equivalen-
cies (TCDD-TEQs) has been developed.
In a variety of short-term tests, the toxicity
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of each single congener has been expressed
as a fraction of the well-known toxicity of
TCDD, the so-called TEFs (54).
Food is considered to be the main
source of exposure to PCDD/PCDFs. The
most important food items are milk and
milk products, meat and meat products,
eggs, and fish and fish products. Data from
Germany (1991) have estimated an average
daily intake of TCDD-TEQs of 130.3
pg/person/day, corresponding to approxi-
mately 2 pg/kg bw/day for a 60-kg person
(0.000000002 mg/kg bw/day) (55).
Comparable results are obtained from a
more limited investigation of Danish food-
stuffs (56). TCDD-TEQs were estimated
in samples of mothers milk from Denmark,
Sweden, and Norway in 1987. The levels
in the three Nordic countries were very
similar, the mean values ranged from 17 to
20 pg/g on a fat basis (54).
In 1988 a Nordic expert group estab-
lished a TWI of 35 pg/kg bw/week for
TCDD (5 pg/kg bw/day) (54). The evalu-
ation was based on a NOAEL of 1000
pg/kg bw/day found in a chronic long-
term toxicity/carcinogenicity study in rats
and a three-generation reproduction study
in rats. The safety factor used was 200. In
both studies effects were observed following
administration of 10,000 pg/kg bw/day. In
the long-term study, liver toxicity and
hyperplastic nodules were observed in
female rats. At a 10-fold higher dose, female
rats developed hepatocellular carcinomas. In
the reproduction study 10,000 pg/kg
bw/day resulted in decreased litter size,
decreased fetal and neonatal survival, and
decreased weight gain in surviving pups.
An overwhelming biochemical and tox-
icological database exists on PCDDs and
PCDFs. These compounds produce a wide
spectrum of responses in experimental
animals and, presumably, in humans. The
toxic effects include teratogenic, repro-
ductive, behavioral, neuroendocrine,
immunotoxic, and hepatotoxic effects. The
tumorigenic actions seen in some rodents
most likely are not the result of a geno-
toxic, but rather the resulst of a promo-
tional, and possibly hormonal, mechanism
(53). The biochemical effects include
induction of a number of cytochromes,
most noticeably CYPlAl and CYP1A2.
Indirect effects, such as alterations of hor-
monal metabolism leading to, for example,
altered sex hormone levels and lowered
thyroid hormone levels may have an
influence on growth and development of
the organism. Most of the toxic and bio-
logical responses are thought to be initiated
through the binding to the Ah receptor.
This binding is followed by translocation
to the dioxin-responsive enhancer (DRE)
elements on DNA for the expression of
many of the species- and tissue-specific,
toxicological and biological responses,
including increased expression of growth
factors. However, there is some evidence
that some effects, e.g., alteration in thyroid
hormone metabolism, are not necessarily
Ah-receptor-mediated.
The effect of TCDD on male repro-
duction in the rat has already been dis-
cussed in "Environmental Chemicals with
Known Estrogenic Effects." TCDD is both
antiestrogenic and antiandrogenic. A com-
prehensive review of a number of endo-
crine and other effects of TCDD has been
given by Pohjanvirta and Tuomisto (57).
Pentachlorophenol. Pentachloro-
phenol (PCP) has been widely used as a
wood preservative. Dietary exposure to
PCP is thought to be limited. An average
intake of 0.00015 mg/kg bw/day has been
estimated. PCP may be present in indoor
and outdoor air, but data on inhalation
exposure are scarce (58).
A RfD for noncarcinogenic effects was
established by the U.S. EPA at 0.03 mg/kg
bw/day based on a no effect level of 3
mg/kg bw/day in a 2-year chronic feeding
study in rats. At 10 mg/kg bw/day pigmen-
tation of liver and kidneys was observed in
females. The safety factor used was 100
(5). The main organs or systems affected in
animals after long-term exposure to low
levels of PCP were the liver, kidney,
nervous system, and immune system (58).
Numerous studies have investigated the
teratogenicity of PCP administered orally
to rodents. These studies did not reveal ter-
atogenic effects; however, feto/maternal
toxicity was seen at 30 mg/kg bw/day.
Since PCP apparently does not cross the
placental barrier, the observed fetotoxicity
may be a reflection of maternal toxicity (5).
In mice, PCP exposure increased the
incidences of hepatocellular adenomas and
carcinomas, adrenal medulla pheochromo-
cytomas and malignant pheochromocy-
tomas, and/or hemangiosarcomas and
hemangiomas in one or both sexes. In two
chronic oral rat studies no significant
increase in tumor incidence as compared
with controls was observed.
Mutagenicity data provides some indica-
tion that PCP has clastogenic potential (5).
Alkylphenol Ethoxylates. Alkylphenol
ethoxylates (APEs) are nonionic surfac-
tants widely used as detergents, emulsifiers,
wetting agents, and dispersing agents in
household products and in agricultural and
industrial applications. They are also used
as spermicides in contraceptive foams, jel-
lies, and creams. The alkyl group typically
is a branched nonyl-, octyl- or dodecyl-
chain. The ethoxylate chain may have 1 to
100 repeating units. Nonylphenol ethoxy-
lates (NPEs; nonoxynols) are the most
common forms of the APEs.
Alkylphenol, alkylphenol mono- and
diethoxylates, and their carboxylic acids are
the products of the microbial breakdown
of APEs and are present in surface waters
and sediments. The alkylphenols are rela-
tively persistent and bioaccumulate in the
lipid of living organisms (see section
"Environmental Chemicals with Known
Estrogenic Effects"). In addition to the
obvious exposure from the use of spermi-
cides and contact with products containing
APEs, it is possible that humans can be
exposed to APE degradation products
through the water supply, sewage sludge
used for fertilizer, and aquatic organisms
used as food. However, virtually nothing is
known about the magnitude of human
exposure to these compounds.
Nonoxynol-9 (9 ethylene oxide units),
which is used as a spermicide, was rapidly
absorbed from the vagina of rats (59).
There is also evidence that nonoxynol-9 can
be metabolized to nonylphenol, which after
glucuronidation was excreted through urine
and bile (60). Intravaginal administration
of nonoxynol-9 in rats caused damage to
the vaginal epithelium and acute inflamma-
tion in the vagina, cervix, and uterus (61).
When administered to rats during the first
week of pregnancy, nonoxynol was found
to be embryotoxic (62).
Meyer et al. (63) observed fetotoxicity
of nonoxynol-9 at a high oral dose level
(500 mg/kg bw/day) that also caused
maternal toxicity. When given epicuta-
neously, no effect was seen. Nonoxynol-30
was without effects. Nonoxynol-9 was not
mutagenic in the Ames test (63).
Octylphenol and nonylphenol were
found to be estrogenic both in vitro and in
vivo (see "Environmental Chemicals with
Known Estrogenic Effects").
Phthalate Esters. Since the 1920s
phthalate esters have been used as plasticiz-
ers for polyvinyl chloride. The most widely
used phthalate ester is di(2-ethylhexyl)-
phthalate (DEHP) (comprising 50% of all
phthalate ester plasticizers). It may account
for 40% or more of the plastic. In addition
to this ester, a range of phthalate esters is
available and used in different plastics,
depending on the intended use of the
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product. Examples are dibutyl phthalate
(DBP) and butylbenzyl phthalate (BBP).
Phthalate esters are produced in enormous
quantities. They are present in many com-
mercially available plastics and are leach-
able or volatilizable from such plastics. The
environmental fate of phthalate esters after
their release from plastics has not been
widely studied (64).
DEHP exists widely in the environ-
ment and is found in most samples,
including air, precipitation, water, sedi-
ment, soil, and biota. Levels up to 300
ng/m3 have been found in urban air. River
sediment levels up to 70 mg/kg have been
reported. DEHP also has been found in
various types of food, such as fish, shellfish,
eggs, and cheese. The average dietary expo-
sure to DEHP was estimated at 300 fg/per-
son/day in the United States in 1974.
Blood transfusions and other medical treat-
ments using plastic devices may lead to
involuntary human exposure to DEHP
(65). When all sources were considered,
the total dietary intake of DEHP in the
United States was estimated to be 5.8
mg/person/day. Maximum exposure to
total phthalate from packaging sources
alone in the United Kingdom was esti-
mated at 4.37 mg/person/day [cited by
Sharman et al. (66)]. Sharman et al. (66)
found total phthalates in dairy products (in
the United Kingdom) ranging from 4 to
20 mg/kg in cheese and butter (DEHP
from 0.6-3 mg/kg).
The extent of human exposure to
phthalate esters in Denmark is not known.
In Denmark, DEHP is not allowed for use
in plastic materials intended to come into
contact with foods. Petersen (67) found a
mean concentration of DEHP lower than
0.05 mg/liter in retail whole milk from
Denmark.
The European Union Scientific Com-
mittee for Food has established an ADI of
0.025 mg/kg bw/day for DEHP (67). An
RfD for non-carcinogenic effects of DEHP
was established by the U.S. EPA at 0.02
mg/kg bw/day based on an LOAEL of 19
mg/kg bw/day in a subchronic to chronic
feeding study in guinea pigs. The effect
observed was increased liver weight. The
safety factor was 1000 (5).
MEHP, the monoester form of DEHP
is the principal metabolite of DEHP (65).
Several studies have shown testicular
atrophy after DEHP administration (high
doses). Younger rats seem to be more
susceptible than older ones, and rats and
mice may be more sensitive than hamsters
and monkeys. The effect was reversible.
MEHP has toxic effects on Sertoli cells
in vitro (65).
Dietary levels of 0, 0.01, 0.1, and
0.3% DEHP were administered to male
and female CD-I mice that were exam-
ined for adverse fertility and reproductive
effects using a continuous-breeding proto-
col. DEHP was a reproductive toxicant
in both sexes, significantly decreasing fer-
tility and the proportion of pups born
alive per litter at the 0.3% level, and
inducing damage to the seminiferous
tubules. DEHP has been observed to be
both fetotoxic and teratogenic.
DEHP is a potent inducer of hepatic
peroxisomal enzyme activity. This effect is
strongly associated with the hepatocarcino-
genic effect of DEHP. In contrast to rat
hepatocytes, DEHP metabolites do not
produce peroxisome proliferation in
human hepatocytes (65). In a long-term
carcinogenicity study, groups of rats were
fed with 0, 300, or 600 mg DEHP/kg
bw/day for 103 weeks. Similarly, groups of
mice received DEHP in the diet for 103
weeks. No clinical signs of toxicity were
observed in either rats or mice. A statisti-
cally significant increase in the incidence of
hepatocellular carcinomas and the com-
bined incidence of carcinomas and adeno-
mas was observed in female rats and both
sexes of mice.
Studies indicate that DEHP is not a
directly acting mutagen. MEHP, the
monoester form of DEHP and a metabo-
lite, was positive in several assays for muta-
genicity and clastogenicity (65).
An RfD for noncarcinogenic effects of
DBP was established by the U.S. EPA at 0.1
mg/kg bw/day based on an NOAEL of 125
mg/kg bw/day in a subchronic to chronic
feeding study in rats. The effect observed
after 600 mg/kg bw/day was increased mor-
tality. The safety factor was 1000 (5).
Fetotoxicity was observed when mice were
fed 2100 mg/kg bw/day DBP throughout
gestation. An increase in terata of border-
line statistical significance was observed in
progeny of this treatment group.
DBP causes degeneration of the semi-
niferous tubules, probably as a result of
increased urinary excretion of zinc. No
data on carcinogenicity are available.
DBP did not induce mutations in
bacteria. It was mutagenic in the mouse
lymphoma forward mutation assay only in
the presence of metabolic activation. In
addition, DBP showed some evidence of
clastogenic activity in mammalian cells. It
is hydrolyzed to monoesters. There is also
evidence that DBP induces peroxisome
proliferation (5).
An RfD for noncarcinogenic effects of
butylbenzyl phthalate (BBP) was estab-
lished by the U.S. EPA at 0.2 mg/kg
bw/day based on an NOAEL of 159 mg/kg
bw/day in a 6-month feeding study in rats.
The effect observed after 470 mg/kg
bw/day was increased liver weight. The
safety factor was 1000 (5). In the previ-
ously mentioned study all rats given 1417
mg/kg bw/day BBP had small testes; 5/11
had soft testes; and 1/11 had a small
prostate and seminal vesicle. In addition,
testicular lesions characterized by atrophy
of seminiferous tubules and aspermia were
also observed. At the lower dose levels
there were no observable effects on male
reproductive organs. A male mating trial
study was performed concomitantly with
the toxicity study. Testicular atrophy was
observed in male rats after 10 weeks of
exposure to 2875 mg/kg bw/day). In an
older rat study no effects were reported
after 250 mg/kg bw/day, while liver
weights were increased in animals fed diets
containing 500, 750, or 1000 mg/kg
bw/day, respectively, for 90 days. A mild
decrease in growth rate was reported for
the two top dose groups.
In a 14-day rat study, BBP at a dose
level of 375 mg/kg bw/day produced
significant increases in liver and kidney
weights and kidney pathology (proximal
tubular regeneration).
In male rats administered 160, 480, or
1600 mg/kg bw/day BBP for 14 days, bio-
chemical or morphological changes in the
liver as well as effects on testes weights
were not observed in the 160 mg/kg/day
dose group. However, at 480 mg/kg
bw/day, liver enzyme activities were
increased and testicular atrophy was
observed in some of the rats. BBP was
tested at dietary levels of 0, 6000, and
12,000 ppm in long-term carcinogenicity
studies in mice and rats.
BBP induced a statistically significant
increase in mononuclear cell leukemia in
female rats; the response in male rats was
inconclusive and there was no such
response in mice. BBP did not induce lung
adenomas in strain A mice administered
24 ip injections of 160, 400, or 800 mg/kg
bw. BBP is not mutagenic in in vitro
assays (5).
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Appendix B: Identification and Assessment
of the Effects of Chemicals on
Reproduction and Development, Focusing
on the Effects on Males
The following effects have to be considered:
* Impairment of male (and female)
reproductive functions or capacity, i.e.,
adverse effects on libido, sexual behav-
ior, any aspect of spermatogenesis (or
oogenesis), or hormonal activity or
physiological response that would inter-
fere with the capacity to fertilize, fertil-
ization alone, or development of the
fertilized ovum up to and including
implantation.
* Induction of noninheritable harmful
effects on the progeny, i.e., in the
broadest sense any effect interfering
with normal development, both before
and after birth up to puberty, should
be included. Both morphological mal-
formation(s) and functional distur-
bances (e.g., hormonal, neurological)
should be evaluated.
The risk assessment includes:
* Hazard identification
* Dose-effect assessment (estimation of a
possible NOAEL)
* Extrapolation (prediction of adverse
effects in other species, particularly
in man)
* Prediction of safe levels of exposure
in man
Experimental Studies in
Laboratory Animals
Many different experimental methods are
being used for the investigation of the repro-
ductive toxicity of chemicals. Several tests
are standardized and guidelines have been
issued by various governmental agencies
and international organizations. Other tests
are still undergoing scientific evaluation.
The group of tests discussed below is
not a comprehensive listing of all available
tests but rather a presentation of represen-
tative examples. (The presentation of the
individual tests and the test strategies are
based on the references given at the end of
this appendix)
Tests for Reproductive Toxicity
The description of the tests is based on the
following references:
* OECD (68)
* Commission of the European
Communities (69)
* Ministry of Health, The National Food
Agency of Denmark (70)
* Nordic Council of Ministers and
National Institute of Occupational
Health, Denmark (71)
* Hansen and Meyer (72)
* European Chemical Industry, Ecology
and Toxicology Centre (ECETOC) (73)
One-, Two-, and Multigeneration
Studies. Generation studies examine suc-
cessive generations to identify possible
effects of a substance on fertility of male
and female animals; pre-, peri-, and post-
natal effects on the ovum, fetus, and prog-
eny, including teratogenic and mutagenic
effects; and peri- and postnatal effects on
the mother.
Various international organizations and
countries have drafted guidelines for these
tests, with a number of common require-
ments. The preferred species are the rat and
the mouse; other species may be used if rele-
vant (e.g., differences in the toxicokinetics
between the preferred species and man to
clarify ambiguous results or to further study
observed effects). The test substances are
administered by the appropriate route to
groups of animals (number of animals per
group should be sufficient to yield about 20
pregnant animals at or near term). The
chemical is administered over at least one
spermatogenic cycle and the last stages of
oocyte maturation before the parent genera-
tion animals are mated. The exposure of the
females is continued throughout the mating
period and the gestation up to weaning of
the last generation. At least three treatment
groups and a control group (untreated or
vehicle in the highest dose used) should be
used. Ideally, unless limited by the physico-
chemical nature or biological effects of the
test substance, the highest dose level should
induce toxicity but not mortality in the
parental animals. The low dose should ide-
ally not induce any observable adverse
effects on the parents or offspring.
The animals are observed daily for clin-
ical changes. Body weight is recorded
weekly for the parent animals and for off-
spring normally at birth, on days 4, 7, and
14, at weaning, and thereafter every week.
Pregnancy rate, duration of pregnancy,
number of pups per litter, number of live
and dead pups, number of pups with
anomalies are recorded, and, if necessary,
histological examinations of dead or sacri-
ficed animals are performed. The number
of live pups on day 4 and at weaning are
recorded and the following indices are
often calculated:
* Mating index: copulation/estrous cycles
required
* Fecundity index: pregnancies/copulations
* Male fertility index: males impregnat-
ing females/males exposed to fertile
nonpregnant females
* Female fertility index: females conceiv-
ing/females exposed to fertile males
* Incidence of parturition: parturitions/
pregnancies
* Live birth index: viable pups born/pups
born
* Survival index for 24 hr, 4 days, 12
days, and 21 days
The number of litters per female per
generation varies in the different guidelines
from one to two.
Fertility assessment by continuous
breeding has been used to study the deple-
tion of oocytes from the ovary in mice
exposed to procarbazine. In this study, pre-
natally treated mice were housed continu-
ously with untreated male mice, and the
cumulative number of offspring was mea-
sured by removing the female when she was
noticeably pregnant and then returning the
female to the male's cage immediately after
the birth of her pup in order to establish a
pattern of forced repetitive breedings.
In proposed guidelines from the U.S.
EPA (74), samples of sperm from the distal
cauda epididymis (or the proximal vas def-
erens) shall be collected for the evaluation
of the percentage of progressively motile
sperm and sperm morphology. In addition,
the entire cauda epididymis shall be
minced in saline to enumerate the total
number of sperm.
A number of useful tests of male repro-
ductive toxicity, which are discussed in
detail, for example, by Thomas (75), are
listed below:
* Testis: size in situ, weight, consistency,
morphometry, spermatid reserves,
DNA flow cytometry, biochemical
assays, gene expression
* Epididymis: weight and histology,
number of sperm in distal half, sperm
motility, sperm morphology, biochemi-
cal assays, gene expression
* Accessory sex glands: weight and histol-
ogy, biochemical assays, gene expression
* Semen: total volume, gel-free volume,
sperm concentration, sperm motility,
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sperm morphology, hamster egg pene-
tration, cervical mucus penetration
* Sperm (special features): video/cine-
micrography, membrane structure,
metabolism
* Fertility: ratio-exposed/pregnant
women; number of embryos per preg-
nant female; ratio-viable embryos/
corpora lutea; number of 2- to 8-cell
eggs; number of abnormal eggs
* Endocrine monitoring: testis-testos-
terone, dihydrotestosterone, estradiol,
estrone, thyroid gland-thyroxin,
triiodothyronine pituitary-FSH, LH,
prolactin, TSH
End points that are used to indicate
reproductive dysfunction include (76):
* Decreased libido, impotence
* Abnormal sexual behavior
* Sperm abnormalities: decreased num-
ber or motility, morphology
* Subfecundity: abnormal sex organs
and/or pubertal development, infertility
* Early fetal loss
* Late fetal loss (stillbirth)
* Intrapartum death
* Death in the first week
* Decreased birth weight
* Prematurity/postmaturity at birth
* Altered sex ratio
* Multiple births, birth defects
* Infant death
* Childhood morbidity
The Conventional Teratologgy Study.
The teratology study is the in vivo method
for studying embryo-fetal toxicity as a con-
sequence of exposure during pregnancy
(e.g., growth retardation, anatomical varia-
tions, teratogenicity, lethality). Various
international organizations and countries
have drafted guidelines for these tests.
These guidelines have a number of com-
mon requirements. The preferred species
include rodents (e.g., rat, mouse) and non-
rodents (e.g., rabbit). Other species may be
used if relevant (e.g., differences in the tox-
icokinetics between the preferred species
and man to clarify ambiguous results or to
further study observed effects).
Young mature virgin females are arti-
ficially inseminated or mated with males.
The time of mating is established by obser-
vation of mating (e.g., rabbits), identi-
fication of a plug (mixture of sperm and
cellular material from the vagina of rats
and mice), vaginal smear (in rats) or by
noting the time of insemination (e.g., for
pigs and rabbits). Normally, three dose
levels and a control group (untreated or
vehicle control; the group size is 20 preg-
nant animals for rats and mice, and 12 for
rabbits) are used to establish a dose-effect
relationship. The pregnant female rats are
exposed during the period of organogene-
sis, i.e., between day 6 when implantation
occurs and day 15. (The corresponding
periods for mice and rabbits are days 6-15
and days 6-18, respectively). This period
has been found to be the most sensitive to
the induction of structural, anatomical
malformations (the corresponding sensitive
period for humans is between days 18 and
60 of pregnancy). Days 6 to 15 are the
indicated dosing period for pregnant rats.
However, this may vary depending on the
substance administered or whether the
effect on a specific organ is to be studied.
The animals are observed daily for
clinical changes. Body weight and food
consumption are recorded throughout
the gestation. The uterus is removed by
cesarean section and the uterus and the
fetuses are examined the day before antici-
pated birth. (The dam is examined macro-
scopically for any structural abnormalities
or pathological changes that may have
influenced the pregnancy). If dosing is ini-
tiated before or at the time of implantation,
the preimplantation loss, i.e., the number
of embryos lost prior to implantation,
is evaluated.
The total number of implantations,
i.e., living embryos, dead embryos, and
resorption (embryos that die early and are
reassimilated, corresponding to early abor-
tions in humans) are noted. The degree of
resorption (i.e., the extent to which the
embryo has been resorbed) is recorded to
establish the time of death of the embryo
during the pregnancy.
The fetuses are sexed, weighed, and
examined for gross malformations. Retarded
growth and effects on visceral and skeletal
development are evaluated, including the
degree of ossification of the bones.
The Perinatal and Postnatal Studies.
Prenatal exposure to chemicals may lead to
a range of functional disturbances in the
offspring. For example, lead and methyl-
mercury affect brain development but
effects on fertility, the immune system,
metabolism of foreign substances, and
development as a whole have been observed.
Behavioral teratology identifies changes
in behavior due to effects on the central
nervous system (CNS) and the peripheral
nervous system (PNS). As behavior is
affected by the function of other organs
such as liver, kidneys, and the endocrine
system, toxic effects on these organs in off-
spring may also be reflected in general
changes in behavior. No single test is able
to reflect the entire complex and intricate
function of behavior. For testing behavior,
therefore, a range of parameters-a test
battery-is used to identify changes in
individual functions.
The most frequently used animal
species are the rat and the mouse. The
guidelines generally recommend groups of
20 animals with dosing from day 15 of ges-
tation to day 21 postgestation, i.e., span-
ning fetogenesis and the entire lactation
period. (However, the recommended dos-
ing period does not cover all events since
the CNS is also susceptible to abnormal
development during the period of organo-
genesis. Consequently, dosing is often
started earlier, for example, on day 1 or day
6 of the pregnancy). After birth, the num-
ber of progeny is recorded and the litters
are adjusted so that each contains the same
number of pups. To determine whether
the chemical substance tested affects the
offspring directly through the mother's
milk or indirectly by a change in milk pro-
duction or as a result of a change in the
behavior of the exposed mother, cross-fos-
tering may be employed. Cross-fostering is
a method by which litters from exposed
mothers are reared by control mothers and
vice versa.
Studies to identify abnormal develop-
ment are conducted on individual animals
over short or long periods. In the rat,
studies last until weaning (although this
period does not cover the entire period of
brain development as the brain does not
attain an approximate adult stage until the
age of 6 weeks, which corresponds to 12 to
15 years of age in humans).
Methodology employed in behavioral
teratology is described in several reviews.
Behavioral teratology tests may generally be
grouped into tests of physical development,
simple reflexes, motor function, develop-
ment of the senses, spontaneous activity,
learning and memory, and functions of the
neurotransmitter systems.
In Vivo Screening Tests
As the capacity for toxicity testing cannot
keep up with the number of chemicals in
the modern society, there is an increasing
demand for new toxicological tests of
shorter duration, using fewer resources.
Especially for older chemicals where the
patent rights no longer exist, or for chemi-
cals introduced into the market years ago
when no or few toxicity data were
required, it is essential to develop tools for
obtaining data for safety assessment. In
recent years such new screening tests for
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reproductive and developmental toxicity
have been developed. By definition, a
screening test is limited in scope compared
to a conventional test. Data from a screen-
ing test indicating a possible toxic potential
of a substance identify the substance as one
of high priority for further evaluation.
A short presentation of two examples of
screening tests for reproductive and devel-
opmental toxicity is given below.
The in Vivo Teratology Screening
Test. This test was introduced as an alter-
native method to the above-mentioned
teratogenicity tests. The hypothesis under-
lying this test is that most prenatal effects
do not just produce specific defects but
also are manifested in the postnatal period
as a lack of viability and reduced growth.
Pregnant mice (rats can also be used)
are exposed to a test substance from day 8
to day 12 of the pregnancy. A control
group is not exposed. One dose level is
employed (the minimum toxic dose for the
mother animal). The mother animals are
weighed during the period of exposure.
After birth the litter is weighed on the first
and third days. Stillborn young and young
that die after birth are dissected and exam-
ined for defects. The test focuses on mal-
formations as the end points of concern.
Results from a validation study have shown
that effects on offspring viability or body
weight indicate a potential for teratogenic
effects, i.e., malformations. A test guideline
for this test has not been established.
Rep roductio n/Develop mental
Toxicity Sereening Tests. Recently OECD
has introduced guidelines for screening
tests for reproductive toxicity, i.e., the
Reproduction/Developmental Toxicity
Screening Test as a part of the Screening
Information Data Sets (SIDS) for older
chemicals that were produced in large vol-
umes (68). The Combined Repeat Dose
and Reproduction/Developmental Toxicity
Screening Test is a combination of the
"Repeated Dose Oral Toxicity-Rodent:
28-Day Study" and a reduced one-genera-
tion study, whereas the Preliminary
Reproduction Toxicity Screening Test is a
reduced one-generation study.
The reduced one-generation test has
been validated with, among other chemicals,
ethylene glycol monoethyl ether (EGME)
and cyclophosphamide (CP). EGME showed
both systemic and reproductive/develop-
mental effects similar to those previously
reported using standard protocols. The
study on CP demonstrated most of the
known toxicological properties of CP,
including developmental toxicity, but not
the (expected) adverse effect on spermato-
genesis and fertility (the use of lower dose
and shorter premating treatment seem to be
possible causes for these negative findings).
On the basis of the experience with
the tests, the OECD has prepared propos-
als for two new guidelines (421 and 422),
to be included in the Test Guideline
Programme. They are being considered for
inclusion as new base set tests among the
tests used for new chemicals in EU because
of a recognition of the need to obtain ini-
tial information on reproduction and
developmental toxicity at an early phase of
hazard identification.
The purpose of the test is to generate
limited information concerning the effects
of a chemical on male and female repro-
ductive performance such as gonadal
function, mating behavior, conception,
development of conceptus, and parturition.
The test is not considered as an alternative
to, nor a replacement for, the existing
generation and teratology studies.
The dosing of the animals is initiated 2
weeks prior to mating and continued until
the end of the study on postnatal day 4.
The number of animals per group (gener-
ally at least three test groups and a control
group) is at least 10 animals of each sex
(expected to provide at least 8 pregnant
females per group). Effects on fertility and
birth are registered. Live pups are counted
and sexed and litters weighed on days 1
and 4 postpartum. The parameters include,
among others, a detailed histological exam-
ination on the ovaries, testes, and epi-
didymides of at least the highest dosed and
the control animals.
Other Toxicity Tests
In Vivo Tests
Other toxicity tests than those mentioned
above can reveal effects that indicate a
potential of a chemical to interfere with
normal reproduction. Thus, in all the toxi-
cological tests involving repeated dosing,
including the carcinogenicity test, the
gonads and accessory sex organs are
subjected to pathological examination
including histopathology.
As an example, a rodent test for genetic
toxicology (OECD guideline for testing
chemicals), the Rodent Dominant Lethal
Test should be mentioned. Male animals
are exposed to the test substance and
mated to untreated virgin females. The var-
ious germ-cell stages can be tested sepa-
rately using sequential mating intervals.
The induction of dominant lethal effects
causing embryonic or fetal death is
evaluated. Dominant lethals are generally
accepted to be the result of chromosomal
aberrations (structural and numerical
anomalies), but gene mutations and toxic
effects cannot be excluded.
In Vtro Tests
During recent years many in vitro test
systems have been proposed as alternatives
to whole animal testing for developmental
toxicity. These tests are not able to replace
animal testing, but can reduce the number
of chemicals to be tested with live animals.
In vitro techniques may also prove useful
in the screening of complex chemical mix-
tures, e.g., in product development (pre-
screen) or in the screening of closely
related chemicals. In addition, in vitro
tests can be used as a tool for pinpointing
the mechanisms underlying a known
embryo-fetotoxic effect, and as such pro-
vide information that can improve the
interpretation of the results and conse-
quently the extrapolation from laboratory
animal experiments to humans. No speci-
fic test is mentioned here but a reference is
given to a recent review.
Test Strategies
Strategies for the assessment of reproductive
toxicity of chemical substances has been
proposed (71,76). The toxicity testing
strategies deal (at present) with evidence
for reproductive toxic effects, i.e., hazard
assessment, but potency should be consid-
ered at a later stage. An example is given in
Table BI (77).
Significance of Experimental
Data and Their Relevance to
Man (Extrapolation)
It has been stated that the ultimate proof
that a substance is a human teratogen can
come only from information on the conse-
quences of human exposure. This state-
ment is valid regarding toxicological effects
in general. However, the experience within
the area of developmental toxicology (and
carcinogenicity) comparing data from
human exposure and data from dosing
experimental animals (irrespective of the
difficulties comparing two different kinds
of data sets), and the biology as expressed
by Calabrese (78) serve as the basis for the
use of laboratory animals in predicting pos-
sible consequences for humans. Calabrese
says the following:
Cellular structure and biochemistry are
remarkably alike across the entire animal
kingdom, starting with the lipoprotein cell
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Table B1. Reproductive toxicity testing strategy.
Data Results Recommended testing
Human data Clear evidence of developmental No further testing
toxicity or impaired fertility
Limited evidence of Teratology study and/or
- developmental toxicity behavioral teratology study
- impaired fertility Fertility study
Full toxicological data set Clear evidence of developmental No further testing
in experimental animals toxicity or impaired fertility
No indication of reproductive toxicity No further testing
- but neurotoxicity in adult Behavioral teratology study
Some indication of reproductive toxicity See below
Acute or repeated Testicular effects Fertility study (males dosed),
dose toxicity studies sperm-test
Ovarian effects Fertility study (females dosed)
Neurotoxicity in adult animals Fertility study combined with
behavioral teratology study
High acute toxicity Generation study or OECD
ReproTox screening test
Reproductive toxicity studies Clear evidence of developmental No further studies
toxicity or impaired fertility
Developmental toxicity at Studies using specific end
maternally toxic doses points and lower doses
Equivocal evidence of impaired Repeat study
fertility
Effects on sperm quality only Epidemiological study of
exposed men
In vitro teratogen study Teratogen effect Teratology study
Teratogen effect plus SAR and No further studies
kinetics indicate effect
Data on kinetics/dynamics Accumulation in fetus, competitive Studies on developmental
metabolism, etc. toxicity
Hormone analogue, accumulation
in testes Fertility study (relevant sex
dosed)
No toxicological data No indications Initial toxicity testing
followed by studies for
reproductive toxicity
Abbreviations: SAR, structure-activity relationship; OECD, Organisation for Economic Cooperation and Development.
membrane, which affects the absorption of
xenobiotics into the cell to metabolic
processes like glycolysis, the Krebs' cycle,
and numerous other aspects of intermedi-
ary metabolism. The similarity among
animals on the cellular level is so apparent
that it serves as the basis upon which
scientists have extrapolated or inferred
functions from one species to another.
Thus, concerning findings in experimental
studies in laboratory animals, demonstrat-
ing developmental toxicity (valid for cancer
as well) is indicative of a potential human
response.
Concerning the predictive value of in
vitro results and their relevance for the man,
the extrapolation between the response in
isolated parts of the organism and that of
the intact organism has to be considered.
Concerning the predictive value of
effects on fertility that were demonstrated
in rodent studies and their relevance for
the man, the experience is limited.
However, it has been stated that effects on
fertility in rodents seem to be a good indi-
cator for effects in humans, and most work
on contraceptive agents in humans stems
from original studies in rodents. In particu-
lar, agents causing toxic damage to the
testis in animals seem to have a similar
effect in humans (79).
Present Situation
Chemicals that Have Been
Subjected to a Full-scale
Toxicological Teting Program
The toxicology testing program includes
testing of the chemical, covering exposure
in all periods of the lifespan, including
the reproductive cycle. Thus, in princi-
ple, it should be possible to detect any
consequence of an exposure to chemicals at
any period, if the test program and the
specific tests are correctly designed.
However, several questions remain:
Is the testing program sufficient to
identify the possible consequences of
exposure?
* Are the effectiveness/sensitivity of the
specific toxicological methods sufficient
(e.g., number of animals involved per
number of species tested per number of
groups per dosage regimen). Do we need
new or additional toxicological tests?
* Are the parameters used relevant and
sufficient? Will the specific test benefit
from the introduction of additional
parameter(s) or do we need additional
parameters (end points)?
Other Chemicals Subjected
to Only a Limited Number of
Toxicological Tests
New chemicals are subjected to a testing
program in the European Union involving
different levels of testing according to the
tonnage on the market. Most chemicals
have only been tested in a limited range of
tests according to the requirements on the
base set level. Only a few new chemicals
will reach a tonnage level triggering the
demand for a full scale testing program
(level 2).
The existing (older) chemicals are
tested according to a strategy that considers
the actual use of the chemical/actual expo-
sure and the potential of health hazard.
Thus, a few of these chemicals have been
subjected to some or more toxicological
tests, while only a very limited set of data is
available for many of the chemicals.
Therefore, the following problems should
be discussed:
* What is the possibility of introducing
one or more screening tests to obtain
data sufficient for an acceptable
assessment of the potential effect on
reproduction?
* What are the possibilities of introduct-
ing additional parameters in the exist-
ing tests at the base level to obtain
additional information on the potential
of the specific chemical to impair the
reproduction?
Introduction of additional parameters
or even new test methodology within
the area of reproductive toxicology will
require more experimental work to help
us better understand the underlying
biological mechanisms.
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